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Vaccinia virus (VACV) is a master manipulator of the immune response, 
and is also a prime candidate for vaccine vectors. This thesis explored both 
properties through (i) identification and characterization of the VACV M1 protein 
as a caspase inhibitor and (ii) investigating a previously unexplored method to 
alter the immunogenicity of the attenuated VACV MVA. 
One anti-viral host response inhibited by VACV during infection is 
apoptosis. The attenuated MVA strain of VACV, however, stimulates apoptosis in 
several immune cell types due to loss of inhibitors. This thesis demonstrates that 
reinsertion of the M1L gene into MVA results in a virus that inhibits apoptosis. 
Furthermore, M1 can specifically inhibit intrinsic apoptosis. Inhibition was 
identified to be via M1-apoptosome (Apaf-1 and caspase-9) interactions, 
resulting in caspase-9 inactivation. This is the first VACV protein shown to inhibit 
after formation of the apoptosome, making M1 a novel inhibitor of apoptosis.  
Because M1 inhibited caspase-9 activation, the inhibition of other 
caspases by M1 was also examined. Via expression of M1 in mammalian cells or 
yeast, M1 inhibited caspases-1, -2, -3, -5, -7 and -8 in addition to its inhibition of 
caspase-9. This suggests M1 is a broad-spectrum caspase inhibitor. Further 
studies determining the mechanism of M1 inhibition of caspases could yield 
valuable information about poxviral-host interactions. Additionally, M1 features 14 
predicted ANK repeat domains, a domain important for protein-protein 
interactions. Novel designed ANK repeat proteins (DARPins), are being created 
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to specifically bind proteins, such as caspases, with high affinity. Therefore, 
information from the study of M1 could potentially aid in DARPin development.  
 Due to the truncation or deletion of multiple viral proteins, MVA is a highly 
attenuated virus that is replication-restricted. These qualities make MVA a safe 
vaccine vector. However, higher doses or multiple boosts of MVA are necessary 
to elicit an immune response similar to wild-type VACV. Multiple strategies have 
been used to create modified MVA viruses that remain safe, but have increased 
immunogenicity, such as deletion of remaining VACV immune regulatory 
proteins. This thesis investigated the opposite and previously unexamined 
strategy; re-inserting three VACV immunomodulatory proteins (M1, K1, and M2) 
into MVA (MVA/5.2kb). The addition of one apoptosis inhibitor (M1) and two 
inhibitors of NF-κB (K1 and M2) was hypothesized to increase immunogenicity by 
delaying viral clearance and increasing the potential for antigen presentation. 
MVA/5.2kb-infection of antigen presenting cells (APCs) in vitro showed similar 
APC maturation and cytokine production compared to MVA-infection. However, 
this did not translate to increased immunogenicity as VACV-specific T-cells were 
dampened in vivo after infection with MVA/5.2kb. While a more immunogenic 
virus was not created, a previously unexplored method for altering MVA 
immunogenicity was tested. 
The studies in this thesis reveal novel information that is pertinent to the 
poxvirus field. First, a function was identified for the previously uncharacterized 
VACV M1 protein. Secondly, a previously unexplored method to alter MVA 
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immunogenicity was explored. The information here expands the knowledge of 
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Chapter 1: Introduction 
1.1 Poxviruses 
Importance of poxviruses 
 Poxviruses are large double-stranded DNA viruses that have played 
significant roles in the fields of cell biology, virology, and immunology (70). 
Probably the most well-recognized member of this family is variola virus (VARV), 
the causative agent of smallpox. Smallpox was one of the most devastating 
human diseases that the world has encountered (123). However, the utilization of 
a safer poxvirus, cowpox virus (CPXV), to protect against smallpox by Edward 
Jenner led to the birth of vaccinology, and eventually resulted in the eradication 
of smallpox in 1977 (70, 72, 107). Although smallpox is eradicated, the study of 
poxviruses continues because these viruses are still used as vaccine vectors and 
also as oncogenic viruses (70, 126). Additionally, the investigation of these 
complex viruses has led to important discoveries about host cell biology, such as 
the polyadenylation of mRNA, and have given vast insight into how viruses 
combat host responses after infection (70, 116). Studies outlined in this thesis 
help expand the knowledge about virus-host interactions through characterization 
of the vaccinia virus (VACV) M1 protein, and investigation of the immune 
responses to a recombinant virus, MVA/5.2kb, whose parent (Modified vaccinia 







Poxviruses are some of the most complicated viruses, with genomes 
ranging in size from 140 kb to over 300 kb. These genomes are linear and 
double-stranded, with inverted terminal repeats (ITRs) at each end that pair 
together to form a terminal loop (70). Poxviruses can contain hundreds of open 
reading frames (ORFs). The original nomenclature of poxvirus genes is based on 
the Hind III restriction pattern of the VACV Copenhagen strain, the first VACV to 
be sequenced (52). Gene names consist of three parts: (i) the DNA fragment 
letter followed by (ii) the ORF number, from left to right in each fragment, and 
finally (iii) the direction of transcription, designated by either an “L” or “R”. For 
protein designation, the “L” or “R” is dropped. Newly sequenced genomes now 
have ORFs numbered from one end of the genome to the other (70). In this 
thesis, the conventional Hind III nomenclature will be used for the investigated 
genes.  
Genes that are essential for poxvirus function, such as replication, 
transcription, and assembly, are located in the center of the genome. The ends of 
the genome contain immunomodulatory genes responsible for interfering with 
host responses to infection (70, 72), some of which are the focus of this thesis. 
Chapter 2 defines a novel mechanism for the previously uncharacterized M1L 
gene. The M1 protein is further discussed in chapter 4, where preliminary data 
suggesting other potential functions is described. Finally, chapter 3 discusses 
how the re-introduction of three immunomodulatory genes (M1L, K1L, and M2L) 
into an attenuated poxvirus genome affects infected immune cells. 
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Poxvirus life cycle 
Poxviruses follow an intricate step-by-step process to infect cells, express 
their genes (such as M1L, K1L, and M2L), replicate their genomes, and to 
package and release infectious virions. These steps are important for a 
successful infection; however, virus infection and replication products also 
activate host immune responses, such apoptosis and pro-inflammatory 
transcription factors, which will be discussed later in this thesis. To counteract 
these responses, poxviruses encode proteins such as the ones described in 
chapters 2-4 of this document to block the host immune response. Much of what 
is known about the poxvirus replication cycle has been investigated using VACV 
(70), a virus that was utilized for some of the experiments in this thesis. 
Therefore, this section describes how wild-type VACV forms fully infectious 
virions (Fig. 1.1).  
The poxvirus life cycle beings with host attachment and entry. The specific 
protein receptor(s) poxviruses use has not been identified, however cell entry of 
this enveloped virus is known to occur either through host membrane fusion or 
endocytosis and utilizes at least 12 viral proteins to accomplish this task. Once 
the virus core enters the cytoplasm, transcription begins. Poxviruses are unique 
amongst DNA viruses as transcription occurs exclusively in the cytoplasm due to 
the presence of a virally-encoded RNA polymerase. Poxvirus genes are 
expressed in a stepwise fashion, consisting of early, intermediate, and late gene 
expression. Transcription of early genes occurs in the viral core, and early mRNA 
transcripts can be detected as early as 20 minutes post-infection. Among these 
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early transcripts includes M1, which we show is an anti-apoptosis product. Other 
early products include growth factors, immunomodulatory proteins, as well as 
genes necessary for uncoating the viral core, DNA replication, and intermediate 
transcription (70). Next, uncoating of the poxvirus core occurs, which leads to 
initiation of viral DNA replication, followed by intermediate transcription. Genes 
transcribed intermediately include transcription factors for late transcription. 
Finally, late genes are transcribed, which consist of structural genes, enzymes 
and early transcription factors that will be packaged and released as infectious 
virions (70, 72). Viral structural proteins, viral DNA and viral RNA can all activate 
intrinsic immune responses. Therefore, poxviruses encode multiple 
immunoregulatory proteins to inhibit these host responses and allow completion 
of the viral life cycle (101). The genes investigated in this thesis are all early 
immunomodulatory genes, making them some of the first responders after 
infection, and therefore crucial for regulation of the host. 
The final steps of the poxvirus life cycle consist of virion assembly and 
release. This process begins in virus factories, areas of the cytoplasm that are 
granular, electron-dense, and contain high levels of viral DNA. Viral membranes 
begin to form first as a crescent-shape that then becomes a circular immature 
virion (IV). The specifics of IV formation are not fully understood, nevertheless, 
viral DNA, core proteins and transcription factors are brought into the IV before 
it’s closure. Loss of viral scaffolding proteins allows the IV to transition to the fully 
infectious mature virion (MV); however, this virion form can only be released 
upon cell lysis. To begin viral dissemination, MVs travel along microtubules to be 
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wrapped with a pair of additional membranes by either the trans-Golgi or 
endosomes, and this is referred to as the wrapped virion (WV). WVs again use 
microtubules to migrate to the cell membrane, where fusion of the outer WV 
membrane occurs, resulting in release of the extracellular enveloped virion (EV). 
Finally, EVs employ virally encoded actin-containing microvilli for efficient cell-to-
cell spread (70, 85). Upon contacting a new cell, the cycle begins anew. Note 
that in this thesis, along with VACV, I will use the attenuated virus strain MVA. 
Human cells, the focus of this thesis, are non-permissive for MVA. However, the 
block in replication occurs during morphogenesis, therefore while MVA is unable 
to form infectious virions, gene expression occurs (Fig. 1.1) (22, 120).  
 
1.2 Vaccinia virus (VACV) and virus-host interactions 
VACV is a well-studied poxvirus. Its origins are unknown, however it is 
thought to have evolved from horsepox (HSPV) as the two viruses have related 
conserved sequences and infection of horses with VACV leads to clinical signs of 
HSPV (107). VACV was utilized during the smallpox vaccination campaign (107), 
but has since become the model virus for investigating aspects of poxvirus 
biology, such as replication (70, 91) (as mentioned in the above section) and 
virus-host interactions (92, 116), which will be the focus of this thesis.  
VACV is a master regulator of the host immune response. Upon infection, 
poxvirus viral proteins and products of replication and transcription can lead to 
activation of many host responses such as interferons, complement, pro-
inflammatory cytokines, chemokines, and apoptosis (92, 116). Therefore, to 
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block these responses, one-third to one-half of the VACV genome is dedicated to 
code for immunomodulatory proteins (116). Chapters 2 and 4 of this thesis will 
introduce the M1 protein of VACV as a modulator of apoptosis, describe the 
novel mechanism as to how it inhibits intrinsic apoptosis, and postulate on other 
potential immune regulatory mechanisms. Chapter 3 will investigate how the 
introduction of inhibitors of apoptosis (M1) and NF-κB (K1, M2) during an 
attenuated MVA infection alters the host response to infection. Therefore, to 
better understand these data, these host responses and how VACV counters 
them will be discussed below. 
 
Apoptosis overview and effector caspases 
 Host-induced death of virally infected cells is a powerful mechanism to 
block virus spread (30, 65, 115). While many forms of cell death can occur, such 
as pyroptosis and necroptosis (30), the focus of this thesis will be apoptosis. 
Along with controlling invading pathogens, apoptosis plays important roles during 
early embryo development and differentiation, making this pathway very 
important for multiple aspects of human biology (69). Cells undergoing apoptosis 
display characteristic morphological changes including chromatin condensation, 
cell shrinkage and plasma membrane blebbing that results in the formation of 
apoptotic bodies (69). There are two classical pathways that stimulate apoptosis 
(i) the extrinsic pathway, mediated by cell surface death receptors, and (ii) the 
intrinsic pathway, mediated by the mitochondria (Fig. 1.2).  
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Both apoptotic pathways lead to the activation of a family of cysteine 
proteases, called caspases (122). There are at least fourteen different 
mammalian caspases, and at least eight of them participate in apoptosis. 
Caspases exist in the cell as catalytically inactive zymogens, denoted 
procaspases, which typically become activated upon cleavage. The individual 
routes of extrinsic and intrinsic apoptosis will be discussed below, however both 
pathways converge at the cleavage and activation of caspases-3, -6 and -7, 
deemed effector caspases. Once activated, these effector caspases 
proteolytically cleave many cellular targets, which culminates in cell death (113). 
One such target is poly ADP-ribose polymerase (PARP) (35), which will be 
examined as a marker of apoptosis in this thesis. While both the extrinsic and 
intrinsic apoptotic pathways have similar downstream events, their upstream 
signaling is quite different. Intrinsic apoptosis will be the focus of chapter 2 and 
important for chapter 3, while extrinsic apoptosis will be investigated in chapter 4 
of this thesis. Therefore, these pathways will be described in this order. 
 
Intrinsic apoptosis 
 One protein that is the focus of this thesis is the VACV M1 protein. 
Chapter 2 will demonstrate that M1 inhibits intrinsic apoptosis and investigate the 
molecular mechanism of action. Therefore, it is important to understand the 
events in this pathway. Intrinsic apoptosis is a mitochondrially mediated event, 
where permeabilization of the outer-membrane must occur for initiation. This 
initiation happens in one of two ways, positively or negatively. Positive activation 
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occurs through activation of host pro-apoptotic factors, which leads to 
mitochondrial permeabilization, and will be the main method of activation 
discussed in this thesis. This type of activation occurs through a variety of 
internal stresses, such as viral infection, introduction of toxic materials, or DNA 
damage. Alternatively, negative regulation occurs through inactivation of host 
anti-apoptotic factors, which can be induced through events such as growth 
factor withdrawal, or through the presence of specific cytokines and hormones 
(69).  
The Bcl-2 family of host proteins makes up these pro- and anti-apoptotic 
factors mentioned above. The Bcl-2 family of proteins are characterized by the 
presence of Bcl-2 homology (BH) domains in the primary amino acid sequence. 
There are four of these domains, numbered in order of their discovery. Bcl-2 
proteins are generally α-helical globular proteins, which consist of a 
transmembrane domain and a Bcl-2 fold which is capable of binding amphipathic 
helices, often BH3 domains of other Bcl-2 proteins (9).  
Pro-apoptotic Bcl-2 proteins exist in two forms, effector proteins and BH3-
only proteins. There are three mammalian pro-apoptotic effector proteins, Bak, 
Bax, and Bok. These proteins contain all four BH domains, the transmembrane 
domain and the Bcl-2 fold, however they work to permeabilize the mitochondria 
differently. Before activation, Bak and Bax shuttle between the cytosol and the 
outer mitochondrial membrane, with Bak favoring the mitochondria and Bax 
favoring the cytosol. Upon activation, protein dimerization occurs allowing each 
protein to insert into the mitochondrial outer-membrane, causing a pore and 
9 
 
permeabilization. The mechanism of Bok is much less understood. It has been 
reported to permeabilize membranes, however it localizes to the endoplasmic 
reticulum (ER) and Golgi apparatus. There are conflicting reports about whether 
Bok can cause mitochondrial outer-membrane permeabilization in the absence of 
Bax and Bak. This is a current area of investigation; however Bok is grouped in 
the effector protein family due to sequence similarity to Bak and Bax (9). 
BH3-only proteins are unique from other Bcl-2 proteins as they are 
generally unstructured and only have the BH3 domain and a transmembrane 
domain. There are eight BH3-only proteins found in mammals: Bad, Bid, Bik, 
Bim, Bmf, Hrk, Noxa and Puma. Apoptotic stimuli activate most of these proteins 
through either transcriptional and/or post-translational mechanisms. Upon 
activation, they are drawn to the mitochondria. BH3-only proteins promote 
apoptosis by acting as activators or sensitizers. Bid, Bim and Puma are 
considered activators. They can directly activate the effector proteins Bak and 
Bax and inhibit anti-apoptotic proteins to lead to mitochondrial outer-membrane 
permeabilization. The rest of the BH3-only proteins are sensitizers, as they can 
only inhibit anti-apoptotic proteins, but cannot activate Bak and Bax. The BH3-
only protein Bid has a unique mechanism of activation. This is important to 
discuss as this protein can link the extrinsic and intrinsic pathways, the extrinsic 
pathway will be later described, and Bid will be discussed in chapter 2 of this 
thesis. Activation of the extrinsic pathway of apoptosis can lead to the cleavage 
and activation of Bid to tBid. Cleavage results in conformational changes in the 
protein, allowing tBid to interact with the mitochondrial outer-membrane and 
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activate Bax (9, 111). Chapter 2 utilizes an infection system which activates both 
extrinsic and intrinsic apoptosis. Because of this, knockout cells will be utilized to 
separate extrinsic and intrinsic activation, and will demonstrate that M1 inhibits 
intrinsic apoptosis independent of any extrinsic, tBid mediated, activation. 
Anti-apoptotic host proteins are the other type of Bcl-2 proteins. The 
proteins in this category are Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bfl-1, and Bcl-b. Like the 
pro-apoptotic effector proteins, the anti-apoptotic protein members contain all 
four BH domains, the Bcl-2 fold, and the transmembrane domain. These proteins 
generally localize to the outer-membrane of the mitochondria to sequester the 
pro-apoptotic Bcl-2 proteins, therefore blocking mitochondrial outer-membrane 
permeabilization and apoptosis (9, 111). Bcl-xL will be utilized as an experimental 
control for a specific assay in chapter 2. Additionally, chapter 2 will investigate if 
the inhibitory function of M1 mimics these anti-apoptotic Bcl-2 proteins. 
Specifically, mitochondrial permeabilization will be examined.  
Upon initiation of intrinsic apoptosis, cytochrome c (cyt c) is released from 
the permeabilized mitochondria. Cyt c then binds to the apoptotic protease-
activating factor-1 (Apaf-1) protein. Apaf-1 is a multidomain protein, consisting of 
a N-terminal caspase recruitment domain (CARD), a nucleotide binding and 
oligomerization domain (NOD), and a C-terminal regulatory domain that is 
composed of 12-13 WD40 repeats (WRD).  In resting cells, Apaf-1 exists in the 
cytoplasm as in inactive monomer, bound to dATP or ATP. Cyt c binds to the 
WDRs of Apaf-1, leading to a dATP or ATP driven conformational change of 
Apaf-1 and oligomerization of the NOD domains of multiple activated Apaf-1 
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molecules to form a circular heptameric complex, with the CARD domains all 
facing towards the center.  After Apaf-1 oligomerization, the main caspase of the 
intrinsic pathway, procaspase-9, is recruited to the complex, forming the 
apoptosome (13, 110). This information is pertinent to understanding the 
molecular mechanism described for M1 later in this thesis. Data will demonstrate 
that M1 associates with the formed apoptosome, a function not seen by other 
poxviral apoptotic inhibitors.  
Procaspase-9 consists of a N-terminal CARD domain, which it uses to 
bind to Apaf-1 CARDs, a large catalytic subunit and a small subunit (75, 110). 
Procaspase-9 is unique among caspases, as cleavage is not required for 
caspase activation. Upon CARD-CARD interactions with Apaf-1, procaspase-9 
gains catalytic activity via one of two proposed mechanisms. First is the “induced 
conformation model,” where procaspase-9-Apaf-1 heterodimers lead to 
conformational changes and activation of procaspase-9. Second is the “induced 
proximity model,” where the apoptosome is thought to allow for dimerization, 
conformational changes, and activation of procaspase-9 molecules (75, 135, 
136). Nevertheless, upon procaspase-9 activation, effector caspases (such as 
procaspase-3) can be cleaved, leading to apoptosis as described above. 
Eventually, procaspase-9 will be cleaved, either via autocleavage at Asp 315 or 
by caspase-3 mediated cleavage at Asp 330, which decreases affinity for the 
apoptosome and will eventually result in caspase-9 release. Still, activated 
procaspase-9 or cleaved caspase-9 can continue to activate procaspase-3 while 
associated with the apoptosome (75, 135, 136). Chapter 2 of this thesis will 
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introduce M1 as a VACV inhibitor of intrinsic apoptosis, describing the novel 
mechanism it uses to block activation of procaspase-9 after binding to Apaf-1. 
Specifically, the cleavage of procaspase-9 just described will be investigated as a 
readout of intrinsic apoptosis activation. 
 
Extrinsic apoptosis 
 Chapter 4 will investigate the role the M1 protein plays on the activation of 
caspase-8, therefore knowledge of this pathway will become pertinent later in this 
thesis. The extrinsic pathway of apoptosis is initiated through binding of cell 
surface death receptors by ligands which are usually classified in the tumor 
necrosis factor (TNF) gene superfamily. The three most characterized death 
receptor/ligand pairs are the TNF receptor (TNFR) with its ligand TNF-α, the Fas 
receptor (FasR) with its ligand FasL, and the TNF-related apoptosis-inducing 
ligand (TRAIL) receptors (TRAIL-R1 or TRAIL-R2) with their ligand TRAIL. 
Ligand binding leads to recruitment and binding of intracellular adaptor proteins 
by the death receptors. For example, activated FasR recruits the Fas-associated 
death domain (FADD) protein, while the TNFR recruits the TNFR-associated 
death domain (TRADD) protein (69). These intracellular adaptor proteins lead to 
the recruitment of procaspase-8 proteins, the main caspase for the extrinsic 
pathway, along with other proteins, leading to formation of the death-inducing 
signaling complex (DISC). The DISC promotes dimerization and autocleavage of 
procaspase-8 molecules, resulting in caspase-8 activation. Active caspase-8 has 
one of two ways it can lead to apoptosis, and the mechanism is cell-type specific. 
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In type I cells there are high levels of caspase-8, therefore active caspase-8 
leads to the cleavage and activation executioner caspases, which culminates in 
apoptosis. In type II cells, there are lower levels of caspase-8 and direct cleavage 
of executioner caspases is also blocked by the host anti-apoptotic X-linked 
inhibitor of apoptosis protein (XIAP). Therefore, active caspase-8 cleaves the 
pro-apoptotic Bcl-2 protein Bid to form tBid, and activation of the intrinsic 
apoptosis occurs as described in the intrinsic apoptosis pathway section above 
(8, 86, 109).  
 
VACV inhibitors of apoptosis 
 Induction of apoptosis after a viral infection can block viral replication and 
hinders the production of infectious virions. Therefore, to be successful, viruses 
often encode multiple inhibitors of this host response. Poxviruses are no 
exception, encoding a plethora of proteins to inhibit the different pathways that 
activate apoptosis (94). As wild-type and attenuated VACV will be the focus of 
this thesis, their mechanisms of inhibition of apoptosis will be discussed.  
 Both the extrinsic and intrinsic pathways can be blocked by VACV (Table 
1.1). As the extrinsic pathway of apoptosis can be activated by binding of ligands 
to death receptors, VACV encodes viral receptors against cytokines such as 
TNF-α (vTNFRs). vTNFRs encoded by VACV include cytokine response modifier 
C (CrmC) and CrmE. These virally-encoded receptors have high affinity for TNF-
α and act as decoys to sequester extracellular TNF-α, therefore blocking binding 
to host TNFRs and inhibiting initiation of extrinsic apoptotic signaling (1, 94).  
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 Much of VACV apoptosis inhibition occurs via viral proteins that function 
intracellularly. VACV anti-apoptotic proteins are expressed early after infection to 
quickly block apoptosis and allow successful viral gene replication. There are five 
intracellular VACV proteins found in the Western Reserve (WR) strain, the wild-
type strain that will be utilized in this thesis, and these include B13, B22, F1, N1 
and E3. VACV strains Lister, USSR and Evans also encode an additional 
inhibitor, the viral Golgi anti-apoptotic protein (vGAAP). Most of these proteins 
either inhibit upstream apoptotic signaling events, or affect activation of the 
caspase proteins directly (127). Chapter 2 of this thesis will introduce M1 as 
another VACV inhibitor of apoptosis and describe its molecular mechanism. 
Therefore, to understand how M1 complements the known VACV apoptosis 
inhibitors, their roles will be discussed here. 
 Two of the anti-apoptotic proteins found in VACV are members of the 
serine protease inhibitor (serpin) family. One of these proteins is VACV B13, also 
known as serpin inhibitor 2 (SPI-2). It was identified as an orthologue of the 
cowpox (CPXV) CrmA protein, a broad-spectrum caspase inhibitor, with 92% 
amino acid identity. CrmA can bind and block the activation of caspases 1, 4, 5, 
8, 9 and 10, and therefore inhibits intrinsic and extrinsic apoptosis. Similarly, 
VACV B13 inhibits multiple caspases and blocks apoptosis induction via multiple 
stimuli such as TNF-α and FasL which activate extrinsic apoptosis, and 
staurosporine (STS), which activates intrinsic apoptosis (94, 127). Additionally, 
B13 is considered the most potent inhibitor of apoptosis, as an attenuated virus 
that expresses B13 has greater inhibition of extrinsic and intrinsic apoptosis than 
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the same attenuated virus expressing other VACV anti-apoptotic proteins (128). 
The second member of the serpin family that contains anti-apoptotic properties is 
VACV B22, also known as SPI-1. With only 46% amino acid identity to CrmA, it is 
unable to inhibit multiple caspases. Instead, B22 binds and inhibits caspase-8, 
blocking extrinsic apoptosis (94, 127). 
 Viruses often mimic host proteins, as mentioned above with CrmC and 
CrmE, and this is also seen with the VACV F1 and N1 proteins. Both proteins 
adopt Bcl-2-like folds, despite lacking amino acid sequence similarity with other 
Bcl-2 proteins (94, 127). Both proteins inhibit intrinsic apoptosis; however, they 
utilize different mechanisms. F1 is a mitochondrially-localized protein, due to the 
presence of a C-terminal hydrophobic domain. Through its Bcl-2-like fold it binds 
to the pro-apoptotic BH3-only protein Bim, and inhibits intrinsic apoptosis (19). 
Additionally, the N-terminus of F1 has been reported to directly bind and inhibit 
caspase-9 (141), however a recent study demonstrated that deletion of the N-
terminus does not alter the ability of F1 to inhibit apoptosis during an infection 
(20). Therefore, inhibition of Bim is thought to be the main function of F1.  
Like F1, the N1 protein also adopts a Bcl-2-like fold, however the role of 
this fold in the inhibition of apoptosis is less clear. It was reported that N1 can 
interact with the pro-apoptotic proteins Bax, Bad and Bid to block STS-induced 
apoptosis (27). However, N1 binding with Bax, as well as inhibition of intrinsic 
apoptosis, was unable to be confirmed by other groups (7, 80, 99, 128). 
Therefore, inhibition is likely due to interactions with Bad and Bid, but not Bax. 
N1 not only inhibits apoptosis, but also inhibits the pro-inflammatory nuclear 
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factor kappa b (NF-κB) transcription factor, which will be described later in this 
thesis. Inhibition of these two pathways occur through distinct mechanisms, 
therefore mutations that abrogate inhibition of one pathway or the other can be 
made. Interestingly, mutations that inhibit the Bcl-2-like fold and anti-apoptotic 
function of N1 do not alter virus virulence in a mouse model. However mutations 
in the NF-κB inhibitory regions of N1 result in a less virulent virus (80). Therefore, 
while direct inhibition of intrinsic proteins may occur by N1, the major mechanism 
of N1 is thought to be its inhibition of NF-κB (127). 
E3 is the last characterized apoptosis inhibitor encoded by the WR strain 
of VACV, apart from M1 which will be described in chapter 2. The function of E3 
is to inhibit dsRNA induced-apoptosis after infection. Poxviruses do not terminate 
transcription efficiently, leading to overlapping transcripts and the accumulation 
of dsRNA. Poxviral dsRNA can be sensed by the host and result in activation in 
many intrinsic immune responses, including apoptosis (94, 127). The best 
characterized method for dsRNA induced apoptosis during a poxvirus infection is 
through the activation of protein kinase R (PKR) (94). Activation of PKR can 
result in activation of FADD, resulting in cleavage of procaspase-8 and activation 
of extrinsic apoptosis (66). Additionally, dsRNA can activate other host signaling 
proteins, such as the mitochondrial antiviral signaling adaptor protein (MAVS). 
Upon activation, MAVS can induce intrinsic apoptosis (73). Therefore, to 
overcome these responses, the VACV E3 protein binds and sequesters dsRNA 
to block activation of dsRNA-induced pro-apoptotic pathways (94, 127). 
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The protein vGAAP is another characterized VACV inhibitor of apoptosis. 
It was originally discovered in camelpox (CMLV), however it is also present in the 
VACV strains Lister, Evans, and USSR. Additionally, a human homolog (hGAAP) 
was discovered based on its similarity to the viral protein. Expression of vGAAP 
inhibits apoptosis induced by both extrinsic and intrinsic stimuli, however its exact 
mechanism of inhibition remains to be elicited. vGAAP is a hydrophobic protein 
that localizes to the Golgi apparatus and forms a viral ion channel, leading to 
release of Ca2+. Changes in cellular calcium results in apoptosis inhibition, 
however these mechanisms are poorly understood. Therefore, it is thought that 
vGAAP inhibits apoptosis through altering the distribution of Ca2+ within the cell 
(94, 127). 
The proteins mentioned above generally work in a non-redundant fashion 
to inhibit multiple areas of the apoptosis pathway. Chapter 2 will introduce M1 as 
another anti-apoptotic protein. This chapter will describe experiments which 
demonstrate M1 inhibits caspase-9 activation after the formation of the 
apoptosome complex. Additionally, chapter 4 will examine the effects of M1 on 
other caspases that. 
 
NF-κB 
 While apoptosis is a pertinent host response to control viral infection, 
activation of other intrinsic innate immune responses is also important to block 
viral propagation. For example, NF-κB proteins are family of pro-inflammatory 
transcription factors that are activated during a VACV infection (116), and will be 
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relevant for chapter 3 of this thesis. Activation of NF-κB results in transcription of 
a multitude of genes that are important for battling pathogens. Some of these 
genes controlled by NF-κB include anti-viral cytokines and chemokines, while 
others are necessary for immune cell activation and function (32), as will be 
discussed later in this thesis. Chapter 3 will investigate differences between cells 
infected with attenuated VACV viruses that either activate or inhibit this pathway. 
Therefore, NF-κB signaling will be discussed here. 
 The NF-κB transcription factor family is composed of five subunits, p50, 
p52, RelA (p65), c-Rel and RelB. These proteins all contain a N-terminal 
conserved DNA-binding and dimerization domain, denoted the Rel homology 
domain, which is used to form homodimers and heterodimers that bind to DNA 
sequences, designated κB sites, upon entering the nucleus. The NF-κB signal 
transduction pathway is summarized in Fig. 1.3. Additionally, RelA, c-Rel and 
RelB contain transcription activation domains (TADs) which activate target gene 
expression (57). The major complex in most cells is the p50-RelA heterodimer 
(51). In resting cells, NF-κB complexes are inactive and sequestered in the 
cytoplasm by the IκB inhibitory proteins, such as IκBα. Various stimuli of the NF-
kB pathway, such as virus infection or TNFR activation, results in activation of 
the IκB kinase (IKK) complex, which mediates degradation of the inhibitory IκB 
proteins. The IKK complex is composed of two kinase subunits (IKKα and IKKβ) 
and the NF-κB essential modulator (NEMO) scaffolding protein. Upon activation, 
the IKK complex phosphorylates two serine residues on IκB proteins, resulting in 
K48-linked polyubiquitination and subsequent proteasomal degradation. IκB 
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degradation frees the NF-κB complex, allowing translocation to the nucleus and 
binding of κB sites. Upon binding κB sites, NF-κB undergoes post-translational 
modifications necessary for recruitment of host transcription machinery, resulting 
in transcription of a multitude of genes (56).  
 Genes transcribed by NF-κB include, but are not limited to, cytokines, 
chemokines, and interferons, all of which are significant for establishing an anti-
viral state. Additionally, it is important to note for this thesis that activation of NF-
κB can also regulate apoptosis. Depending on the stimuli, NF-κB can have pro- 
or anti-apoptotic effects (71). However, the general consensus is NF-κB 
activation is anti-apoptotic, as it can lead to expression of anti-apoptotic Bcl-2 
and Bcl-xL proteins, cellular inhibitors of apoptosis (cIAPs) and caspase-8/FADD-
like IL-1β-converting enzyme (FLICE) inhibitory protein (c-FLIP) (32, 76). This 
validates the need for poxviruses to encode inhibitors of multiple pathways. Viral 
inhibition of NF-κB decreases pro-inflammatory responses that lead to virus 
clearance. However, as NF-κB expresses anti-apoptotic factors, inhibition of NF-
κB would increase apoptosis, which is also anti-viral.  
These are just two pathways that viruses must overcome to be successful; 
justifying why a large portion of the VACV genome is dedicated towards 
encoding immunomodulatory factors (116). Knowledge of how these viral 
proteins function is essential for decoding the virus-host response. Data 
presented in thesis expand the knowledge of viral-host interactions through 
introduction of a new inhibitor and investigation of whether addition of a subset of 
viral immune evasion proteins alter infection by an attenuated VACV virus. 
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VACV inhibitors of NF-κB 
 As poxvirus infection can activate NF-κB, which contributes to an anti-viral 
state, poxviruses encode multiple antagonists of this host response pathway. 
There are over a dozen characterized VACV inhibitors of NF-κB (Fig. 1.4), 
demonstrating the importance of viral-inhibition of this pro-inflammatory 
transcription factor. Most of these inhibitors function upstream in the pathway, 
working at the level of IκB degradation or above, in attempts to block NF-κB 
nuclear translocation and transcription initiation (116). While each of these 
inhibitory proteins play an important role in inhibiting NF-κB during infection, the 
K1 and M2 proteins will be utilized in chapter 3 of this thesis. Therefore, the 
mechanisms of inhibition by these two proteins will be discussed. 
 The VACV K1 protein is multi-functional, affecting host range, interferon 
products, and, the focus for this thesis, NF-κB activation (12, 15, 87, 114). K1 
possesses two mechanisms for inhibition of NF-κB. The first is a PKR-dependent 
mechanism. As mentioned earlier, PKR is a host cell-signaling molecule that 
recognizes dsRNA. Activation of PKR has multiple fates. Induction of apoptosis 
by PKR was described above, however PKR activation can also activate NF-κB 
(66). K1 inhibits PKR-induced activation of NF-κB during infection, an upstream 
event in the pathway (133, 134). Therefore, during a VACV infection, K1 uses 
this mechanism to block the degradation of IκBα and inhibit nuclear translocation 
of NF-κB (114). 
 The second mechanism K1 utilizes is a PKR-independent mechanism. 
NF-κB can be activated by a variety of stimuli (32). As just described, some 
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stimuli, such as viral dsRNA, lead to PKR-induced activation of NF-κB. However, 
other stimuli, such as phorbol 12-myristate 13-acetate (PMA), do not signal 
through PKR to activate NF-κB (142). When PKR-independent stimuli are used 
to activate NF-κB in the presence of K1, NF-κB activation is inhibited, however 
IκBα degradation occurs, unlike during the PKR-dependent mechanism. Instead, 
during PKR-independent stimuli, K1 translocates to the nucleus to inhibit 
acetylation of the RelA subunit of NF-κB and therefore inhibits translation of pro-
inflammatory genes. K1 is the first VACV inhibitor of NF-κB demonstrated to 
function in the nucleus (15), and is an important VACV inhibitor of NF-κB as it 
can inhibit both upstream and downstream in the pathway. 
 M2 is another inhibitor of NF-κB encoded by VACV. The inhibition of M2 is 
dependent on its cellular localization, as deletion of the N-terminal endoplasmic 
reticulum (ER) localization sequence in M2 blocks NF-κB inhibitory activity (59). 
M2 inhibits yet another stimulus of NF-κB, and that is through MEK/ERK 
signaling. Upon phosphorylation, and subsequent activation, complexes with the 
ERK2 protein can activate the IKK complex. The VACV M2 protein blocks 
phosphorylation of ERK2, therefore inhibiting NF-κB activation (48). 
 The VACV K1 and M2 proteins use unique mechanisms to inhibit NF-kB 
activation. Chapter 3 of this thesis will investigate if changes occur in immune 
cells infected with an attenuated virus that now expresses the K1, M2 (and M1) 
genes. Activation of NF-κB plays an important role in activation of the immune 
response, which will be discussed below, however, it also leads to virus 
clearance (57). Chapter 3 of this thesis will explore this balance by examining if 
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NF-κB inhibition during an attenuated VACV infection is beneficial, as inhibition of 
pro-inflammatory cytokines could potentially delay virus clearance.  
 
Host innate and adaptive immunity overview 
 Upon infection, there is a battle that occurs between the virus and the 
host. Viruses encode multiple inhibitors against numerous intrinsic host signaling 
pathways to allow successful virus propagation. Despite this, the host is usually 
successful in recognizing viruses and mounting a response, resulting in viral 
clearance. This is due to activation of the host innate immune response during 
infection. Additionally, the innate response can activate the host adaptive 
immune response, resulting in specific protection upon re-infection with that 
same virus (5). This is the basis of vaccines, which will be discussed later. 
VACV is no exception, as innate and adaptive immune responses occur 
after infection. While VACV viral inhibitors cannot stop these responses from 
occurring, the presence of immunoregulatory proteins can affect the strength of 
the immune response. This thesis focuses on VACV infection of antigen 
presenting cells (APCs), cells that are important for establishing an immune 
response (130). Chapters 2-4 all examine how VACV immunomodulatory 
proteins affect infected APCs. In chapters 2 and 4, infected APCs are utilized to 
help determine the function of VACV M1. Chapter 3 investigates how the 
presence of viral inhibitors affects the activation and function of APCs, and if 
there are any changes to the strength of the elicited immune response. 
Therefore, an understanding of innate and adaptive responses (Fig. 1.5), the 
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cells involved, and how VACV activates this response are pertinent to this thesis 
and will be described here.  
 
Innate immunity and its recognition of VACV 
The main purpose of the innate immune response is to clear the host of 
infected cells. Additionally, the innate response can lead to activation of the 
adaptive response, which will be described shortly. There are many types of 
innate immune cells, such as neutrophils, eosinophils, and NK cells. These cells 
can phagocytose infected cells (e.g., neutrophils and eosinophils) or release 
molecules to destroy infected cells (e.g., NK cells), aiding in viral clearance (130). 
Cells infected with VACV are recognized by receptors on NK cells, therefore 
these immune cells aid in the clearance of VACV-infected cells (78). Additional 
innate immune cells include antigen presenting cells (APCs), which will be an 
important focus of this thesis. APCs, specifically macrophages and dendritic cells 
(DCs), play an important role in activating the adaptive immune response through 
presentation of antigens to T cells (49, 130). Interestingly, APCs are 
preferentially infected by VACV (23), and therefore are critical players during 
VACV infection.  
Innate immune cells recognize viruses via pathogen recognition receptors 
(PRRs). PRRs recognize pathogen-associated molecular patterns (PAMPs), 
such as viral nucleic acids (124). Upon activation, PRRs initiate signaling 
cascades that result in activation of transcription factors which produce cytokines 
and interferons, such as NF-κB. Therefore, PRR recognition of viruses initiates a 
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pro-inflammatory response which induces an anti-viral state, recruits more 
immune cells, and activates APCs (which will be discussed later) (124).  
There are many different PRRs that are present both on the cell surface 
and within the cell. Toll-like receptors (TLRs) are a family of membrane bound 
receptors that are important for pathogen recognition. There are two types of 
TLRs: cell surface TLRs (TLR1, TLR2, TLR4, TLR5, and TLR6) and endosomal 
TLRs (TLR3, TLR7, TLR8, and TLR9). TLRs recognize a wide range of ligands, 
allowing identification of multiple pathogens, however the expression of each 
TLR can vary depending on cell type (124). VACV can be recognized by TLR2 
during infection, resulting in interferon production. However, it remains unclear 
what viral component is recognized by TLR2 as this TLR generally recognizes 
bacterial ligands such as peptidoglycan (78, 143). VACV infection also triggers 
TLR8-dependent activation of NF-κB, potentially through TLR8 recognition of 
VACV DNA (78, 83) . Interestingly, VACV protein A46 inhibits TLR4, the first TLR 
shown to respond to a viral pathogen, demonstrating attempts by VACV to 
lessen the host response (78, 124). 
Other PRRs exist in the cytosol of immune cells to aid in recognition and 
clearance of a viral infection. These generally detect viral DNA or RNA in infected 
cells, which in the case of poxviruses is pertinent as replication occurs in the 
cytoplasm. There are a multitude of cytosolic proteins to detect viral nucleic 
acids, however they can be divided into two general types based on the 
responses they elicit. One type leads to the production of interferons. Interferons 
help create an anti-viral state, therefore aiding in viral clearance. The other type 
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of cytosolic sensors activates the inflammasome, which is dependent on the pro-
inflammatory caspase-1 protein, leading to maturation and secretion of IL-1β and 
IL-18. IL-1β aids in recruiting immune cells and activating T cells. IL-18 also 
helps recruit immune cells. Therefore, both cytokines assist in controlling 
infection (101, 124).  
Interferon-inducing sensors that recognize DNA consist of proteins such 
as DNA-dependent activator of interferons (DAI) and interferon-inducible protein 
16 (IFI16), among others. These proteins induce interferon production through 
activation of stimulator of interferon genes (STING), which results in signaling to 
the transcription factors interferon regulatory factor 3 and 7 (IRF3 and IRF7) 
(101). Other sensors detect cytosolic RNA, such as the retinoic acid-inducible 
gene I (RIG-I)-like receptors (RLRs). This family includes RIG-I, melanoma 
differentiation-associated gene 5 (MDA-5), and laboratory of genetics and 
physiology-2 (LGP-2) (124). During a VACV infection, viral RNA can be detected 
by MDA-5, resulting in interferon production (78). However, VACV does not 
activate all RNA sensors as another similar protein, DDX3, which also recognizes 
viral RNA, is inhibited by the VACV K7 protein (124).  
Cytosolic sensors can also lead to production of the inflammasome. The 
inflammasome is a multi-protein complex that, when formed, cleaves and 
activates caspase-1 resulting in pro-inflammatory cytokine secretion. Multiple 
forms of the inflammasome complex can exist depending on the proteins 
present. Two cytosolic proteins that sense viral DNA have been identified which 
activate the inflammasome: NLRP3 and AIM2 (101). During a wild-type VACV 
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infection, viral DNA can be recognized by AIM2, resulting in secretion of IL-1β 
and an inflammatory response by innate immune cells (78). Therefore, despite 
inhibitory proteins present in VACV, infection promotes activation of the innate 
immune system which leads to viral clearance. 
 
Adaptive immunity and VACV protective correlates 
Activation of the innate immune response is important for clearing a viral 
infection. However, this is a non-specific response, meaning general PAMPs 
activate of the innate immune system. To provide specific protection against a 
pathogen, the adaptive immune response is vital. Once activated, cells of the 
adaptive immune system can identify specific antigens of a virus that the innate 
immune system may miss. Therefore, if successful activation of the adaptive 
immune system occurs, re-infection with the same virus will activate both innate 
and adaptive responses. This functions as a two-pronged immune response, 
which can speed up viral clearance and lessen severity. Therefore, activation of 
the adaptive immune memory is the basis of vaccines, which will be discussed 
later (5, 11).  
APCs are responsible for activation of the adaptive immune system, which 
is composed of T and B lymphocytes. Adaptive immune activation occurs 
through antigen presentation, a process where APCs process viral antigens, 
display antigens on the cell surface via major histocompatibility complex (MHC) 
proteins, and present these antigens to T cells (81, 96). There are two types of 
MHCs, MHC class I (MHC-I) and MHC class II (MHC-II). MHC-I molecules are 
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found on all nucleated cells and are generally used to display cytosolic proteins. 
MHC-II molecules are specific to APCs and present extracellular peptides that 
have become internalized (81, 130). There are two pathways that can lead to 
antigen presentation, denoted direct and cross presentation. During direct 
presentation, infected APCs breakdown viral components to display them on the 
cell surface, via MHC-II molecules (130). For cross presentation, instead of being 
infected directly, the APC internalizes infected cells and uses those antigens to 
display via MHC-I (16, 62). 
APCs must undergo a maturation process before they can activate T cells. 
Maturation increases surface levels of both MHC-II proteins and T cell co-
stimulatory molecules, such as CD80 and CD86. Mature APCs can interact with 
T cells, resulting in T cell activation. Additionally, cytokine expression by APCs 
can help differentiate T cells (29). Recognition of PAMPs by PRRs initiates the 
maturation process, as activation of pro-inflammatory transcription factors, such 
as NF-κB, also produce proteins necessary for APC maturation (64). Specifically, 
during a VACV infection, recognition by TLR2 and secretion of IFN-β is required 
for APC maturation and full activation of T cells. Additionally, it is of interest to 
note that while VACV preferentially infects APCs, an in vitro infection with wild-
type VACV is abortive and results in decreased APC maturation. However, in 
vivo infection leads to proper DC maturation and an adaptive immune response 
(78). Chapter 3 of this thesis will investigate APC activation both in vitro and in 
vivo, therefore it is important to note that in vitro results do not always translate in 
vivo, which will be discussed. 
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T cells interact with an APC displaying an MHC-antigen complex via its T 
cell receptor (TCR), resulting in activation. Activated T cells differentiate into 
either cytotoxic T cells (CD8+) or helper T cells (CD4+). Cytotoxic T cells are 
activated by MHC-I complexes, and their main function is to destroy infected 
cells. This occurs through CD8+ T cell release of proteins that lyse cells (perforin 
and granzyme) or release of proteins that induce apoptosis of target cells 
(granulysin). T helper cells are activated via MHC-II complexes. Upon activation, 
CD4+ T cells release cytokines to recruit and activate innate and adaptive 
immune cells to aid in viral clearance. Most CD8+ and CD4+ are cleared after 
infection, however a small subset of these cells can remain as memory cells that 
quickly respond to interaction with the same antigen (130).  
As T cells themselves result in responses to infection, this adaptive 
response is often referred to as cell-mediated immunity. This contrasts with the 
main function of B cells, the other important cell type of the adaptive immune 
response, whose main function is to induce humoral, or antibody-mediated, 
immunity. B cells also recognize antigens to begin their activation process, 
however as B cells themselves have antigen recognition receptors they do not 
need APCs. After antigen recognition, B cells differentiate into plasma cells that 
produce antibody upon re-exposure to the same antigen (130). This 
differentiation can either occur with just the B cell, or can be assisted by CD4+ T 
cells (11). Upon re-infection, secretion of antibodies by plasma memory cells 
leads to identification of infected cells, targeting them for destruction. Therefore, 
while cell-mediated responses help with clearance of the initial infection, humoral 
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responses are not helpful for initial responses but instead for clearance of future 
infections (130). 
VACV virus infection, the focus of this thesis, stimulates CD4+ T cell, CD8+ 
T cell, and humoral adaptive immune responses. CD4+ T cells are important 
during VACV infection to activate B cells and elicit an antibody response (116). 
Originally, humoral responses were attributed to VACV protective responses. 
However, further studies demonstrate that memory CD8+ T cells, which are 
generally induced through direct presentation during a wild-type VACV infection, 
are also important for virus clearance upon re-infection. Therefore, both CD8+ 
and humoral responses serve as protective correlates against a VACV infection 
(63, 116, 140). This will be pertinent for chapter 3 of this thesis, where CD8+ T 
cell responses after VACV infection will be investigated as a readout of 
immunogenicity. Overall, VACV infection results in activation of the innate and 
adaptive immune responses, that ultimately result in protection against re-
infection. 
 
VACV as a vaccine: pros and cons 
 As just described, VACV infection stimulates protective CD8+ T cell and 
antibody responses. Additionally, infection with VACV protects against other 
poxviruses in the same genus, such as VARV, due to the antigenic relatedness 
of these viruses. These properties made VACV a successful smallpox vaccine 
during the smallpox eradication campaign. Strains of wild-type VACV were used 
around the world to protect individuals against VARV, the causative agent of 
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smallpox. VACV utilization, and the fact that humans are the only reservoir for 
VARV, led to the eradication of smallpox, making VACV the most successful 
vaccine in history (38, 63). 
 VACV has the capacity for the addition of at least 25 kb of foreign DNA. 
Therefore, multiple foreign genes can be inserted and expressed by VACV (116). 
This quality, along the immune response elicited, made VACV a popular vaccine 
candidate against a wide range of diseases. However, VACV is a live, replication 
competent vaccine. This led to complications in certain vaccinated individuals, 
especially those who were immunocompromised. Therefore, while VACV was a 
prime candidate for vaccines, its safety profile needed to be altered. This led to 
the creation of recombinant and attenuated VACV, whose goals were to still 
create an immunogenic response, but have increased safety (42, 63, 107, 116). 
One such attenuated virus, MVA, will be the focus of this thesis, and will be 
described in the next section of the introduction.  
 
1.3  Modified Vaccinia virus Ankara (MVA) 
MVA was one of the attenuated viruses created in attempts to improve the 
safety of VACV-based vaccines (107). It was made by serially passaging the 
wild-type Ankara VACV strain over 500 times in chicken embryo fibroblast (CEF) 
cells (84). This resulted in loss of approximately 15% of the parental genome, 
and many of these deleted or mutated genes were responsible for modulation of 
the host immune response (4, 89). MVA is also greatly restricted in its host 
range. It is unable to produce infectious viruses in most cell types, including 
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human cells (10, 22), however gene expression of early, intermediate, and late 
proteins occurs, along with formation of immature virions. Additionally, MVA can 
express recombinant proteins, allowing the insertion of genes into this attenuated 
background (120, 137). 
This thesis will use the attenuated MVA virus and recombinant MVA 
viruses for many of the experiments. Chapters 2 and 4 utilizes MVA as a viral 
background to identify the M1 protein as an inhibitor of apoptosis. Additionally, 
chapter 3 investigates how immune responses to MVA are altered by the 
insertion of a gene cassette of three lost immunomodulatory proteins (M1, K1 
and M2). Because MVA-induced immune responses, which serve as the basis 
for vaccination, as well as MVA-induced apoptosis will be investigated in this 
thesis, these topics will be discussed below.  
 
MVA as a vaccine: safety vs immunogenicity 
 Wild-type VACV was a successful vaccine, however its safety required 
improvement. This led to the creation of viruses such as MVA. The qualities of 
producing viral PAMPs and not replicating in human cells made MVA an 
attractive candidate as a safer vaccine candidate. After its creation, MVA was 
successfully utilized during the last decades of the smallpox eradication 
campaign with no complications seen (84). This safety profile has been validated 
in studies that occurred after the eradication of smallpox as well (40, 138). 
However, to elicit the same level of protection as wild-type VACV, higher doses 
or multiple boosts of MVA need to be given (40, 88, 138). While MVA has 
32 
 
continued to be a popular vaccine vector candidate for a multitude of diseases 
(50, 53), efforts continue to increase the immunogenicity of MVA without hurting 
its safety profile.  
 
Immune responses to MVA 
To discuss the strategies explored to improve MVA immunogenicity, which 
will be the focus of chapter 3 of this thesis, an understanding of how immune 
responses elicited by MVA is needed, which will be discussed here. As MVA 
lacks many immunomodulatory proteins compared to wild-type VACV, clearance 
of the virus is quick. Nevertheless, anti-viral responses still occur (53). Like wild-
type VACV, MVA preferentially infects APCs, which will be utilized in this thesis 
(3). However, the innate immune response recognizes MVA in a different manner 
(Table 1.2). MVA infection activates TLR2 and TLR6, and one study 
demonstrates MVA activation of TLR9 (78). Therefore, the only common TLR 
activated by wild-type VACV and MVA is TLR2.  
 MVA is not only recognized by membrane-bound TLRs, but also by 
cytosolic PRRs. During an MVA infection, interferon production is stimulated via 
MVA-induced activation of MDA-5, just as wild-type VACV. As both viruses utilize 
the same RLR, this suggests that MDA-5 is important for recognition of VACV 
RNA. Inflammasome activation, however, is induced by NALP3 during an MVA-
infection while wild-type VACV utilizes AIM2 (53, 78). Therefore, despite different 




 The innate immune system activates adaptive responses (130). As 
mentioned, MVA preferentially infects APCs as wild-type VACV does, and APCs 
are critical to activate the adaptive immune system (3, 23). Infection with MVA 
stimulates APC maturation. However, unlike wild-type VACV which only induces 
APC maturation in vivo, MVA infection stimulates APC maturation in vitro due to 
its attenuation (34). But, as MVA lacks many immunomodulators, infection with 
MVA also induces extrinsic and intrinsic apoptosis of APCs (24, 55). Therefore, 
cross-presentation by MVA-infected APCs is important for activation of the 
adaptive immune system, as the quick onset of cell death makes it difficult to 
utilize direct presentation as wild-type VACV does (47, 140). The properties of 
maturation and APC cell death after infection will be examined in chapter 3 of this 
thesis. Nevertheless, MVA infection leads to activation of the adaptive immune 
system. Unfortunately, the level of the response is often not as robust as wild-
type VACV, and therefore MVA is less immunogenic (126). This has sparked 
efforts to increase the immunogenicity of MVA-based vaccine vectors without 
compromising their safety profile. Chapter 3 of this thesis will explore if re-
introduction of a subset of wild-type VACV inhibitors induces more wild-type like 
immune responses. However, to see how this strategy compares, efforts to 







Modified MVA viruses and advances in immunogenicity 
 MVA is a safe, attenuated virus, however its induction of productive 
responses does not match that of wild-type VACV (126). Therefore, researchers 
have attempted to create modified MVA viruses for increases in immunogenicity. 
Two of the popular strategies to improve MVA are to delete remaining immune 
evasion molecules present in MVA in attempts to enhance attenuation and 
response to the virus, or express co-stimulatory molecules of the adaptive 
immune response in hopes of better activation (42, 107). Examples are given 
below. Chapter 3 of this thesis will investigate a less-explored route of MVA 
alteration, the addition of immunomodulatory proteins. The hypothesis is that 
since MVA is cleared quickly due to robust immune responses and cell death, 
then inhibition of these pathways may allow for longer presentation of MVA-
specific antigens and increase the immune response. To investigate how this 
method compares to the others, the attempts and progress at increasing MVA 
efficacy will be discussed here.  
 One potential method to increase MVA immunogenicity is to delete 
remaining viral immune-regulatory proteins to enhance induction of the immune 
system. This has been explored in the context of MVA as a smallpox vaccine, as 
well as via recombinant MVA viruses that express heterologous antigens against 
diseases, such as HIV (42, 107, 129). Viral genes remaining in MVA that regulate 
host cytokine/chemokine signaling, pro-inflammatory transcription factors, 
antigen presentation, and apoptosis have been further deleted to determine their 
immune-activating effects (Table 1.3). 
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 As mentioned previously, cytokines and chemokines are important 
stimulators of the immune system. To counter this, VACV encodes viral cytokine 
and chemokine binding proteins, which sequester these molecules to delay 
immune responses and allow viral propagation (116). VACV B16 is a viral 
cytokine-binding protein for IL-1β, an important activator of the immune system 
which was described above (119). MVA retains the B16R ORF (4). To determine 
if deletion of B16R increases or dampens the immune response, an MVA devoid 
of B16R was tested. Infection with this deletion virus increased virus-specific 
CD8+ T cells, a correlate of protection against VACV. Consequentially, increased 
protection against a wild-type VACV challenge was observed after prior infection 
with the deletion virus compared to wild-type MVA infection (119).  In a similar 
fashion, deletion of the C12 protein, a VACV IL-18 binding protein, from MVA 
increased both VACV-specific CD8+ T cells and CD4+ T cell responses after 
infection, resulting in increased protection (36). However, this is an inconsistent 
finding, as another group found no difference in responses to MVA or a MVA 
virus lacking C12 (28). Finally, a few viral chemokine-binding proteins are left in 
the MVA genome. Two that remain are A41 and B7 (4, 25, 28). Deletion of the 
A41L gene from MVA increases CD8+ T cell responses as well as protection after 
infection (25). However, a virus deleted for the B7 protein shows no change from 
MVA infection (28). Therefore, while some results show no change, further 
attenuation of viral cytokine and chemokine binding generally increases immune 
responses to the MVA virus. 
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Another class of proteins wild-type VACV encodes are inhibitors of pro-
inflammatory transcription factors such as NF-κB and IRF3, pathways previously 
discussed in this chapter. MVA lacks many of these inhibitors due to its 
attenuation, however retains coding capacity for the K7, A46 and A49 NF-κB 
inhibitory proteins (4). Still, due to lack of many of the other viral inhibitors, MVA 
induces NF-κB activation (95, 129). A hypothesis to increase MVA 
immunogenicity is to delete remaining inhibitors to induce a more robust pro-
inflammatory response. In support of this, deletion of K7R, or A46R from the 
MVA genome increased CD4+ and CD8+ T cell responses, as well as increased 
antibody titers, after MVA infection (41, 129). However, the response increase by 
A46 was not seen by another group (28). VACV C6 is an inhibitor of interferon 
production (125). Deletion of the C6L ORF resulted in a virus whose infection 
also increased CD4+ and CD8+ T cell responses compared to MVA (41, 44). The 
VACV N2 protein is another interferon inhibitor present in MVA, however it 
harbors a five amino acid deletion (aa 31-35) compared to wild-type VACV-
encoded N2 (37). Interestingly, full deletion of N2 increases MVA-induced 
immunogenicity, suggesting functional activity remained despite the lack of five 
amino acids (43). Overall, these data demonstrate that the deletion of remaining 
inhibitors of pro-inflammatory transcription factors from MVA generally improves 
immunogenicity. Chapter 3 of this thesis will examine the opposite hypothesis: 
whether addition of pro-inflammatory inhibitors increases the immunogenicity of 




To activate the adaptive immune system, APCs need to mature and 
present antigens to T cells. This includes presentation of internalized pathogen 
antigens via MHC-II (130). The VACV A35 protein suppresses MHC class II 
specific antigen presentation, and therefore inhibits induction of VACV-specific 
antibody and T cell responses (102, 103). As this gene remains present in MVA, 
a deletion virus was tested for immunogenicity. Infection with a MVA virus lacking 
the A35R results in increased VACV-specific antibodies and T cell responses, 
suggesting deletion of this protein and increasing MHC-II presentation during a 
VACV is another mechanism to increase MVA immunogenicity (104). Chapter 3 
of this thesis will also examine changes in APC maturation, however this will be 
utilizing a recombinant MVA virus and examining surface expression of co-
stimulatory molecules such as CD86. 
Another important mechanism VACV utilizes to suppress the immune 
response is expression of anti-apoptotic proteins, including M1, which will be 
investigated throughout this thesis. One of the inhibitors that remains present in 
the attenuated MVA virus is the F1 protein, an inhibitor of intrinsic apoptosis (4, 
132). As MVA infection relies on cross presentation to present antigens, which is 
dependent on apoptosis of infected cells (47), deletion of the F1L ORF from MVA 
virus was examined for increases in immunogenicity. Infection with this deletion 
virus enhances VACV-specific T cell responses to infection and enhances 
memory T cell responses (97). This supports the conclusion that MVA induces 
immune responses through cross presentation, as increased apoptosis increased 
T cell responses. Chapter 2 of this thesis will introduce M1 as a novel VACV 
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inhibitor of apoptosis. Furthermore, chapter 3 will examine if addition of M1 into a 
recombinant MVA will increase immune responses, potentially through increasing 
the time for antigen presentation, which may allow more direct presentation to 
occur as in the more immunogenic wild-type virus. 
In addition to deleting remaining viral immunomodulators, another avenue 
for increasing MVA immunogenicity that has been explored is the addition of 
adaptive co-stimulatory molecules, such as stimulatory cytokines or T-cell 
adaptor molecules. This has been examined via creation of recombinant viruses 
which express co-stimulatory genes under the control of a viral promoter, or 
through exogenous expression of the molecule in tandem with infection. Not 
surprisingly, addition of co-stimulatory molecules during MVA infection generally 
increases immunogenicity. This is observed with co-expression of cytokines such 
as IL-2, IL-12, IL-15 or IFN-γ, as well as T-cell co-stimulatory molecules such as 
CD80 and CD86 (42). Therefore, addition of genes can also increase MVA 
immunogenicity, specifically if they are activators of the immune response. 
Chapter 3 of this thesis will also examine the insertion of genes into the MVA 
genome. However, instead of inserting known stimulatory molecules, the 
introduced genes examined will be viral inhibitors. This virus, MVA/5.2kb, will 
allow investigation of whether the attenuated qualities of MVA can remain in 







 The MVA/5.2kb virus, the focus of chapter 3 of this thesis, is a 
recombinant MVA virus in which the 5.2kb EcoRI fragment of the parental Ankara 
DNA was inserted into MVA by homologous recombination. Addition of this 
fragment introduces the K1L, M1L, and M2L ORFs into the MVA genome (89). 
As described earlier, K1 and M2 are VACV inhibitors of NF-κB (15, 48, 59, 114, 
133, 134). Chapter 2 will demonstrate the VACV M1 protein is an inhibitor of 
intrinsic apoptosis. Just as MVA, MVA/5.2kb cannot replicate in human cells 
(137). However, the addition of the K1 and M2 genes blocks MVA-induced NF-κB 
in Jurkat, 293T, and RK13 cells (114). Shisler and Jin reported no differences in 
etoposide-induced apoptosis between MVA and MVA/5.2kb, as measured by 
TUNEL assay (114). However, virally-induced differences in apoptosis of infected 
APCs will be explored between these viruses in chapter 3, suggesting the 
stimulation, cell type, and assay of detection may be critical factors for apoptotic 
inhibition by MVA/5.2kb. Chapter 3 of this thesis will investigate MVA/5.2kb 
infection of APCs. As this virus contains inhibitors of NF-κB and apoptosis, the 
hypothesis is that viral clearance will be delayed, potentially increasing changes 
for antigen presentation. Specifically, APC maturation and cytokine production as 
well as T-cell activation will be compared between MVA and MVA/5.2kb.  
 
Identification of anti-apoptotic proteins, using MVA as a platform 
While MVA is being tested and altered as a vaccine vector against 
multiple diseases, it is also a valuable research tool (129). The attenuated nature 
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of MVA results in activation of pathways after infection that are often inhibited by 
the wild-type VACV. One such pathway is the apoptosis pathway. The attenuated 
MVA virus retains only three viral intracellular inhibitors of apoptosis: E3, F1 and 
B22. As mentioned previously, infection of APCs with MVA induces apoptosis 
due to the lack of other viral immunomodulators of apoptosis (24). However, 
MVA-induced apoptosis is not a characteristic of all infected cells. For example, 
HeLa cells infected with MVA do not demonstrate hallmarks of apoptosis, such 
as caspase activation. Interestingly, deletion of the VACV anti-apoptotic E3 
protein from MVA results in a virus that induces apoptosis in HeLa cells after 
infection (39). This demonstrates the ability of different VACV viral proteins to 
function in different cell types. As MVA infection induces apoptosis in APCs, 
despite the presence of E3, F1 and B22, this serves as a platform to examine if 
re-introduction of uncharacterized VACV proteins into MVA results in inhibition of 
apoptosis. This platform not only allows characterization of VACV anti-apoptotic 
proteins, but also allows identification of proteins whose molecular functions are 
distinct from the three remaining inhibitors in MVA.  
Chapters 2 and 4 of this thesis will utilize this system to investigate the M1 
protein and its ability to inhibit apoptosis. These chapters will demonstrate how 
M1 inhibits intrinsic apoptosis (chapter 2) and preliminary data which suggests 
M1 can inhibit extrinsic apoptosis and inflammasome activation will be presented 
in chapter 4. M1 is a protein that, until this work, had no characterized function. 
The only information known prior to this thesis was that M1 was an ankyrin (ANK) 
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repeat containing protein. Therefore, ANK repeats and their functions will be 
discussed in the following section.  
 
1.4  Poxviral ankyrin (ANK) repeat proteins 
ANK repeat motif 
 The ANK repeat motif is one of the most abundant motifs found in nature, 
and is often associated with protein-protein interactions. One repeat consists of 
33 amino acid (aa) residues arranged in a helix-loop-helix configuration, where 
two α-helices are arranged in an antiparallel manner and connected by a loop 
that projects outward at approximately a 90° angle, sometimes forming a β-
hairpin structure (Fig. 1.6A). Canonically, the inner helix of an ANK repeat is 
seven residues long, spanning from positions 5-12 of the 33 aa motif, while the 
outer helix is nine residues long, spanning from positions 15-24 (74, 90). 
Because of this, ANK repeats generally have curved structure, which is attributed 
to the length differences between the helices. Additionally, the recognizable 
shape of ANK repeat-containing proteins is influenced by signature residues that 
are found in the repeat motif. The most well-known motif is TPLH located at 
positions 4-7 of the 33 aa repeat. In this motif, a turn occurs due to the presence 
of a proline at position 5, which is held in position via hydrogen bonding with the 
threonine at position 4 and the histidine at position 7. Transition from the helix 
into the loop structure is mediated by glycine residues at positions 13 and 25 of 
the ANK repeat. The helices interact through hydrophobic interactions, which are 
mediated by nonpolar residues at positions 6, 8, 9, 10, 17, 18, 20, 21, and 22, 
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forming a hydrophobic core (74, 90). When multiple ANK repeats are present, the 
helices from one repeat pack against the helices of the next repeat, which is 
stabilized by multiple hydrophobic interactions (Fig. 1.6B). The loops of multiple 
ANK repeats interact via hydrogen bonding to form a continuous β-sheet (Fig. 
1.6C). Additionally, each repeat is rotated from the other counterclockwise by 2-
3°, resulting in an overall left-handed superhelical twist (Fig. 1.6D). Chapters 2 
and 4 of this thesis will investigate the poxviral ANK protein M1. Therefore, an 
understanding of ANK repeats is pertinent to gain insight into the structure of M1. 
Known proteins containing ANK repeats have anywhere from 1 to 34 ANK 
repeat motifs, however the majority of ANK proteins contain six or fewer repeats. 
The M1 protein, which is the focus of this thesis, has 14 ANK repeats. ANK-
containing proteins can consist solely of ANK repeats (as is the case with M1), or 
have these in combination with other domains. Despite the conserved nature of 
ANK repeats, proteins containing this motif have a variety of functions. Functions 
such as cell cycle regulation, transcriptional control, cytoskeleton integrity, cell-
cell signaling, and control of the inflammatory response have been attributed to 
this family of proteins (90).  
A unifying theme is most ANK-containing proteins mediate protein-protein 
interactions, however ANK repeat domains themselves have no enzymatic 
function. Instead, this motif is regulatory, where the outcome is dependent on the 
bound protein. For example, the IκBα protein, which was described previously in 
the NF-κB section, is an ANK repeat protein. The ANK repeats of IκBα sequester 
the p50-RelA complex in the cytoplasm via interactions such as hydrogen bonds, 
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salt bridges, and hydrophobic interactions, not sequence specificity (74). Thus, 
what an ANK protein interacts with is not due to the sequence of the motif, but 
rather the shape, therefore sequence cannot predict function. Rather, the 
concave or convex shape of the ANK repeat creates binding sites for other 
molecules (58, 77).  
ANK repeat proteins are found in all domains of life, however they are 
most abundant in eukaryotes. Viral and bacterial ANK proteins are thought to 
have been obtained through horizontal transfer (90). Interestingly, as compared 
to all other viruses, poxviruses contain a particularly large amount of ANK repeat 
proteins, however many remain uncharacterized (58). Chapter 2 will demonstrate 
that the VACV M1 ANK protein is a regulator of apoptosis, exerting its function 
through interactions with the apoptosome. Additionally, chapter 4 will examine 
other caspase inhibitory functions by the M1 protein. To understand how M1 
compares to other known poxviral ANK repeats in terms of structure and 
function, they will be discussed in the next section. 
 
Poxviral ANK proteins 
ANK proteins form the largest family of poxvirus proteins. They are 
encoded by almost all Orthopoxviruses, which will be the focus of this section as 
VACV is contained in this genus. These are usually large proteins ranging from 
400-800 residues in length (118). Structurally, poxviral ANK repeat-containing 
proteins have N-terminal ANK repeats often followed by a C-terminal domain that 
has sequence homology to the cellular F-box. This arrangement is denoted as 
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the pox protein repeats of ankyrin-C-terminal (PRANC) domain. The cellular F-
box motif is associated with E3 ubiquitin ligase complexes, which result in 
ubiquitination and proteasomal degradation of the target protein. Poxviral ANK 
proteins that lack F-boxes often have this domain deleted or truncated. Until this 
thesis, the absence of an F-box which was not due to deletion or truncation was 
seen only in certain poxviral proteins with host range function (58, 118). Chapter 
2 will describe how M1, a poxviral ANK protein lacking an F-box, inhibits intrinsic 
apoptosis. Therefore, this thesis will expand the functions associated with the 
small group of poxviral ANK proteins which lack a F-box. 
ANK-repeat containing proteins are found in the terminal regions of the 
poxviral genome, and therefore remain separate from the central, critical proteins 
needed for the poxviral life cycle. CPXV is the only orthopoxvirus whose genome 
contains all orthopoxvirus ANK repeat-containing proteins, approximately 18 
proteins, in their fully intact form. Interestingly, a correlation exists between the 
size of the orthopoxviral genome and the number of ANK proteins encoded. For 
example, the VARV genome is the smallest genome in the orthopoxviruses, and 
possesses only four intact ANK repeat-containing proteins. As mentioned above, 
CPXV has the largest genome and possesses 18 ANK proteins. Additionally, the 
difference in the number of ANK-containing poxviral proteins associates with viral 
host range, with CPXV having the highest range and VARV the smallest. 
Therefore, poxviral ANK proteins are often thought to play an important role in 
virus host range. This is because of the observation that attenuated poxviruses, 
which also have restricted host ranges, and have lost many ANK proteins (58). 
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For example, the MVA genome, retains only one ANK protein, the 68-kDa 
Ankyrin-like (68k-ANK) protein. As described previously, MVA has a very narrow 
host range (137). Interestingly, a mutant virus lacking 68k-ANK has impaired late 
protein synthesis due to decreased transcription of late viral genes, again 
demonstrating the correlation between ANK proteins and life cycle completion in 
the host (129).  
The host range function of poxviral ANK proteins is often associated with 
protein-protein interactions mediated by ANK repeats, and not the presence of an 
F-box. This was influenced by investigation of the K1 protein, which was 
described earlier in this chapter. K1 is composed solely of ANK repeats, and a 
VACV lacking K1 demonstrates replication restriction in human cells. Therefore, 
ANK repeats must be responsible for this function. To corroborate this, the F-box 
region present in 68k-ANK of MVA is dispensable for rescuing the mutant 
phenotype described above (58, 129). 
Altering host range is not the only function of poxviral ANK proteins. As 
mentioned above, most poxviral ANK proteins contain a cellular F-box-like motif. 
Therefore, much of what is known about this family of ANK proteins is how they 
interact with cellular ubiquitination machinery. To ubiquitinate a protein, three 
classes of enzymes are used. First, ubiquitin is activated, via the attachment of 
ATP, by the ubiquitin activating enzyme (E1). Second, the activated ubiquitin is 
transferred to a ubiquitin conjugase (E2). Finally, ubiquitin ligases (E3) transfer 
ubiquitin to the target protein. There are multiple types of E3 ubiquitin ligases, 
each of which recognizes different substrates; however, one of the most well-
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studied E3 ligases is the SCF1 complex. This complex consists of the RING-
domain protein RBX1 (RING-box 1), cullin 1 (CUL1), S-phase-kinase associated 
protein 1 (SKP1), and a protein with an F-box, which binds SKP1. Cellular F-box 
proteins typically have a second-protein binding domain which can bind and 
recruit proteins to the E3 complex for ubiquitination and proteasomal 
degradation. Bioinformatic analyses identified homology between the C-terminus 
of poxviral ANK repeat-containing proteins and cellular F-boxes. Since then, 
multiple poxviral ANK proteins have been demonstrated to bind SKP1 via 
immunoprecipitation assays. Therefore, poxviral ANK proteins can mimic host F-
box proteins, where the ANK domain determines the bound substrate, and the F-
box-like domain binds SKP1 of the SCF1 complex, resulting in ubiquitination (58, 
118).  
There are other functions attributed to poxviral ANK proteins beyond host 
range and protein ubiquitination, however this information is more limited. As 
mentioned previously, VACV K1 is a poxviral ANK protein. Earlier in this chapter, 
K1 was described as an inhibitor of the NF-κB pathway. Inhibition of this pathway 
is also observed with other orthopoxvirus ANK proteins, such as the VARV G1 
protein, the CPXV 006 protein, and the monkeypox virus (MPXV) protein 003. 
However, unlike K1, which works at the level of PKR or transcriptional regulation 
and has no F-box, these other poxvirus proteins contain an F-box and prevent 
formation of an active NF-κB complex through biding of the p50 subunit (15, 58, 
134). Regulation of viral replication has also been observed by the CPXV CP77 
protein. CP77 binds with the chromosome remodeling protein HMG20A, resulting 
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in HMG20A release from the viral DNA and an increase in viral replication. 
Alternative functions, other than what has been described, have been observed 
in poxviruses outside in the Orthopoxvirus genus. For example, avipoxviruses 
have ANK proteins that can inhibit chicken IFN-2. Additionally, the OV126 protein 
of ORF virus (ORFV), a poxvirus which infects sheep and goats, localizes to the 
mitochondria. However, no apoptotic effect was observed. Therefore, the OV126 
protein represents one of many ANK proteins whose full molecular mechanism 
remains unknown (58).  
While much has been deciphered in terms of poxviral ANK protein 
function, there are still gaps in the knowledge as to how each of these proteins 
function. For example, and of specific importance for this thesis, VACV strain WR 
contains approximately eight ANK ORFs (58), however prior to this thesis the 
function of only three were known (Table 1.4) (14, 15, 18, 26, 87, 98, 133, 134). 
This demonstrates a need to elucidate the mechanism of uncharacterized ANK 
proteins. Experiments presented in this thesis will expand the knowledge of 
VACV ANK repeat proteins. Chapter 2 will establish the previously 
uncharacterized M1 ANK protein as an inhibitor of intrinsic apoptosis, a feature 
not found in other characterized VACV WR ANK proteins. Additionally, chapter 4 
will explore other caspase-binding abilities of the M1 protein. To appreciate the 
importance of these findings, what was known about M1 prior to this thesis, as 
well as information discovered at the early stages of this study, will be reviewed 




VACV M1 protein 
The M1L gene is located in the left terminal region of the VACV genome 
and is transcribed early during infection, with mRNA detectable after 30 minutes 
(4, 139). The encoded M1 protein is a 54 kDa protein which consists solely of 
ANK repeats (4). Utilizing the protein structure prediction software Protein 
Homology/analogY Recognition Engine V 2.0 (PHYRE2), and the expertise of 
our colleague Mark Kvansakul, we created a predicted M1 crystal structure (Fig. 
1.7). This structure suggests M1 harbors 14 predicted ANK repeats, and 
confirmed the absence of a C-terminal F-box. Therefore, the function of M1 is 
likely mediated via protein-protein interactions and not cellular ubiquitin ligase 
machinery. Like M1, the K1 protein is composed only of ANK repeats. Because 
of homology between these two proteins, M1 was originally proposed to be a 
host range protein. However, this had not been validated (112). In chapter 2 we 
will present evidence against this proposition. 
To grasp the potential importance of the M1 protein, we examined M1 
orthologs amongst the Orthopoxvirus genus, utilizing the online poxviral Viral 
Ortholog Clusters (VOCs) database, available from the open access Viral 
Bioinformatics Resource Center (VBRC). Orthologs of M1 were found throughout 
orthopoxviruses, including VARV, CPXV and MPXV, among others. Additionally, 
we aligned a subset of these orthologs using ClustalOmega to visualize 
sequence similarity among M1 proteins (Fig. 1.8). Despite an initial region of non-
conserved area, which is attributed to an improperly designated start codon, 
conservation was observed amongst the aligned sequences. Overall, the high 
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number of M1 orthologs, and the sequence conservation amongst them, 
suggests that M1 is likely an important poxviral protein. Therefore, elucidating the 
mechanism of this protein could shed important information about poxvirus 
biology, and is one of the main objectives covered in this thesis. 
 
1.5  Thesis outline 
The goals of this thesis are to (i) elucidate the mechanism of the poxviral 
M1 ANK protein, and (ii) investigate the efficacy of APC activation in vitro and T 
cell activation in vivo by the recombinant MVA/5.2kb virus, a virus which adds the 
M1L gene (in addition to other genes) back into MVA. This thesis expands the 
knowledge of VACV immunomodulatory proteins and their effects on VACV-
specific immune responses. 
Chapter 2 describes the characterization of the M1 protein as an inhibitor 
of intrinsic apoptosis. Here, data demonstrate that the addition of M1 back into 
the MVA genome blocks MVA-induced apoptosis of infected APCs. M1 is further 
characterized to inhibit intrinsic apoptosis independent of extrinsic cross-
activation. Ectopic expression of M1 corroborates the infection data, showing M1 
inhibits STS-induced intrinsic apoptosis. This transfection system further 
demonstrates M1 inhibits downstream of mitochondrial permeabilization, a key 
event for intrinsic apoptosis. Finally, evidence is provided suggesting inhibition is 
due to binding of M1 to the formed apoptosome, and likely to active procaspase-
9, specifically. Therefore, M1 binding blocks downstream executioner caspase 
cleavage and apoptosis activation. This is the first poxviral protein demonstrated 
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to inhibit apoptosis after formation of the apoptosome, therefore adding to the 
repertoire of poxviral anti-apoptotic functions. 
Chapter 3 investigates the recombinant MVA/5.2kb virus for its ability to 
activate innate and adaptive immune responses after infection. Data demonstrate 
that addition of the M1, K1 and M2 proteins inhibit MVA-induced apoptosis and 
NF-κB activation, as expected based on their published functions. The 
hypothesis that addition of these inhibitors will delay viral clearance, therefore 
extending antigen presentation and increasing immune responses, is examined. 
Data demonstrate that APC maturation occurs after infection with the MVA/5.2kb 
virus, suggesting potential for antigen presentation. Additionally, while certain 
pro-inflammatory cytokine responses are dampened (such as TNF-α), 
examination of interleukin production demonstrates this is not a universal trait, 
and suggests infiltration of immune cells may occur. However, when taken in 
vivo, data reveal that infection of mice with the MVA/5.2kb virus results in fewer 
VACV-specific T cells than infection with MVA. This study highlights the disjunct 
findings between in vitro and in vivo studies, and suggests that the MVA/5.2kb 
virus does not increase immune responses compared to MVA infection.  
 Chapter 4 will introduce preliminary data investigating the ability of M1 to 
inhibit caspases, other than caspase-9, using the MVA/M1L virus, ectopic 
expression of M1, and the yeast system that are described in chapter 2. Infection 
of APCs with MVA activates caspase-8 and caspase-1, important for extrinsic 
apoptosis and inflammasome activation, respectively. Utilizing immunoblotting, 
data show that addition of M1L into the MVA genome inhibits cleavage of both 
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procaspase-8 and procaspase-1. This is corroborated for caspase-1 using an 
ELISA measuring secreted IL-1β, a product of inflammasome activation, and for 
caspase-8 utilizing the transfection system and extrinsic apoptosis activation by 
TNF+CHX. Finally, data utilizing a yeast system, which allows direct inhibition to 
be examined, suggests M1 can additionally inhibit caspases 1, 2, 3, 5 and 7. 
Future directions of validating the inhibition of these caspases in mammalian 






Figure 1.1: Poxvirus replication cycle. Poxviruses bind and enter host cells, 
leading to transcription and translation of early genes. Next, uncoating of the viral 
core occurs, which is followed first by DNA replication and then by intermediate 
and late transcription and translation. Viruses assemble and transition from 
immature virions (IVs) to mature virions (MVs). MVs acquire additional 
membranes forming a wrapped virion (WV) which traverses to the cell 
membrane. WV fusion with the cell membrane leads to release of infectious 
extracellular enveloped virions that can infect neighboring cells. The step in 
which MVA replication is blocked in human cells is denoted. Figure adapted from 















Figure 1.2: Extrinsic and intrinsic apoptosis pathways. Extrinsic apoptosis is 
initiated through ligand binding of cell membrane death receptors, leading to 
formation of the death-inducing signaling complex (DISC). Procaspase-8 is 
cleaved to active caspase-8 which can lead to apoptosis by cleaving executioner 
caspases 3, 6 and 7 directly or through cleavage of Bid, resulting in tBid, and 
activation of intrinsic apoptosis. Intrinsic apoptosis is activated either through tBid 
or by internal stresses. Intrinsic stimuli result in regulation of the Bcl-2 proteins, 
resulting in Bax and Bak insertion into the mitochondrial outer-membrane, 
forming pores that lead to mitochondrial permeabilization and release of 
cytochrome c. Cytochrome c activates Apaf-1 which can then pair with 
procaspase-9, resulting in the apoptosome and active procaspase-9. Executioner 
caspases are again cleaved, leading to cleavage of host proteins, resulting in 
apoptosis. Figure adapted from Sendoel A, Hengartner MO. 2014. Apoptotic Cell 
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Figure 1.3: NF-κB pathway. Activation of NF-κB occurs through a variety of 
stimuli, such as TNFR activation or PKR activation, shown above. Stimuli 
converge on the IKK complex, composed of IKKα, IKKβ, and NEMO, leading to 
IKK activation and subsequent phosphorylation of IκB proteins. After 
phosphorylation, IκB undergoes polyubiquitination-driven proteasomal 
degradation, releasing the NF-κB transcription factor. NF-κB, designated as a 
p50-RelA complex, translocates to the nucleus where it binds κB DNA sites, 
resulting in transcription. Figure adapted from Gilmore TD. 2006. Introduction to 











Figure 1.4: Poxviral inhibitors of NF-κB. The NF-κB pathway is outlined, 
showing pertinent cell surface an internal signaling molecules that converge at 
the IKK complex, resulting in its activation. IKK phosphorylates IκB, leading to its 
polyubiquitination and degradation, freeing NF-κB, designated as a p50-RelA 
complex, and allowing nuclear translocation. In the nucleus, NF-κB binds DNA 
resulting in transcription. The characterized poxviral inhibitors, and where in the 
pathway they inhibit, are designated in red. Figure adapted from Smith GL, 
Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, Ferguson BJ, 
Sumner RP. 2013. Vaccinia virus immune evasion: mechanisms, virulence and 






Figure 1.5: Innate and adaptive immune system. The innate immune system 
is activated through pattern recognition receptor (PRR) identification of 
pathogens, such as viruses. This leads to activation of pro-inflammatory 
transcription factors that recruit immune cells to clear the infected area, such as 
NK cells. Additionally, infection of antigen presenting cells (APCs), such as 
dendritic cells (DCs), leads to maturation and upregulation of T cell co-
stimulatory molecules CD80 and CD86. APCs then interact with T cells via their 
major histocompatibility complex (MHC) to differentiate them into CD4+ or CD8+ 
T cells, initiating the adaptive immune system. Additionally, after antigen 
recognition, antibody producing B cells differentiate either with or without the 
assistance of CD4+ T cells. Figure adapted from Gi M, Im W, Hong S. 2009. 




















Figure 1.6: Ankyrin (ANK) repeat structure. (A) The ribbon structure of the 
fourth ankyrin repeat of the gankyrin protein protein is shown as an example of 
the structure of an individual ANK repeat. (B) Side chains of the residues which 
form the hydrophobic core the p18 protein are shown to demonstrate these 
interactions. (C) The hydrogen bonding that occurs between the loops (b-sheets) 
of ankyrin repeats are shown in purple from the p18 protein. (D) The human 
ankyrin-R protein is depicted, showing the curved structure that often occurs in 
ANK-containing proteins. Figure adapted from Li J, Mahajan A, Tsai M-D. 2006. 








     
Figure 1.7: M1 predicted crystal structure. Protein Homology/analogY 
Recognition Engine V 2.0 (PHYRE2) software was used to create a predicted 
crystal structure of M1, utilizing the poxviral K1 protein as a reference. The N- 
and C-terminus are marked, and each of the 14 predicted ANK residues is 
represented by a different color. (A) A side view of the predicted M1 protein. (B) 














Figure 1.8: Alignment of M1 orthologs. Amino acid sequences of M1 orthologs 
from different orthopoxvirus strains were collected from the Viral Ortholog 
Clusters (VOCs) database, available from the open access Viral Bioinformatics 
Resource Center (VBRC). Sequences were then aligned to the VACV WR 
sequence of M1 for comparison. Positions with a single, fully conserved residue 
are marked by an asterisk (*). Positions where conservation occurs in amino acid 
properties is represented by a colon (:). Abbreviations: VACV: Vaccinia virus; 
ECTV: Ectromelia virus; CMLV: Camelpox virus; CPXV: Cowpox virus; MPXV: 
Monkeypox virus; RPXV: Rabbitpox virus; RCNV: Racconpox virus; TATV: 








Table 1.1: VACV inhibitors of apoptosis. 
Protein  Pathway Inhibited Function 
CrmC / CrmE Extrinsic Sequesters TNF-α (2) 
B13 Extrinsic and Intrinsic Binds caspase-8 and -9 (33, 45, 67) 
B22 Extrinsic Binds caspase-8 (17, 79) 
F1 Intrinsic Binds Bim (19, 121, 131) 
N1 Intrinsic Binds Bad and Bim (6, 27) 
E3 Extrinsic and Intrinsic Binds dsRNA (46, 68) 
vGAAP Extrinsic and Intrinsic Alter Ca2+ distribution? (21, 54, 108) 
*M1 Intrinsic Inhibits caspase-9 (105) 
 











Table 1.2: Innate immune activation by wild-type VACV vs. MVA. 
Pattern Recognition Receptor Wild-type VACV MVA 





RIG-I-like receptors MDA-5 (93) MDA-5 (31) 
















Table 1.3: VACV proteins whose deletion increase MVA immunogenicity. 
Protein Function 
B16 Secreted IL-1β binding protein (28, 119, 144) 
C12 IL-18 binding protein (36) 
A41 Secreted chemokine binding protein (25) 
K7 NF-κB inhibitor (41) 
A46 NF-κB inhibitor (60, 129) 
C6 IRF3 inhibitor (41, 44, 125) 
N2 IRF3 inhibitor (43) 
A35 Inhibits MHC-II presentation (104) 













Table 1.4: VACV WR ANK repeat proteins and functions. 
ORF (12, 58, 117) Protein Function 
005-008L / 211-214R B25 Unknown  
014-017L VARV D8 homolog Unknown  
019L C9 Unknown  
030L M1 Inhibits caspase-9* (105) 
031L K1 Host range protein (98) 
Inhibits NF-κB (14, 15, 133, 134) 
Inhibits IFN (87)  
186R B4 Facilitates viral spread (18) 
188R B6 Unknown  
199R / 202R B18 Type I IFN binding protein (26) 
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Chapter 2: Vaccinia virus encodes a novel inhibitor of apoptosis that 
associates with the apoptosome 
2.1 Introduction 
 Apoptosis is a powerful anti-viral mechanism (23, 46). There are two 
classical forms of apoptosis: extrinsic (mediated by caspase-8) and intrinsic 
(mediated by caspase-9) (7, 50). Intrinsic apoptosis often is triggered during virus 
infection of the host cell (23).  In this case, there is depolarization and 
permeabilization of the outer mitochondrial membrane. Released cytochrome c 
(cyt c) and dATP then stimulate Apaf-1 oligomerization (7, 34, 49, 71). The 
apoptosome is next formed when monomeric, inactive procaspase-9 proteins are 
recruited to Apaf-1 oligomers via caspase recruitment domain (CARD)-CARD 
interactions (54, 78). In the apoptosome, procaspase-9 can exist as either 
homodimers or Apaf-1-procaspase-9 heterodimers. In both cases, procaspase-9 
conformationally changes to an active state, and cleaves procaspase-3 to trigger 
apoptosis. Autocleavage of procaspase-9 also occurs after activation resulting in 
processed caspase-9 complexes that retain ability to cleave procaspase-3 while 
associated with Apaf-1 (94, 95).  Thus, both unprocessed and processed forms 
of active caspase-9 can cleave procaspase-3. Activated caspase-3, in turn, 
cleaves cellular PARP-1 and other protein substrates, culminating in cell death 
(50). 
 Poxviruses are master manipulators of the host, using multiple strategies 
to evade apoptosis and other anti-viral immune responses (60, 79, 87). Wild-type 
vaccinia virus (VACV) strain WR is one of the best-studied poxviruses, and it 
77 
 
expresses at least five intracellular anti-apoptosis proteins: B13 (SPI-2), F1, N1, 
B22 (SPI-1) and E3, suggesting that apoptosis is an important host response to 
defend against during virus infection (87). A few other VACV strains (Lister, 
USSR and Evans, but not WR) and camelpox virus encode vGAAP, a protein 
that inhibits ER-induced apoptosis (35, 36, 74).  The current hypothesis is that 
VACV expresses multiple apoptosis antagonists to protect against a variety of 
pro-apoptotic pathways triggered in different host cells during an infection in vivo.   
Modified Vaccinia virus Ankara (MVA) is an attenuated VACV that was 
created by serially passaging wild-type VACV over 500 times (58). As a result, 
approximately 15% of the VACV genome is deleted or truncated in MVA (3).  
With respect to anti-apoptosis genes, MVA retains only E3L, F1L and B22R (3). 
Despite the presence of these three genes, MVA infection nevertheless induces 
apoptosis in several immune cell types (18, 37, 55, 68). Thus, MVA infection of 
immune cells provides an excellent platform to identify novel WR-encoded anti-
apoptosis proteins not encoded by MVA, which have mechanisms distinct from 
E3, F1 and B22 (13, 15, 33, 57).   
 Ankyrin (ANK) repeats are one of the most abundant motifs in nature (9, 
53).  These are 33-residue motifs that form alpha helical structures and provide 
platforms for protein-protein interactions (53). This property has led to the use of 
designed ANK repeat proteins (DARPins) as a drug development platform (30, 
66). VACV strain WR encodes at least eight known or predicted ANK proteins, 
including: 005-008 and 211-214 (Copenhagen B25R homologs), 014-017 (variola 
virus strain Bangladesh D8L homologs), 019 (Copenhagen C9L homolog), 030 
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(M1L), 031 (K1L), 186 (B4R), 188 (B6R), 199 and 202 (B18R) (40, 81). However, 
only three of the WR ANK proteins (K1, B4 and B18) have reported functions (2, 
11, 12, 14, 24, 59, 65, 92, 93). Thus, the study of the remaining ANK proteins is 
likely to uncover novel aspects of poxvirus biology.   
The goal of this study was to identify a function for the VACV ANK-
encoding M1L gene, a gene with no previously ascribed function that is located 
within a region of the WR genome that was deleted during the derivation of MVA. 
Because multiple natural and synthetic ANK proteins (e.g., DARPINs) inhibit 
apoptosis (25, 27, 30, 56, 76), M1 may possess this same function. Interestingly, 
M1 inhibited intrinsic apoptosis under several conditions and in multiple cell lines. 
Next, biochemical hallmarks of the intrinsic apoptosis signal transduction 
pathway were examined to define the step of the apoptosis pathway that M1 
targets.  
 
2.2 Materials and methods 
Cell lines 
Human cervical carcinoma (HeLa) cells, human embryonic kidney 293T 
(293T) cells and human acute monocytic leukemia (THP-1 cells) were obtained 
from the American Type Culture Collection (ATCC). Rabbit kidney (RK13) cells 
were a kind gift from Dr. Grant McFadden (Arizona State University). Chicken 
embryo fibroblast (CEF) cells were obtained from Charles River Laboratories.  
Wild-type and Caspase-8 knockout Jurkat cells were obtained from Dr. Ralph 
Budd (University of Vermont). HeLa and 293T cells were cultured in Eagle’s 
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minimal essential medium (EMEM) supplemented with 10% FBS and 2 mM L-
glutamine.  MEF, HeLa, and 293T cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% FBS and 2 mM L-glutamine.  
THP-1 and Jurkat lines were cultured in RPMI-1640 medium supplemented with 
10% FBS and 2mM l-glutamine.  For all experiments using THP-1 cells, cells 
were differentiated with medium containing 100ng/mL phorbol 12-myristate 13-
acetate (PMA; Sigma) for 48 h prior to infection.  
 
Plasmids and transfections 
Plasmid pM1L-V5 was created by PCR amplification of the VACV strain 
WR M1L gene in which a Kozak sequence was engineered onto the N-terminus 
of M1L, and a V5 epitope tag sequence was engineered onto the C-terminus of 
the gene.  The M1L ORF was amplified using the primers (5’-TAAGAATTCGCCA 
CCATGGCTATATTTGTTATAGAG-3’) and (5’- GGT ACC TTA TGT AGA ATC 
AAG ACC AAG TAG AGG ATT AGG GAT AGG TTT TCC AAA ATA ATC ATC-
3’), containing the Eco RI and Kpn I restriction enzyme sites (in italics), Kozak 
(italics and underlined) and stop codon (underlined) sequences and the V5 
sequence (bolded). The amplicon was cloned into plasmid pCI (Promega). A 
synthetic M1L gene with codons optimized for E. coli expression was purchased 
from Bioneer Pacific (Kew East, Victoria, Australia) and the coding region was 
amplified using these following primers: 5’-GCGGATCCGCCATGATCTTCGTTA 
TTGAAAG-3’ and 5’- GCCTCGAGCTAAAAATAGTCATCAAAAAC-3’. The 
product was cut with BamHI and XhoI and ligated into pGALL-(TRP1)-MCS for 
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yeast expression (45).  pF1L-FLAG encodes a FLAG-tagged F1 protein and has 
been described previously (90). Plasmid pC9DN-FLAG contains a C287S 
mutation of pro-caspase-9. Therefore, this plasmid expresses a dominant 
negative mutant pro-caspase-9 protein that interacts with Apaf-1 but lacks 
enzymatic activity. pN-Apaf-1-myc expresses the N-terminal region (aa 1-559) of 
Apaf-1 that interacts with caspase-9 (44). Both pC9DN-FLAG and pN-Apaf-1-
myc were kind gifts from Dr. Gabriel Núñez (University of Michigan). Plasmid 
pHA-K1L expresses a hemagglutinin (HA)-tagged K1 protein and has been 
described previously (12, 92).  All mammalian expression plasmids were 
transiently transfected into cells using the TransIT 2020 reagent (Mirus) following 
the manufacturer’s instructions.   
 
Creation and characterization of MVA/M1L viruses  
The modified vaccinia virus Ankara (MVA) strain of VACV was obtained 
from Dr. Bernard Moss (National Institutes of Health) (3).  An MVA virus 
containing the M1L transcriptional unit (MVA/M1L) was created by using 
homologous recombination in CEFs. The M1L gene and its natural promoter 
were PCR amplified from purified vaccinia virus strain WR DNA using primers 
(5’-ACCGGATCCTTCTTGACATAAAAG-3’) and (5’-CTCTCTATGAATCATCATC 
TGTTCC-3’). The resultant PCR product was inserted into pLW44 (provided by 
Dr. Bernard Moss, National Institutes of Health) in a multiple cloning site (MCS) 
directly downstream of the GFP gene to create pLW44/M1L. pLW44/M1L 
retained the GFP gene linked to the vaccinia virus p11 promoter, but lacked the 
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adjacent vaccinia virus modified H5 promoter that might have otherwise 
influenced the expression of the inserted M1L gene. GFP expression was used 
as a stable screening marker during isolation.  Sequence analysis of a 
representative plasmid indicated that no new mutations had been introduced into 
the amplicon.  MVA/M1L viruses were generated when recombination occurred 
between the homologous del III regions in both the MVA genome and 
pLW44/M1L in cells that were infected and transfected. Cells were infected with 
MVA (MOI = 0.05 PFU/cell) and then transfected with pM1L/pLW44. Using this 
approach, the M1L gene and a GFP gene would be inserted into the del III region 
of MVA. After a 48 h incubation period, cells were collected and subjected to 
three freeze-thaw cycles to release viruses. Serial dilutions of viruses were 
inoculated onto CEF monolayers, and then monolayers were incubated in 
medium containing 0.5% methylcellulose.  Recombinant viruses were selected 
based on the development of GFP-expressing foci. Four rounds of plaque 
purification were performed. The presence of the M1L gene in the MVA del III 
region and the lack of contaminating parental viral DNA was verified by PCR 
analysis of the isolated viruses’ genome, using primers that were specific for site 
either flanking the del III region or present in and unique to the M1L gene. The 
primer sets used were: M1F (5’-CATCGAATACTTCGTAAGATACTCC-3’) and 
M1R (5’-GAGAGTAAATTGTTGCAAAATATACAGAAA-3’) to detect M1L and F1 
(5’-GTAACAAAAGTATTGGTAATCGTGTC-3’) and R1 (5’-GAATCTACTCATCTA 
AACGATTTAG-3’) to PCR amplify the del III region to ensure that M1L was 
inserted in the correct region.  PCR products were analyzed by agarose gel 
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electrophoresis and amplicons were detected by staining the gel with an ethidium 
bromide solution (Pierce). 
The expression of the M1L gene was detected by using semi-quantitative 
RT-PCR. PMA-simulated THP-1 cells were either mock infected or infected with 
MVA, MVA/M1L or WR at an MOI of 2. At 6 h pi RNA was collected using the 
RNeasy Mini kit (Qiagen), following the manufacturer’s instructions. From each 
sample, 500 ng of RNA was reverse transcribed into cDNA as follows: First, total 
RNA for each sample was incubated with 0.5 µg of oligo dT primer (IDT) at 70°C 
for 5 min, followed by a 5 min incubation at 4°C to anneal primers. Next, samples 
were reverse transcribed into cDNA using 10 units/µL of M-MulV Reverse 
Transcriptase (New England Biolabs). 10 µl of template cDNA from each sample 
were used for PCR amplification, using a Mastercycler (Eppendorf) and Go Taq 
Flexi DNA polymerase (Promega) as per manufacturer’s instructions.  Primers 
designed to amplify M1L were (5’-CGAGTATTATCTATCTCTTTATG-3’) and (5’-
GTTTATATGAAGTAAAGTATC-3’).  Primers to amplify β-Actin were (5’-AGTTG 
CGTTACACCCTTTCT-3’) and (5’-ACCTTCACCGTTCCAGTTT-3’). PCR 
conditions were 1X (95°C, 2 min), 25X (95°C, 45 s; 41°C 30 s; 72°C 90 s), and 
1X 72°C, 5 min. PCR conditions for β-Actin were 1X (95°C, 2 min), 25 X (95°C, 
45 s;54°C, 45 s; 72°C, 20 s), 1X 72°C, 5 min. PCR products were analyzed by 
agarose gel electrophoresis, and amplicons were detected by staining the gel 




Immunostaining and quantification of foci formation in infected cellular 
monolayers 
 CEF or RK13 cellular monolayers in six-well plates were infected (MOI = 
50 PFU/well) with either MVA, MVA/M1L or WR.  After 24 h, infected monolayers 
were fixed and permeabilized with methanol-acetone (1:1) for 2 min at room 
temperature.  Cells were then washed with PBS and incubated for 1 h at room 
temperature with anti-vaccinia virus antiserum (1:1,000; Accurate Chemical and 
Scientific Corp, YVS8101) in PBS containing 3% FBS.  After two washes with 
PBS, fixed monolayers were incubated with HRP-conjugated anti-rabbit 
antiserum (1:1,000; Calbiochem) in PBS containing 3% FBS for 1 h at room 
temperature.  Cells were washed two times with PBS and foci were visualized 
using PBS containing o-Dianisidine (Sigma) and 0.2% H2O2.  Images of foci were 
taken using a Powershot SD1300 IS camera (Cannon).  The diameters of foci 
were measured by using Image J software.  Pixels were scaled to mm by 
determining the number of pixels needed to draw a 1 mm using the ruler as a 
reference, and foci were subsequently measured using this scale.  Foci size is 
represented as mean size ± SEM of 35 (CEF) or 10 (RK13) foci per sample.  The 
Student’s t-test was used to determine statistically significant differences in size 
amongst experimental conditions. 
 
Viability assays 
For trypan blue exclusion assays, PMA-stimulated THP-1 (1x106) cells in 
12-well plates were mock-infected, infected at a MOI of 5 or treated with 1 µM of 
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staurosporine (STS; Selleck Chemicals) for 24 hr.  Detached and adherent cells 
were collected, centrifuged (250 X g, 5 min), and resuspended in complete 
medium.  An aliquot was mixed 1:1 with trypan blue dye (Thermo Scientific).  
Cells were counted by using a hemocytometer (Fisher) and viability was 
calculated as the percentage of cells that excluded trypan blue divided by the 
total number of cells.  Results are represented as the mean ± SD.  The Student’s 
t-test was used to determine statistically significant differences in cellular viability 
amongst experimental conditions.  
For PrestoBlue assays, PMA-stimulated THP-1 (5x104) cells in a 96-well 
plate were infected at an MOI = 5 or treated with 1 µM of STS in a total volume of 
90 µL.  At 24 h pi or STS incubation, 10 µL of PrestoBlue dye (Invitrogen) was 
added to each well and incubated at 37°C for 5 h before recording fluorescence 
(560/590 ex/em) using a SpectraMax M2 Microplate Reader (Molecular Devices).  
Viability is represented as mean fluorescence intensity ± SD.  The Student’s t-
test was used to determine statistically significant differences in cellular viability 
amongst experimental conditions.  
  
Detection of PARP-1 and procaspase cleavage by using immunoblotting 
For assays involving infections, cells were either mock-infected or infected 
with MVA or MVA/M1L for the times indicated. Infections of adherent PMA-
stimulated THP-1 cells were performed by removing PMA-containing medium 
and inoculating monolayers with medium containing viruses.  For infection of the 
Jurkat suspension cell lines, cells were first concentrated by centrifugation (250 x 
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g, 5 min), resuspended and then counted prior to infection.  The absorption 
phase of infection for Jurkat cells occurred in a small volume at 37°C.  After the 
absorption phase, Jurkat cells were centrifuged (250 x g, 5 min), supernatants 
were removed, and infected cells were resuspended in complete medium and 
transferred to 12-well tissue culture plates. Unless otherwise stated, infected 
cells were harvest at 24 h pi. For transfection assays, subconfluent HeLa cellular 
monolayers in six-well plates were transfected with 1000 ng of either pCI, pM1L-
V5 or pF1L-FLAG. At 24 h post-transfection, cells were incubated in medium 
absent for or containing 0.5 µM STS (Selleck Chemicals) for 24 h. 
For both infected and transfected cells, cells were collected and cellular 
pellets were lysed in 100 µL RIPA buffer (150 mM NaCl, 1% sodium 
deoxycholate, 1% NP-40, 0.1% SDS and 0.01M Tris-HCl) containing HALT 
protease inhibitor (Thermo Scientific) for 20 min at 4°C.  Cellular lysates were 
then centrifuged (18,000 x g for 10 min). Clarified supernatants were collected 
and transferred to new tubes. The protein concentration of lysates from each 
sample was determined using the BCA Protein Assay Kit (Pierce).  30 µg of 
protein from each lysate was incubated with 5X Non-Reducing Lane Marker 
(Thermo Scientific) and 2 µL of 2-mercaptoethanol (Fisher Scientific), boiled for 5 
min and then separated using SDS-PAGE.  Proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes (Millipore) and membranes were 
incubated in 5 % (w/v) milk in Tris-buffered saline and Tween 20 (TBST; 150mM 
NaCl, 50mM Tris base and 0.05 % Tween 20) for at least 30 min at room 
temperature.  Membranes were incubated with the indicated primary antibodies 
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overnight at 4°C.  Next, membranes were washed three times in large volumes of 
TBST, and incubated with the appropriate HRP-conjugated secondary 
antibodies.  Immunoblots were developed by using chemilluminescence reagents 
(Thermo Scientific and Amersham) according to the manufacturer’s instructions 
and images were detected by autoradiography.   
Primary antibodies used in these experiments were: anti-PARP-1 
(1:1,000; Santa Cruz, sc-25780), anti-caspase-3 (1:1,000; Cell Signaling, 9665), 
anti-caspase-9 (1:1,000; Cell Signaling, 9502). These antibodies were chosen 
because they detect both non-processed and cleaved forms of PARP-1, 
caspase-3 and caspase-9, respectively.  Other antibodies used included mouse 
monoclonal anti-E3L (1:5,000; a gift from Dr. Stuart Isaacs, University of 
Pennsylvania), anti-V5 (1:5,000; Millipore, AB3792), anti-FLAG (1:2,000; Sigma, 
F7425) and anti-β-Actin (1:5,000; Sigma, A5060).  Secondary HRP-conjugated 
antibodies were obtained from either Calbiochem (goat anti-rabbit IgG; 1:10,000) 
or Thermo Scientific (goat anti-mouse IgG; 1:5,000). 
 
Detection of caspase 3/7 activity 
Wild-type or caspase-8-deficient Jurkat cells (1x103) or PMA-stimulated 
THP-1 (1x104) cells were infected at a MOI of 2 or treated with 1µM STS (Selleck 
Chemicals) in a total volume of 50 µL 96 well-plate. At 24 h pi, 50 µL of Caspase-
Glo 3/7 substrate (Promega) was added to each well.  Plates were incubated in 
the dark at 37°C for 1 h before recording luciferase activity using SpectraMax M2 
Microplate Reader (Molecular Devices). All experiments were performed in 
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triplicate.  For each sample, background media levels were subtracted and 
triplicates were averaged.  The resultant values were then normalized to that of 
mock-infected cells, whose value was set to 1.  Values are shown as mean 
normalized luminescence ± SD.  The Student’s t-test was used to determine the 
statistical significance of decreased luminescence of MVA/M1L-infected cells 
compared to MVA-infected cells.  Statistically significant changes are indicated 
by asterisks (p < 0.05). 
 
Tetramethylrhodamine ethyl ester (TMRE) staining to detect mitochondrial 
membrane potential 
Subconfluent HeLa cells in six-well plates were transfected with 1000 ng 
of either pCI, pM1L-V5 or pF1L-FLAG. At 24 h post-transfection, cells were 
incubated in medium either lacking or containing 5 µM STS (Selleck Chemicals) 
at 37°C.  After 2 h, medium was removed and cells were incubated with fresh 
medium containing 0.2 µM TMRE (Thermo Fisher) for 30 min at 37°C.  Cells 
were harvested by trypsinization, collected by centrifugation (500 x g, 5 min), and 
resuspended in PBS + 2% FBS and incubated on ice.  Next, samples were 
analyzed by using the BD FACSCanto™ II (BD Biosciences) equipped with 488 
nm and 633 nm lasers. TMRE dye was excited by the 488 nm laser and its 
fluorescence was captured using the 585/42 nm bandpass filter. At least 10,000 
events (live and apoptotic cells) were collected for each sample.  Cell doublets 
and debris, identified on the basis of their scatter characteristics, were excluded 
from analysis. Data analysis was performed using FCS Express 6 (De Novo 
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Software).  The percent apoptosis was calculated as the percentage of cells that 
had low fluorescence divided by the total number of cells.  A separate portion of 
each sample was instead lysed in 100 µL RIPA buffer (150 mM NaCl, 1% sodium 
deoxycholate, 1% NP-40, 0.1% SDS and 0.01M Tris-HCl) containing HALT 
protease inhibitor (Thermo Scientific) for 20 min at 4°C.  Cellular lysates were 
then centrifuged (18,000 x g, 10 min), clarified supernatants were collected, and 
30 µg of protein was used to assess protein expression levels via 
immunoblotting.  
 
Yeast death assays 
The Saccharomyces cerevisiae yeast strain W303α was transformed and 
analyzed in survival assays as previously described (8). Plasmids directing yeast 
expression of caspase-3 (43), caspase-9 (39), reverse-caspase-9 (38), Bcl-xL (5) 
and Bax (45) have been previously described. Construction of the M1L yeast 
expression plasmid is outlined above. pGALL-(HIS3)-ApafFL was created by first 
inserting an internal HindIII fragment of the Apaf-1 coding region into pGALL-
(URA3)-Apaf1-530 (39), then adding a PCR-generated SpeI/NotI fragment 
encompassing the 3’ portion of the coding sequence. An EcoRI/NotI fragment 
containing the 3’ part of the compiled open reading frame was then ligated into 







Subconfluent 293T cellular monolayers in six-well plates were transfected 
with 500 ng C9DN-FLAG, 500 ng Apaf-1N-myc, and 1000 ng of either pCI, 
pM1L-V5 or pHA-K1L.  At 24 h post-transfection, cells were detached from plates 
by scraping and collected by centrifugation (18,000 x g, 1 min). Cellular pellets 
were resuspended in 150 µL NP-40 lysis buffer (142.5 mM NaCl, 5 mM MgCl2, 
10mM Hepes (pH 7.2), 1mM EGTA and 0.2% NP-40) containing HALT protease 
inhibitor (Thermo Scientific) for 30 min at 4°C.  Cellular lysates were then 
centrifuged (18,000 x g, 10 min).  50 µL of the supernatants were set aside and 
used to detect protein expression levels via immunoblotting.  The remaining 100 
µL of clarified lysates were used for immmunoprecipitations (IP) to detect protein-
protein interactions.  For IPs, clarified lysates were pre-cleared for 1 h with 50 µL 
of protein G-Sepharose beads (Invitrogen) at 4°C with rotation.  Beads were 
collected by centrifugation (18,000 X g, 1 min) and clarified lysates were 
incubated overnight with 1 µL of either anti-FLAG (Sigma, F3165), anti-V5 (Cell 
Signaling, 13202), anti-HA (Sigma, H9658), or the appropriate IgG isotype 
control (mouse; Sigma, I5381; rabbit; Cell Signaling, 3900) with constant rotation 
at 4°C.  The next day, 50 µL of protein G-Sepharose beads (Invitrogen) were 
added to the samples and rotated at 4°C for another 4 hours.  Beads were 
collected by centrifugation (18,000 X g, for 1 min) and washed four times with 
750 µL of NP-40 lysis buffer.  Pelleted bead-protein complexes were 
resuspended in 33uL of 2x Laemmli buffer containing 10% 2-mercaptoethanol 
and boiled for 5 min.  15 µL of each sample was then analyzed for the presence 
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of proteins using immunoblotting. Primary antibodies and concentrations used for 
these experiments were as follows: anti-FLAG (1:2,000; Sigma, F7425), anti-myc 
(1:2,000; Cell Signaling, 2272), anti-V5 (1:5,000; Millipore, AB3792), anti-HA 
(1:10,000; Cell Signaling, 3724) and anti-β-Actin (1:5,000; Sigma, A5060). 
 
2.3 Results 
Creation and characterization of a recombinant MVA virus containing the M1L 
gene  
 There is no reported function for the WR M1 protein, which is predicted to 
harbor 14 ANK repeat sequences (40, 81). ANK-containing proteins expressed 
by polydnavirus (27) and intracellular bacteria (25, 56) possess anti-apoptotic 
properties, suggesting that M1 may have a similar function. An initial approach to 
answer this question was to capitalize on the fact that MVA infection induces 
apoptosis in immune cells (18, 37, 55, 68). The M1L gene is present in wild-type 
VACV but absent in MVA (3). Thus, if M1L encodes an anti-apoptosis protein, 
then a recombinant MVA virus engineered to express M1 (MVA/M1L) was 
expected to decrease MVA-induced apoptosis.  
A two-gene cassette containing the GFP gene (under control of the 
poxvirus p11 promoter) and M1L gene (under the control of its natural promoter) 
was inserted into the del III region of MVA, an area commonly used for 
placement of genetic material into the MVA genome (Figure 1A). PCR analysis of 
viral genomes revealed that the M1L gene was indeed stably inserted into del III 
using DNA from MVA/M1L-infected cells, but not MVA-infected cells (Figure 1B). 
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Additionally, a set of primers that are specific to the del III region (F1, R1) PCR-
amplified a 3.3 kb product (Figure 1B), which is the expected size of an amplicon 
if GFP and M1L are present.  
Multiple attempts were made to raise polyclonal antiserum against M1 
peptides in rabbits. Each attempt failed; raised antisera did not detect M1 from 
virus-infected cellular lysates. Thus, we analyzed virus-infected cells for M1L 
mRNA using semi-quantitative RT-PCR.  M1L is an early gene (85, 99). M1L 
mRNA is detected as early as 30 minutes post-infection (85, 99) and remains 
detectable until 12 hours post-infection (85, 97). We chose to examine M1L 
transcription at 6 hours post-infection, a time at which M1L transcription was 
reported to occur (85, 99). As shown in Figure 1C, an M1L-containing amplicon 
was detected when using RNA isolated from cells infected with MVA/M1L or the 
WR strain of wild-type vaccinia virus, but not from MVA-infected or mock-infected 
cells.  These data indicated that the M1L gene was expressed during infection.   
MVA lacks about 15% of the parental (wild-type) vaccinia virus genome 
(3). MVA has a narrow host range due to this loss of genes, and only replicates 
in chicken embryo fibroblasts (CEFs) and a few other avian cell lines (17). 
Another vaccinia virus ANK repeat protein, K1, increases the host range of MVA 
to include RK13 cells (17, 96). Consequently, we asked if M1L insertion also 
would increase the MVA host range in a similar fashion as K1L. The formation 
and size of foci were examined as an indirect readout for virus replication. This 
was performed in infected monolayers of CEFs (permissive for MVA infection) 
and rabbit RK13 cells (non-permissive for MVA infection) (Figure 1D). The 
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addition of M1L neither increased the size of MVA-based foci in CEFs nor 
allowed focus formation in RK13 cells. Of course, this does not rule out the 
possibility that M1L may increase the host range in other cell types, and this 
possibility will be examined in the future. Nevertheless, the M1L gene product did 
not increase the host range of MVA in RK13 cells, and therefore had properties 
distinct from the ANK repeat containing K1 protein.  
 
The M1L gene increases viability of MVA-infected cells 
   MVA infection of primary antigen presenting cells (APCs) induces 
apoptosis (18, 37, 55, 68). We used the human monocytic THP-1 cell line to 
assess the effect of M1L on viability after virus infection.  We used this cell line 
instead of primary human cells because it removes potential problems with 
donor-to-donor variation.  For all experiments shown here, THP-1 cells were 
incubated with phorbol 12-myristate 13-acetate (PMA) for 48 h to differentiate 
cells into macrophage-like cells.  As shown in Figure 2A, 85% of the mock-
infected cells were viable, as evaluated by trypan blue dye staining. In contrast, 
MVA infection reduced viability such that only 23% of cells remained viable.  The 
viability of the cell population increased to 53% during MVA/M1L infection, 
implying that M1L encoded an inhibitor of cell death. As a control, a separate set 
of PMA-matured THP-1 cells was incubated in medium containing staurosporine 
(STS), a drug that triggers intrinsic apoptosis (88). As expected, nearly all THP-1 
cells died following STS treatment. 
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 We repeated the above assay using a red-fluorescent viability dye to 
quantify cell viability (Fig. 2B).  Using this approach, we observed similar trends 
as seen in Figure 2A.  Mock-infected cells had the highest fluorescence, 
indicating that a large percentage of the cell population was viable. This was 
dramatically decreased by incubation of cells with STS or by infecting cells with 
MVA. In comparison, MVA/M1L infection provoked only a slight decrease in 
fluorescence values compared to mock infected cells, demonstrating that M1L 
reduced MVA-induced cell death. 
 
M1L inhibits MVA-induced apoptosis 
 There are many types of cell death, including apoptosis, necrosis, and 
necroptosis (46). Apoptosis has unique biochemical hallmarks, including 
activation of procaspases, resulting in the cleavage of downstream substrates of 
caspases (50). For example, the 116-kDa PARP-1 protein is a preferred 
substrate for caspase-3, and PARP-1 cleavage into its 89-kDa and 24-kDa 
products is a downstream event in apoptosis that can be detected by 
immunoblotting (48).  
 To ask if M1L blocked apoptosis, we infected THP-1 cells with MVA or 
MVA/M1L and examined lysates of cells for full-length or cleaved PARP-1, using 
antiserum that recognizes both the full-length (116-kDa) and cleaved (24-kDa) 
PARP-1 (Figure 3A). In mock-infected cells, the majority of detected PARP-1 was 
the full-length form. In contrast, treatment of cells with STS, which induces 
intrinsic apoptosis, resulted in increased cleaved PARP-1 and decreased full-
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length PARP-1.  Full-length and cleaved PARP-1 were detected in MVA-infected 
cells. However, cleaved PARP-1 (24-kDa) was dramatically decreased when 
comparing lysates from MVA/M1L-infected cells to those infected with MVA.  
Caspase-3 and -7 are executioner caspases, and their activation occurs 
upstream of PARP-1 cleavage. Activation of these two caspases can be 
quantified using a luciferase-based assay that detects their proteolytic activity.  
Figure 3B showed that caspase-3 and -7 activity was decreased when M1 was 
expressed during virus infection, indicating that M1 inhibited apoptosis. When 
examining PARP-1 cleavage and caspase-3/7 activity in infected Jurkat T cells, 
similar results were observed (Figures 3C and 3D). Namely, MVA/M1L infection 
decreased levels of cleaved PARP-1 (Figure 3C) and caspase-3 and caspase-7 
(Figure 3D) activities as compared to MVA infection. Thus, this anti-apoptotic 
function of M1L is not cell-type specific. It should be noted that PARP-1 cleavage 
was more extensive in STS-treated cells versus MVA-infected cells. In contrast, 
caspase-3/7 activity was similar between STS-treated and MVA-infected cells. 
One expectation would be that caspase-3/7 activity should also be increased in 
lysates from STS-treated versus MVA-infected cells. One reason for this 
discrepancy may be as follows: PARP cleavage was examined at 16 hours post-
infection while caspase-3/7 activity was examined at 24 hours post-infection. For 
immunoblotting, infected cells were harvested at earlier time points because we 
observed reduced amounts of protein levels in samples (due to cell death) at 
later time points. Nevertheless, the presence of the M1L gene consistently 
decreased apoptotic events in both THP-1 and Jurkat cells. 
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Jurkat cells are type II cells, in which active caspase-8 feeds into the 
intrinsic pathway via its cleavage of Bid, leading to caspase-9-induced apoptosis 
(75). MVA infection is reported to activate both intrinsic and extrinsic apoptosis 
(18, 37, 55, 68).  We examined apoptosis in Jurkat cells that are deficient in 
caspase-8 (C8 -/- Jurkat) to focus solely on M1 inhibition of intrinsic apoptosis 
(47). In these cells, MVA induced PARP-1 cleavage and executioner caspase 
activation (Figures 3E and 3F), consistent with reports that MVA triggers intrinsic 
apoptosis (37). Because MVA induces both caspase-8 and caspase-9 activation, 
caspase-3/7 activity was lower in caspase-8-deficient versus wild-type Jurkat 
cells as one pathway that contributes to the apoptotic phenotype was missing. 
While M1 inhibition of caspase-3/7 activity was stronger in wild-type than 
caspase-8 -/- Jurkat cells, MVA/M1L inhibition was still significantly different from 
MVA, suggesting that M1 inhibits intrinsic apoptosis.  
  
M1 inhibits procaspase-9 processing 
 Procaspase-9 (47-kDa) is inactive until it interacts with Apaf-1 in the 
apoptosome (67). Apaf-1-associated procaspase-9 homodimers will then 
autocleave at Asp315, resulting in processing to 35-kDa and 12-kDa forms (82, 
94). In addition, once activated, caspase-3 can cleave procaspase-9 to produce 
a 37-kDa caspase-9 (82).  To explore the impact of M1 on procaspase-9 
cleavage, a step that follows procaspase-9 activation, lysates from virus-infected 
cells were probed by immunoblotting using an antibody that simultaneously 
detected the zymogen (47-kDa), autoprocessed (35-kDa) and caspase-3 cleaved 
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(37-kDa) forms of caspase-9 in the same three cell lines used in Figure 3. Note 
that procaspase-9 cleavage was examined at different times post-infection as 
compared to Figure 3, and that procaspase-9 cleavage was examined at different 
times post-infection in each cell line. Time course assays were first performed to 
detect maximal procaspase-9 cleavage during MVA infection for each cell line 
(data not shown). Once this time point was determined for each cell line, we then 
compared procaspase-9 cleavage in MVA- versus MVA/M1L-infected cells. As 
shown in Figure 4, only the 47-kDa form of procaspase-9 was detected in mock-
infected THP-1 or Jurkat cells. MVA infection triggered intrinsic apoptosis, as 
evidenced by the presence of the 35-kDa form of caspase-9 in THP-1 cells 
(Figure 4A). Both the 35- and 37-kDa forms were detected in MVA-infected 
Jurkat cells (Figures 4B and 4C), reflecting autoprocessing and caspase-3 
cleavage of procaspase-9, respectively. The 37-kDa form was not detected in 
THP-1 cellular lysates; this may reflect more efficient procaspase-9 
autoprocessing in these cells. Regardless, the intensities of the 37- and 35-kDa 
bands were greatly reduced in MVA/M1L-infected cells, implying that M1 blocked 
infection-induced capsase-9 activity.  
 
M1 inhibits biochemical hallmarks of intrinsic apoptosis when it is expressed 
independent of infection 
 We were interested in identifying the portion of the pro-apoptotic signal 
transduction pathway that M1 targets. For these experiments, we moved away 
from infections and expressed M1 ectopically.  The reason for using this 
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approach is that MVA encodes at least 3 other anti-apoptotic proteins (F1, B22, 
and E3) (3). Thus, expression of these proteins during MVA/M1L infection may 
make it difficult to identify the molecular mechanism of M1. Additionally, MVA 
infection triggers apoptosis via both intrinsic and extrinsic apoptosis (18, 28, 37, 
55, 68, 91).  Thus, moving away from an MVA infection system affords the 
opportunity to examine intrinsic apoptosis alone.  
 HeLa cells were used for transient expression of M1L.  With this system 
we observed a 90% transfection efficiency.  Additionally, staurosporine (STS) 
treatment of HeLa cells stimulates intrinsic apoptosis (98). As observed in the 
infection system, the 116-kDa PARP-1 protein was cleaved to a 24-kDa form in 
STS-treated HeLa cells (Figure 5).  M1 expression greatly decreased the amount 
of detectable cleaved PARP-1.  Similarly, M1-expressing HeLa cells also 
decreased detectable cleaved caspase-3 and capase-9. Note that the detection 
of M1, the full-length PARP-1, and zymogenic forms of procaspase-3 and -9 
decreased slightly over time.  Of these proteins, the decrease in procaspase-3 
perhaps was the most severe. This decrease could not be attributed to overall 
protein degradation or uneven protein levels in gels because actin levels 
remained similar between samples. At this time, it is not clear why procaspase-3 
levels would decrease in M1-expressing cells. Nevertheless, in the apoptosis 
field it is the cleaved forms of caspase-3 and -9 that are hallmarks of apoptosis. 
The presence of cleaved forms of cellular proteins responsible for apoptosis were 
lower in M1-transfected cells compared to pCI-transfected cells. Thus, M1 
blocked intrinsic apoptosis triggered by an infection-independent stimulus.  
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The M1 protein does not prevent mitochondrial depolarization 
Depolarization of the mitochondria often accompanies Bax/Bak-mediated 
permeabilization of the outer mitochondria membrane and cyt c release to the 
cytoplasm in cells undergoing intrinsic apoptosis (84). M1-expressing HeLa cells 
were incubated with tetramethylrhodamine ethyl ester (TMRE) to gauge 
mitochondrial polarization during STS treatment. TMRE is a cell-permeable, 
positively-charged dye that accumulates in active mitochondria, which have a 
relative negative charge (22). Thus, healthy cells have a higher fluorescence 
than cells with depolarized or inactive mitochondria. In untreated cells, no more 
than 20% of the population lost fluorescence, indicating that most of the cells 
were viable (Figure 6). STS treatment of these cells increased membrane 
depolarization to 71% of the cellular population, concomitant with apoptosis. The 
VACV F1 protein binds to Bim to prevent mitochondrial outer membrane 
permeabilization and subsequent mitochondrial depolarization (15, 86, 89).  Only 
49% of the F1-transfected cells lost TMRE staining after exposure to STS, 
consistent with F1’s previously reported anti-apoptosis function.  In contrast, M1 
expression did not inhibit mitochondrial damage: 75% of M1-expressing cells lost 
TMRE fluorescence upon STS treatment, similar to empty vector (pCI)-
expressing cells. Both F1 and M1 protein levels were detected by immunoblotting 
to show protein expression. Thus the M1 protein, while inhibiting procaspase-9 




M1 inhibits yeast cell death induced by expression of mammalian apoptosome 
components  
Data above suggested that M1 inhibited the intrinsic apoptosis signal 
transduction pathway at a step downstream of mitochondrial membrane 
permeabilization but upstream of procaspase-9 processing. The most likely 
possibility was that M1 interfered with apoptosome formation or function.  
To further examine this, we used S. cerevisiae as a system to reconstitute 
the apoptosome and study its regulation by M1. In this system, the over-
expression of mammalian apoptosis effectors (e.g., caspases, Bax) are lethal to 
yeast (8). Thus, this system can identify direct inhibitors of these proteins by 
using suppression of lethality as a readout. For example, co-expression of 
mammalian Apaf-1, procaspase-9 and procaspase-3 proteins is sufficient to 
trigger cell death (Figure 7A, lane 2) (38).  This system identifies a candidate 
protein’s ability to interact with mammalian apoptosis inducers because death is 
blocked only if an inhibitor acts directly on the proteins used to induce death (8). 
For example, the mammalian anti-apoptotic Bcl-xL protein blocks mitochondrial 
outer membrane permeabilization by binding to Bax and Bak (7). Expression of 
Bcl-xL did not inhibit yeast death when Apaf-1, procaspase-9 and procaspase-3 
were co-expressed because Bcl-xL acts prior to apoptosome formation (Figure 
7A, Lane 4). However, Bcl-xL inhibited Bax-induced death (Figure 7A, Lane 9) 
consistent with its mode of action in mammalian cells (7).  The baculovirus P35 
protein binds to caspase-9 and caspase-3 (10, 21), and therefore inhibited Apaf-
1/procaspase-9/procaspase-3 induced death (Figure 7A, Lane 3) but not Bax-
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induced death (Figure 7, Lane 8). M1 inhibited lethality of Apaf-1/procaspase-
9/procaspase-3-expression (Figure 7A, Lane 5), but not Bax-induced death 
(Figure 7A, Lane 10), suggesting M1 inhibited death at the level of the 
apoptosome.   
A separate experiment was performed in which a constitutively active 
caspase-9 protein (rCasp-9) and procaspase-3 were co-expressed (Figure 7B).  
This allows cell death in an Apaf-1-independent manner because rCasp-9 has 
the small and large subunit orders swapped to mimic the structure of the active 
caspase (8, 38). Under these conditions both M1 (Figure 7B, Lane 5) and P35 
(Figure 7B, Lane 3) rescued yeast viability. These data suggest that M1 
interacted with the active form of caspase-9, and that such interactions were 
sufficient to block yeast lethality.  
 
The M1 protein co-immunoprecipitates with caspase-9-Apaf-1 complexes  
To examine the molecular targets of M1, we performed co-
immunoprecipitations in 293T cells ectopically co-expressing epitope-tagged M1, 
a truncated Apaf-1 (N-Apaf-1; amino acids 1-559) and a dominant-negative (DN) 
procaspase-9 (DNC9). N-Apaf-1 lacks the WD40 repressive domain; thus this 
construct allows for the formation of an apoptosome complex in the absence of 
cyt c (44). DNC9 was used instead of wild-type procaspase-9 to prevent 
apoptosis and maximize detection of protein-protein interactions.  DNC9 still 
binds to N-Apaf-1 and forms homodimers, but is not catalytically active and is not 
processed (78).  
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Figure 8A showed that the myc-tagged N-Apaf-1 co-immunoprecipitated 
with FLAG-tagged DNC9 regardless of M1 co-expression, demonstrating that M1 
allowed apoptosome formation.  Interestingly, the V5-tagged M1 protein also co-
immunoprecipitated with FLAG-tagged DNC9, showing that M1 associated with 
the N-Apaf-1-DNC9 complex. Another VACV ANK containing protein (K1) did not 
co-immunoprecipitate with the N-Apaf-1-DNC9 complex (Figure 8A), suggesting 
the specificity of the M1 ANK repeats for the apoptosome. Reverse co-
immunoprecipitations were performed in which M1 or K1 were 
immunoprecipitated (Figures 8B and 8C). High backgrounds and non-specific 
bands were observed in Figure 8B because rabbit IgG was used as an isotype 
control and the anti-FLAG and anti-myc antibodies were also rabbit. 
Nevertheless, a distinct DNC9-containing band was detected when M1 was 
immunoprecipitated, but this band was absent in empty vector (pCI)-transfected 
cells. This same blot was re-probed for the presence of myc-tagged N-Apaf-1 
and a unique band was observed at the molecular weight expected for N-Apaf-1 
(Figure 8B).  Figure 8C showed that the epitope-tagged version of DNC9 and N-
Apaf-1 did not co-immunoprecipitate with K1. Overall, these results demonstrate 
that M1 associates with the apoptosome. 
 
2.4 Discussion 
Apoptosis is an evolutionarily conserved mechanism to remove infected 
cells (46). Many intracellular pathogens possess strategies to prevent apoptosis 
of infected host cells. Here we show that M1 is a novel VACV apoptosis 
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antagonist. Expression of M1 inhibited biochemical hallmarks of apoptosis 
including PARP-1 and procaspase-3 cleavage induced by either infection with 
MVA or STS treatment.  
 Procaspase-9 is a unique initiator caspase. Other initiator caspases like 
procaspase-8 must be cleaved, separating active subunits in order to achieve 
optimal catalytic activity (62). However, a conformational change in procaspase-9 
due to Apaf-1 interactions can activate apoptosis without caspase-9 cleavage. 
Cleavage will occur after activation, but is not necessary for catalytic activity (94). 
We observed that M1 (i) co-immunoprecipitated with procaspase-9 and Apaf-1, 
(ii) prevented procaspase-9 processing, and (iii) blocked caspase-9-dependent 
yeast lethality in the absence of Apaf-1.  Together, these data suggest that M1 
interacts with the Apaf-1-associated form of procaspase-9. Our current model is 
that M1 allows formation of the apoptosome, but inhibits apoptosome function 
(e.g., procaspase-9 processing and procaspase-3 cleavage). The most likely 
possibility is that M1 binds to a procaspase-9 region other than the CARD since 
M1 does not block procaspase-9-Apaf-1 interactions and M1 lacks an obvious 
CARD domain. These data do not preclude the possibility that M1 may also bind 
to Apaf-1. It is unlikely that M1 acts as a competitive substrate for caspase-9 
because there are no obvious caspase-9 cleavage motifs in the M1 amino acid 
sequence.  
 To the best of our knowledge, M1 is the first poxviral protein that targets 
apoptosome function. VACV B13 was also reported to interact with caspase-9 in 
vitro (32, 69).  However, unlike M1, B13 did not inhibit intrinsic apoptosis despite 
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these interactions (69). Vaccinia virus F1 originally was reported to function 
upstream of M1, inhibiting mitochondrial membrane pore formation to prevent 
apoptosome formation (90). More recently, it was shown that the N-terminus of 
F1 binds to procaspase-9 to inhibit recruitment of procaspase-9 to Apaf-1 (100, 
101). The physiological relevance of this interaction was recently called into 
question when Caria et. al. show that this N-terminus of F1 is dispensable for 
anti-apoptosis function (16). Regardless, M1 appears to have an inhibitory 
strategy distinct from F1 because F1 prevents apoptosome formation and 
prevents mitochondrial depolarization (100, 101) while M1 allows Apaf-1-
procapase-9 interactions and does not suppress depolarization of the 
mitochondrial membrane. In addition, the M1 and F1 mechanisms are likely 
biochemically distinct because MVA induces apoptosis despite the presence of 
F1, and the introduction of M1 into MVA results in a virus whose infection is 
much less apoptotic than MVA.   
 ANK repeats are one of the most abundant motifs found in nature (9, 
53). Mammalian cells have ANK proteins that either induce or inhibit apoptosis. 
Cellular cardiac ankyrin repeat protein Ankrd1/CARP (ASPP1 and ASPP2) 
promote apoptosis via interactions with cellular p53 (52, 77). Murine nucling, an 
ortholog of the human uveal autoantigen with coiled-coil domains and ankyrin 
repeats (UACA) protein, associates with and promotes apoptosome nuclear 
translocation to further promote stress-induced apoptosis (70). In contrast, 
proteins like human gankyrin, an ANK-containing oncoprotein often 
overexpressed in many hepatocellular carcinomas, inhibits apoptosis by binding 
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to the Mdm2 E3 ubiquitin ligase, leading to ubiquitination and degradation of pro-
apoptotic p53 (41, 42). Because these proteins are critical to the survival of 
healthy versus damaged cells, synthetic ANKs (DARPins) have been engineered 
as a means to control apoptosis (29, 30, 66).  New information concerning ANK 
proteins that alter apoptosis, such as the novel way that M1 inhibits intrinsic 
apoptosis at the level of the apoptosome, could potentially benefit the 
development of novel DARPins. 
 There are reports of other ANK-containing proteins with anti-apoptosis 
properties from viruses, bacteria and eukaryotes. The Campoletis sonorensis 
ichnovirus (CsIV) P-vank-1 protein inhibits caspase-3 activity via an as-yet-
characterized mechanism in the insect Sf9 cell line (27). Like M1, P-vank-1 
retains this function independent of infection (27). Intracellular Coxiella burnetii 
encodes the AnkG protein, which binds to the pro-apoptotic cellular p32 protein 
to inhibit apoptosis through a currently uncharacterized nuclear mechanism (25). 
Erlichia chaffeensis and E. canis each express p200, which is proposed to inhibit 
apoptosis by binding an adenine-rich motif found in Alu-Sx elements, a motif 
found in promoters and introns for various host genes, including those for 
apoptosis (102). Each of these ANK-containing proteins has strategies distinct 
from M1. This implies that intracellular pathogens have capitalized on 
manipulating ANK domains to inhibit the predominant pro-apoptosis signaling 
pathways triggered during the infection of different host cell types.  
 There are myriad non ANK-containing proteins from viruses, bacteria 
and eukaryotes that also inhibit intrinsic apoptosis.  The cellular Bcl-2 family of 
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proteins, along with their viral homologs, are well known for their inhibition of 
mitochondrial permeabilization (7).  The mitochondria itself is also a popular 
target for inhibition of intrinsic apoptosis, with viruses and bacteria both encoding 
a plethora of proteins to block cytochrome c release (26, 31).  Additionally, there 
are proteins that target caspases, which more closely relate to the function of M1.  
African swine fever virus A224 as well as effector proteins from S. typhimurium, 
P. aeruginosa, F. tularensis and L. pneumophila directly or indirectly inhibit 
caspase-3 (1, 4, 51, 61, 73), however we demonstrated that M1 inhibited 
procaspase-9 and therefore functions in a distinct manner.  Other proteins 
function, like M1, directly on the apoptosome. For example: cellular APIP, Aven, 
Hsp70, Hsp90, and TUCAN bind Apaf-1 or procaspase-9 to prevent either Apaf-1 
oligomerization or caspase-9 binding to Apaf-1 oligomers (6, 19, 20, 63, 64, 72).  
M1, on the other hand, allowed apoptosome formation, and therefore functions 
downstream of these inhibitors. Baculovirus P49 interacts with caspase-9 and 
works as a direct competitive substrate (103). M1 lacks an obvious caspase-9 
cleavage site, suggesting that M1 functions in a manner distinct from P49.  
Mammalian X linked inhibitor of apoptosis (XIAP) is likely the closest in function 
to M1, as it also inhibits apoptosis after formation of the apoptosome.  However, 
XIAP can only bind to the processed/cleaved form of caspase-9 (83), while M1 
inhibited caspase-9 cleavage.  Therefore, while targeting the apoptosome is a 
tactic used by multiple organisms to inhibit apoptosis, the mechanism employed 
by M1 is a new poxviral strategy, and gives important insight as to how viruses 
may control intrinsic apoptosis. 
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It is striking to observe that VACV WR has multiple weapons in its arsenal 
to neutralize myriad pro-apoptotic events including mitochondrial membrane 
permeabilization (F1), caspase-8 activation (B13, B22), Bid cleavage (N1), and 
PKR-induced apoptosis (E3) (80). M1 is now the sixth weapon of this intracellular 
arsenal, acting at the level of the apoptosome for its antagonistic function. One 
favored hypothesis is that each of these anti-apoptosis proteins is necessary 
during infection of numerous different cell types in vivo to neutralize the multiple 
intracellular responses (e.g., virus infection itself) and extracellular responses 
(e.g., TNF, cytotoxic T cells) to infection.  For example, while MVA encodes 
inhibitors of intrinsic apoptosis that work upstream of M1 function (F1 and N1), 
apoptosis can still be induced in certain immune cells by MVA (18, 37, 55, 68). 
However, MVA does not induce apoptosis in other non-immune cell types (28). 
This supports the hypothesis that each VACV inhibitor of apoptosis functions in a 
non-redundant fashion, and highlights the key role M1 plays to dampen the host 













Figure 2.1: Creation and characterization of an M1L-expressing MVA virus. 
(A) Schematic showing insertion of tandem GFP and M1L genes into the del III 
region of the MVA genome, in which the GFP gene is under the control of the 
poxvirus p11 promoter (p11) and the M1L gene is under the control of its natural 
promoter (NP).  Primers used for verifying insertion of this GFP-M1L cassette are 
shown. (B) CEF monolayers were mock-infected or infected with MVA, MVA/M1L 
or WR (MOI = 10). At 24 h pi, infected cells were harvested and lysed. DNA was 
subjected to PCR amplification using either the M1F and M1R primer sets to 
amplify the M1L gene, or the F1 and R1 primers to PCR amplify the MVA del III 
region.  A portion of each PCR amplification reaction was separated by agarose 
gel electrophoresis and DNA was visualized using ethidium bromide staining.  
Reactions were analyzed in the same gel and gel images were spliced for 
labeling purposes. (C) Detection of M1L gene transcription using semi-
quantitative RT-PCR. PMA-stimulated THP-1 cells were mock-infected or 
infected with the indicated viruses (MOI = 2). At 6 h pi, cells were collected and 
total RNA was extracted from lysed cells. Total RNA was reverse transcribed into 
cDNA.  A portion of cDNA was incubated with primers either nested inside the 
M1L gene or for the actin gene as a control.  A portion of each PCR reaction was 
analyzed by agarose gel electrophoresis and PCR amplicons were detected by 
using ethidium bromide staining of the gel. Reactions were analyzed in the same 
gel and gel images were spliced for labeling purposes. (D) CEF or RK13 cellular 
monolayers were infected with MVA, MVA/M1L or WR (50 PFU/well of a 6-well 
plate). At 24 h pi, cells were fixed and incubated in a solution containing anti-
vaccinia virus antiserum, followed by a solution containing HRP-conjugated goat 
anti-rabbit antiserum.  Diameters of at least 10 foci per condition were measured, 





Figure 2.2: M1L increases viability during MVA infection. PMA-stimulated 
THP-1 cells were either mock-infected or infected with MVA or MVA/M1L (MOI = 
5) or incubated in medium containing 1 µM staurosporine (STS). (A) At 24 h pi or 
post-STS treatment, all cells were collected and cell death was quantified by 
using a trypan blue dye exclusion assay. Results are presented as the mean 
percentage of cells that excluded trypan blue (live) cells divided by the total 
number of live and dead cells. Each sample was counted in triplicate, and data 
shown here are the mean ± SD from three independent experiments. (B) At 24 h 
pi or post-STS treatment, PrestoBlue reagent was added to wells. The 
fluorescence of each well was quantified using a microplate reader. Results are 
presented as the mean fluorescence ± SD for each sample. Presto Blue-based 
assays were performed in technical triplicate. The graphs shown here represent 
data obtained from at least three independent experiments. Asterisks indicate 
conditions in which the viability of MVA/M1L-infected cells was statistically 





Figure 2.3: M1L inhibits MVA-induced apoptosis. (A,B) PMA-treated THP-1 
cells (C,D) Jurkat cells or (E,F) caspase-8 deficient (C8 -/-) Jurkat cells were 
either mock-infected, or infected with MVA or MVA/M1L (MOI = 2). A separate 
set of uninfected cells was incubated in medium containing 1 µM of staurosporine 
(STS). (A, C, E) At 16 h pi or post-STS treatment, cells were collected and lysed 
in RIPA buffer. 30 μg of each sample were separated by using SDS-12% PAGE, 
and proteins were transferred to a PVDF membrane. Membranes were probed 
with an anti-PARP-1 antibody that detects full-length (116-kDa) and cleaved (24-
kDa) PARP-1. An asterisk denotes a non-specific band. Blots subsequently were 
incubated with either anti-E3 or anti-actin antisera, and re-developed. Data are 
representative of at least three independent experiments. In (A) and (C), 
reactions were analyzed in the same gel and gel images were spliced for labeling 
purposes.  (B, D, F) At 24 h pi or post-STS treatment, cells were lysed, and 
caspase-3 and -7 activities were quantified using the Caspase-Glo 3/7 assay kit. 
Results are presented as the mean fold induction of caspase activity for each 
sample ± SD above mock-infected cells, whose value was set to one.  Data were 
obtained from at least three independent experiments. Statistically significant 







Figure 2.4: M1L inhibits MVA-induced procaspase-9 cleavage. (A) PMA-
treated THP-1 cells (B) Jurkat cells or (C) caspase-8-deficient (C8 -/-) Jurkat cells 
were either mock-infected, or infected with MVA or MVA/M1L (MOI = 2). A 
separate set of uninfected cells was incubated in medium containing 1 µM 
staurosporine (STS) for 12 h. At either (A) 12h, (B) 20 h or (C) 16 h pi, cells were 
collected and lysed in RIPA buffer. 30 μg of each sample was analyzed by SDS-
10% PAGE and proteins were transferred to a PVDF membrane. The membrane 
was probed with anti-caspase-9 antiserum which detects the 47- , 37- and 35-
kDa forms of caspase-9. Blots were subsequently incubated with either anti-E3 
or anti-actin antisera, and developed. Data shown are a representative of data 






Figure 2.5: Biochemical hallmarks of staurosporine-induced apoptosis are 
reduced when M1 is expressed independent of infection. Subconfluent HeLa 
cellular monolayers were transfected with 1 µg of either empty vector (pCI) or 
pM1L-V5.  At 24 h post-transfection, cells were treated with medium either 
lacking (-) or containing 0.5 µM staurosporine (STS). At 2, 4 or 6 h post-STS 
incubation, cells were collected and lysed in RIPA buffer. Lysates were 
separated by SDS 12%-PAGE, and proteins were transferred to a PVDF 
membrane. Membranes were probed with either anti-PARP-1, anti-caspase-3 or 
anti-caspase-9 antisera. Membranes were developed and bands detected using 
chemilluminescence. Blots were subsequently incubated with either anti-V5, anti-
FLAG or anti-actin antiserum and re-developed. Data shown are representative 





Figure 2.6: M1 does not block the loss of mitochondrial membrane 
potential during staurosporine-induced apoptosis. Subconfluent HeLa 
cellular monolayers were transfected with 1 µg of either empty vector (pCI), 
pM1L-V5, or pF1L-FLAG.  At 24 h post-transfection, cells were treated with 
medium lacking (-) or containing (+) 5 µM staurosporine (STS) for 2 h. Cells were 
incubated in 0.2 µM TMRE for 30 min at 37°C. The percentage of cells with 
decreased TMRE fluorescence are shown in each histogram. Data shown are a 
representative of at least three independent experiments. A portion of each 
cellular population was collected and lysed in RIPA buffer, and vaccinia virus 
protein levels were examined by immunoblotting. This same blot was incubated 






Figure 2.7: M1 inhibits yeast lethality that is triggered by a reconstituted 
apoptosome or constitutively active caspase-9.  
Yeast were transformed with the indicated expression plasmids and lethality was 
induced either by over-expressing (A) Apaf-1, procaspase-9 (Casp-9) and 
procaspase-3 (Casp-3) or Bax or (B) reverse caspase-9 (rCasp-9) and 
procaspase-3. Suspensions containing equivalent concentrations of each 
transformant were serially diluted and 5 µl of each dilution were spotted onto 
plates containing galactose (to induce transgene expression) or glucose (to 
repress transgene expression). Growth on inducing plates indicates survival and 





Figure 2.8: M1 interacts with and does not disrupt procaspase-9-Apaf-1 
interactions. Subconfluent 293T cellular monolayers were co-transfected with 
500 ng C9DN-FLAG, 500 ng Apaf-1N-myc, and 1000 ng of either pCI, pM1L-V5 
or pHA-K1L.  At 24 h post-transfection cells were lysed in NP-40 lysis buffer.  
Some lysates were set aside to monitor protein expression.  For the remaining 
clarified cellular lysates, immunoprecipitations (IP) were performed using (A) 
murine IgG or anti-FLAG, (B) rabbit IgG or anti-V5 or (C) murine IgG or anti-HA 
antibodies conjugated to protein G-Sepharose beads.  IP’ed samples or 20 µg of 
cellular lysates were analyzed by SDS 8%-PAGE and proteins were transferred 
to a PVDF membrane for immunoblotting.  Membranes were probed with the 
indicated antibodies to detect the epitope-tagged versions of C9DN, N-Apaf-1, 
M1, K1 or cellular actin.  For (B) all immunoprecipitated and cellular lysates were 






1. Abu-Zant A, Jones S, Asare R, Suttles J, Price C, Graham J, Kwaik 
YA. 2007. Anti-apoptotic signalling by the Dot/Icm secretion system of 
L. pneumophila. Cellular Microbiology 9:246-264. 
2. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL. 1998. 
Blockade of chemokine activity by a soluble chemokine binding protein 
from vaccinia virus. J Immunol 160:624-633. 
3. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete 
genomic sequence of the modified vaccinia Ankara strain: comparison 
with other orthopoxviruses. Virology 244:365-396. 
4. Ashare A, Monick MM, Nymon AB, Morrison JM, Noble M, Powers LS, 
Yarovinsky TO, Yahr TL, Hunninghake GW. 2007. <em>Pseudomonas 
aeruginosa</em> Delays Kupffer Cell Death via Stabilization of the X-
Chromosome-Linked Inhibitor of Apoptosis Protein. The Journal of 
Immunology 179:505-513. 
5. Beaumont TE, Shekhar TM, Kaur L, Pantaki-Eimany D, Kvansakul M, 
Hawkins CJ. 2013. Yeast techniques for modeling drugs targeting Bcl-2 
and caspase family members. Cell Death Dis 4:e619. 
6. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, 
Tailor P, Morimoto RI, Cohen GM, Green DR. 2000. Heat-shock protein 
70 inhibits apoptosis by preventing recruitment of procaspase-9 to the 
Apaf-1 apoptosome. Nat Cell Biol 2:469-475. 
7. Birkinshaw RW, Czabotar PE. 2017. The BCL-2 family of proteins and 
mitochondrial outer membrane permeabilisation. Semin Cell Dev Biol 
doi:10.1016/j.semcdb.2017.04.001. 
8. Bloomer DT, Kitevska T, Brand IL, Jabbour AM, Nguyen H, Hawkins 
CJ. 2016. Modeling Metazoan Apoptotic Pathways in Yeast. Methods Mol 
Biol 1419:161-183. 
9. Bork P. 1993. Hundreds of ankyrin-like repeats in functionally diverse 
proteins: Mobile modules that cross phyla horizontally? Proteins: 
Structure, Function, and Bioinformatics 17:363-374. 
10. Brand IL, Green MM, Civciristov S, Pantaki-Eimany D, George C, Gort 
TR, Huang N, Clem RJ, Hawkins CJ. 2011. Functional and biochemical 
characterization of the baculovirus caspase inhibitor MaviP35. Cell Death 
Dis 2:e242. 
11. Bravo Cruz AG, Han A, Roy EJ, Guzman AB, Miller RJ, Driskell EA, 
O'Brien WD, Jr., Shisler JL. 2017. Deletion of the K1L gene results in a 
vaccinia virus that is less pathogenic due to muted innate immune 




12. Bravo Cruz AG, Shisler JL. 2016. Vaccinia virus K1 ankyrin repeat 
protein inhibits NF-kappaB activation by preventing RelA acetylation. J 
Gen Virol 97:2691-2702. 
13. Brooks MA, Ali AN, Turner PC, Moyer RW. 1995. A rabbitpox virus 
serpin gene controls host range by inhibiting apoptosis in restrictive cells. 
Journal of Virology 69:7688-7698. 
14. Burles K, Irwin CR, Burton R-L, Schriewer J, Evans DH, Buller RM, 
Barry M. 2014. Initial characterization of Vaccinia Virus B4 suggests a 
role in virus spread. Virology 456–457:108-120. 
15. Campbell S, Thibault J, Mehta N, Colman PM, Barry M, Kvansakul M. 
2014. Structural Insight into BH3 Domain Binding of Vaccinia Virus 
Antiapoptotic F1L. Journal of Virology 88:8667-8677. 
16. Caria S, Marshall B, Burton RL, Campbell S, Pantaki-Eimany D, 
Hawkins CJ, Barry M, Kvansakul M. 2016. The N Terminus of the 
Vaccinia Virus Protein F1L Is an Intrinsically Unstructured Region That Is 
Not Involved in Apoptosis Regulation. J Biol Chem 291:14600-14608. 
17. Carroll MW, Moss B. 1997. Host range and cytopathogenicity of the 
highly attenuated MVA strain of vaccinia virus: propagation and generation 
of recombinant viruses in a nonhuman mammalian cell line. Virology 
238:198-211. 
18. Chahroudi A, Garber DA, Reeves P, Liu L, Kalman D, Feinberg MB. 
2006. Differences and similarities in viral life cycle progression and host 
cell physiology after infection of human dendritic cells with modified 
vaccinia virus Ankara and vaccinia virus. J Virol 80:8469-8481. 
19. Chau BN, Cheng EHY, Kerr DA, Hardwick JM. 2000. Aven, a Novel 
Inhibitor of Caspase Activation, Binds Bcl-xL and Apaf-1. Molecular Cell 
6:31-40. 
20. Cho D-H, Hong Y-M, Lee H-J, Woo H-N, Pyo J-O, Mak TW, Jung Y-K. 
2004. Induced Inhibition of Ischemic/Hypoxic Injury by APIP, a Novel 
Apaf-1-interacting Protein. Journal of Biological Chemistry 279:39942-
39950. 
21. Clem RJ, Fechheimer M, Miller LK. 1991. Prevention of apoptosis by a 
baculovirus gene during infection of insect cells. Science 254:1388-1390. 
22. Cottet-Rousselle C, Ronot X, Leverve X, Mayol J-F. 2011. Cytometric 
assessment of mitochondria using fluorescent probes. Cytometry Part A 
79A:405-425. 
23. Danthi P. 2016. Viruses and the Diversity of Cell Death. Annu Rev Virol 
3:533-553. 
24. Drillien R, Koehren F, Kirn A. 1981. Host range deletion mutant of 
vaccinia virus defective in human cells. Virology 111:488-499. 
117 
 
25. Eckart RA, Bisle S, Schulze-Luehrmann J, Wittmann I, Jantsch J, 
Schmid B, Berens C, Luhrmann A. 2014. Antiapoptotic activity of 
Coxiella burnetii effector protein AnkG is controlled by p32-dependent 
trafficking. Infect Immun 82:2763-2771. 
26. Faherty CS, Maurelli AT. 2008. Staying alive: bacterial inhibition of 
apoptosis during infection. Trends in Microbiology 16:173-180. 
27. Fath-Goodin A, Kroemer JA, Webb BA. 2009. The Campoletis 
sonorensis ichnovirus vankyrin protein P-vank-1 inhibits apoptosis in 
insect Sf9 cells. Insect Molecular Biology 18:497-506. 
28. Fischer SF, Ludwig H, Holzapfel J, Kvansakul M, Chen L, Huang DC, 
Sutter G, Knese M, Hacker G. 2006. Modified vaccinia virus Ankara 
protein F1L is a novel BH3-domain-binding protein and acts together with 
the early viral protein E3L to block virus-associated apoptosis. Cell Death 
Differ 13:109-118. 
29. Flutsch A, Ackermann R, Schroeder T, Lukarska M, Hausammann 
GJ, Weinert C, Briand C, Grutter MG. 2014. Combined inhibition of 
caspase 3 and caspase 7 by two highly selective DARPins slows down 
cellular demise. Biochem J 461:279-290. 
30. Flutsch A, Schroeder T, Barandun J, Ackermann R, Buhlmann M, 
Grutter MG. 2014. Specific targeting of human caspases using designed 
ankyrin repeat proteins. Biol Chem 395:1243-1252. 
31. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. 2008. Viral 
Control of Mitochondrial Apoptosis. PLOS Pathogens 4:e1000018. 
32. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, 
Thornberry NA. 1998. Inhibition of human caspases by peptide-based 
and macromolecular inhibitors. J Biol Chem 273:32608-32613. 
33. Garcia MA, Guerra S, Gil J, Jimenez V, Esteban M. 2002. Anti-apoptotic 
and oncogenic properties of the dsRNA-binding protein of vaccinia virus, 
E3L. Oncogene 21:8379-8387. 
34. Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, 
Carson DA, Leoni LM. 2000. Nucleotide requirements for the in vitro 
activation of the apoptosis protein-activating factor-1-mediated caspase 
pathway. J Biol Chem 275:29-34. 
35. Gubser C, Bergamaschi D, Hollinshead M, Lu X, van Kuppeveld FJ, 
Smith GL. 2007. A new inhibitor of apoptosis from vaccinia virus and 
eukaryotes. PLoS Pathog 3:e17. 
36. Gubser C, Smith GL. 2002. The sequence of camelpox virus shows it is 




37. Guzman E, Cubillos-Zapata C, Cottingham MG, Gilbert SC, Prentice 
H, Charleston B, Hope JC. 2012. Modified vaccinia virus Ankara-based 
vaccine vectors induce apoptosis in dendritic cells draining from the skin 
via both the extrinsic and intrinsic caspase pathways, preventing efficient 
antigen presentation. J Virol 86:5452-5466. 
38. Hawkins CJ, Silke J, Verhagen AM, Foster R, Ekert PG, Ashley DM. 
2001. Analysis of candidate antagonists of IAP-mediated caspase 
inhibition using yeast reconstituted with the mammalian Apaf-1-activated 
apoptosis mechanism. Apoptosis 6:331-338. 
39. Hawkins CJ, Wang SL, Hay BA. 1999. A cloning method to identify 
caspases and their regulators in yeast: identification of Drosophila IAP1 as 
an inhibitor of the Drosophila caspase DCP-1. Proc Natl Acad Sci U S A 
96:2885-2890. 
40. Herbert MH, Squire CJ, Mercer AA. 2015. Poxviral ankyrin proteins. 
Viruses 7:709-738. 
41. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo 
Y, Masuda T, Dawson S, Shimada Y, Mayer RJ, Fujita J. 2005. The 
oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and 
degradation of p53. Cancer Cell 8:75-87. 
42. Higashitsuji H, Liu Y, Mayer RJ, Fujita J. 2005. The Oncoprotein 
Gankyrin Negatively Regulates Both p53 and RB by Enhancing 
Proteasomal Degradation. Cell Cycle 4:1335-1337. 
43. Ho PK, Jabbour AM, Ekert PG, Hawkins CJ. 2005. Caspase-2 is 
resistant to inhibition by inhibitor of apoptosis proteins (IAPs) and can 
activate caspase-7. FEBS J 272:1401-1414. 
44. Hu Y, Benedict MA, Wu D, Inohara N, Núñez G. 1998. Bcl-X(L) interacts 
with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. 
Proceedings of the National Academy of Sciences of the United States of 
America 95:4386-4391. 
45. Jabbour AM, Puryer MA, Yu JY, Lithgow T, Riffkin CD, Ashley DM, 
Vaux DL, Ekert PG, Hawkins CJ. 2006. Human Bcl-2 cannot directly 
inhibit the Caenorhabditis elegans Apaf-1 homologue CED-4, but can 
interact with EGL-1. J Cell Sci 119:2572-2582. 
46. Jorgensen I, Rayamajhi M, Miao EA. 2017. Programmed cell death as a 
defence against infection. Nat Rev Immunol 17:151-164. 
47. Juo P, Kuo CJ, Yuan J, Blenis J. 1998. Essential requirement for 
caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. 




48. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. 
1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an 
early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976-
3985. 
49. Kim J, Parrish AB, Kurokawa M, Matsuura K, Freel CD, Andersen JL, 
Johnson CE, Kornbluth S. 2012. Rsk-mediated phosphorylation and 14-
3-3varepsilon binding of Apaf-1 suppresses cytochrome c-induced 
apoptosis. EMBO J 31:1279-1292. 
50. Kiraz Y, Adan A, Kartal Yandim M, Baran Y. 2016. Major apoptotic 
mechanisms and genes involved in apoptosis. Tumour Biol 37:8471-8486. 
51. Knodler LA, Finlay BB, Steele-Mortimer O. 2005. The Salmonella 
Effector Protein SopB Protects Epithelial Cells from Apoptosis by 
Sustained Activation of Akt. Journal of Biological Chemistry 280:9058-
9064. 
52. Kojic S, Nestorovic A, Rakicevic L, Belgrano A, Stankovic M, Divac A, 
Faulkner G. 2010. A novel role for cardiac ankyrin repeat protein 
Ankrd1/CARP as a co-activator of the p53 tumor suppressor protein. 
Archives of Biochemistry and Biophysics 502:60-67. 
53. Li J, Mahajan A, Tsai M-D. 2006. Ankyrin Repeat:  A Unique Motif 
Mediating Protein−Protein Interactions. Biochemistry 45:15168-15178. 
54. Li Y, Zhou M, Hu Q, Bai X-c, Huang W, Scheres SHW, Shi Y. 2017. 
Mechanistic insights into caspase-9 activation by the structure of the 
apoptosome holoenzyme. Proceedings of the National Academy of 
Sciences 114:1542-1547. 
55. Liu L, Chavan R, Feinberg MB. 2008. Dendritic cells are preferentially 
targeted among hematolymphocytes by Modified Vaccinia Virus Ankara 
and play a key role in the induction of virus-specific T cell responses in 
vivo. BMC Immunol 9:15. 
56. Luhrmann A, Nogueira CV, Carey KL, Roy CR. 2010. Inhibition of 
pathogen-induced apoptosis by a Coxiella burnetii type IV effector protein. 
Proc Natl Acad Sci U S A 107:18997-19001. 
57. Macen JL, Garner RS, Musy PY, Brooks MA, Turner PC, Moyer RW, 
McFadden G, Bleackley RC. 1996. Differential inhibition of the Fas- and 
granule-mediated cytolysis pathways by the orthopoxvirus cytokine 
response modifier A/SPI-2 and SPI-1 protein. Proceedings of the National 
Academy of Sciences 93:9108-9113. 
58. Mayr A, Hochstein-Mintzel V, Stickl H. 1975. Abstammung, 




59. Meng X, Jiang C, Arsenio J, Dick K, Cao J, Xiang Y. 2009. Vaccinia 
virus K1L and C7L inhibit antiviral activities induced by type I interferons. J 
Virol 83:10627-10636. 
60. Nichols D, De Martini W, Cottrell J. 2017. Poxviruses Utilize Multiple 
Strategies to Inhibit Apoptosis. Viruses 9:215. 
61. Nogal ML, González de Buitrago G, Rodríguez C, Cubelos B, 
Carrascosa AL, Salas ML, Revilla Y. 2001. African Swine Fever Virus 
IAP Homologue Inhibits Caspase Activation and Promotes Cell Survival in 
Mammalian Cells. Journal of Virology 75:2535-2543. 
62. Oberst A, Pop C, Tremblay AG, Blais V, Denault J-B, Salvesen GS, 
Green DR. 2010. Inducible Dimerization and Inducible Cleavage Reveal a 
Requirement for Both Processes in Caspase-8 Activation. Journal of 
Biological Chemistry 285:16632-16642. 
63. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, 
Weichselbaum R, Nalin C, Alnemri ES, Kufe D, Kharbanda S. 2000. 
Negative regulation of cytochrome <em>c</em>‐mediated oligomerization 
of Apaf‐1 and activation of procaspase‐9 by heat shock protein 90. The 
EMBO Journal 19:4310-4322. 
64. Pathan N, Marusawa H, Krajewska M, Matsuzawa S-i, Kim H, Okada 
K, Torii S, Kitada S, Krajewski S, Welsh K, Pio F, Godzik A, Reed JC. 
2001. TUCAN, an Antiapoptotic Caspase-associated Recruitment Domain 
Family Protein Overexpressed in Cancer. Journal of Biological Chemistry 
276:32220-32229. 
65. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Limbach K, Norton 
EK, Paoletti E. 1990. Vaccinia virus host range genes. Virology 179:276-
286. 
66. Pluckthun A. 2015. Designed ankyrin repeat proteins (DARPins): binding 
proteins for research, diagnostics, and therapy. Annu Rev Pharmacol 
Toxicol 55:489-511. 
67. Rodriguez J, Lazebnik Y. 1999. Caspase-9 and APAF-1 form an active 
holoenzyme. Genes & Development 13:3179-3184. 
68. Royo S, Sainz B, Jr., Hernandez-Jimenez E, Reyburn H, Lopez-
Collazo E, Guerra S. 2014. Differential induction of apoptosis, interferon 
signaling, and phagocytosis in macrophages infected with a panel of 
attenuated and nonattenuated poxviruses. J Virol 88:5511-5523. 
69. Ryan CA, Stennicke HR, Nava VE, Burch JB, Hardwick JM, Salvesen 
GS. 2002. Inhibitor specificity of recombinant and endogenous caspase-9. 




70. Sakai T, Liu L, Teng X, Mukai-Sakai R, Shimada H, Kaji R, Mitani T, 
Matsumoto M, Toida K, Ishimura K, Shishido Y, Mak TW, Fukui K. 
2004. Nucling Recruits Apaf-1/Pro-caspase-9 Complex for the Induction of 
Stress-induced Apoptosis. Journal of Biological Chemistry 279:41131-
41140. 
71. Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES. 1999. 
Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a 
prerequisite for procaspase-9 activation. J Biol Chem 274:17941-17945. 
72. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. 2000. 
Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 
2:476-483. 
73. Santic M, Pavokovic G, Jones S, Asare R, Kwaik YA. 2010. Regulation 
of apoptosis and anti-apoptosis signalling by Francisella tularensis. 
Microbes and infection / Institut Pasteur 12:126. 
74. Saraiva N, Prole DL, Carrara G, Maluquer de Motes C, Johnson BF, 
Byrne B, Taylor CW, Smith GL. 2013. Human and viral Golgi anti-
apoptotic proteins (GAAPs) oligomerize via different mechanisms and 
monomeric GAAP inhibits apoptosis and modulates calcium. J Biol Chem 
288:13057-13067. 
75. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, 
Debatin KM, Krammer PH, Peter ME. 1998. Two CD95 (APO-1/Fas) 
signaling pathways. EMBO J 17:1675-1687. 
76. Schweizer A, Roschitzki-Voser H, Amstutz P, Briand C, Gulotti-
Georgieva M, Prenosil E, Binz HK, Capitani G, Baici A, Pluckthun A, 
Grutter MG. 2007. Inhibition of caspase-2 by a designed ankyrin repeat 
protein: specificity, structure, and inhibition mechanism. Structure 15:625-
636. 
77. Shen L, Chen C, Wei X, Li X, Luo G, Zhang J, Bin J, Huang X, Cao S, 
Li G, Liao Y. 2015. Overexpression of ankyrin repeat domain 1 enhances 
cardiomyocyte apoptosis by promoting p53 activation and mitochondrial 
dysfunction in rodents. Clinical Science 128:665-678. 
78. Shiozaki EN, Chai J, Shi Y. 2002. Oligomerization and activation of 
caspase-9, induced by Apaf-1 CARD. Proceedings of the National 
Academy of Sciences 99:4197-4202. 
79. Shisler JL. 2015. Immune evasion strategies of molluscum contagiosum 
virus. Adv Virus Res 92:201-252. 
80. Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, 
Ferguson BJ, Sumner RP. 2013. Vaccinia virus immune evasion: 
mechanisms, virulence and immunogenicity. J Gen Virol 94:2367-2392. 
122 
 
81. Sonnberg S, Fleming SB, Mercer AA. 2011. Phylogenetic analysis of the 
large family of poxvirus ankyrin-repeat proteins reveals orthologue groups 
within and across chordopoxvirus genera. J Gen Virol 92:2596-2607. 
82. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. 1998. 
Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol 
Cell 1:949-957. 
83. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee R-
A, Robbins PD, Fernandes-Alnemri T, Shi Y, Alnemri ES. 2001. A 
conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO 
regulates caspase activity and apoptosis. Nature 410:112-116. 
84. Tait SW, Green DR. 2010. Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nat Rev Mol Cell Biol 11:621-632. 
85. Tamin A, Villarreal EC, Weinrich SL, Hruby DE. 1988. Nucleotide 
sequence and molecular genetic analysis of the vaccinia virus HindIII N/M 
region encoding the genes responsible for resistance to α-Amanitin. 
Virology 165:141-150. 
86. Taylor JM, Quilty D, Banadyga L, Barry M. 2006. The vaccinia virus 
protein F1L interacts with Bim and inhibits activation of the pro-apoptotic 
protein Bax. J Biol Chem 281:39728-39739. 
87. Veyer DL, Carrara G, Maluquer de Motes C, Smith GL. 2017. Vaccinia 
virus evasion of regulated cell death. Immunology Letters 186:68-80. 
88. Voth DE, Howe D, Heinzen RA. 2007. Coxiella burnetii inhibits apoptosis 
in human THP-1 cells and monkey primary alveolar macrophages. Infect 
Immun 75:4263-4271. 
89. Wasilenko ST, Meyers AF, Vander Helm K, Barry M. 2001. Vaccinia 
virus infection disarms the mitochondrion-mediated pathway of the 
apoptotic cascade by modulating the permeability transition pore. J Virol 
75:11437-11448. 
90. Wasilenko ST, Stewart TL, Meyers AF, Barry M. 2003. Vaccinia virus 
encodes a previously uncharacterized mitochondrial-associated inhibitor 
of apoptosis. Proc Natl Acad Sci U S A 100:14345-14350. 
91. Wenzel M, Wunderlich M, Besch R, Poeck H, Willms S, Schwantes A, 
Kremer M, Sutter G, Endres S, Schmidt A, Rothenfusser S. 2012. 
Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling 
proteins independently of AIM2 and RNA polymerase III. J Immunol 
188:394-403. 
92. Willis KL, Langland JO, Shisler JL. 2011. Viral double-stranded RNAs 
from vaccinia virus early or intermediate gene transcripts possess PKR 
activating function, resulting in NF-kappaB activation, when the K1 protein 
is absent or mutated. J Biol Chem 286:7765-7778. 
123 
 
93. Willis KL, Patel S, Xiang Y, Shisler JL. 2009. The effect of the vaccinia 
K1 protein on the PKR-eIF2alpha pathway in RK13 and HeLa cells. 
Virology 394:73-81. 
94. Wu C-C, Lee S, Malladi S, Chen M-D, Mastrandrea NJ, Zhang Z, 
Bratton SB. 2016. The Apaf-1 apoptosome induces formation of caspase-
9 homo- and heterodimers with distinct activities. Nature Communications 
7:13565. 
95. Wu CC, Bratton SB. 2017. Caspase-9 swings both ways in the 
apoptosome. Mol Cell Oncol 4:e1281865. 
96. Wyatt LS, Carroll MW, Czerny CP, Merchlinsky M, Sisler JR, Moss B. 
1998. Marker rescue of the host range restriction defects of modified 
vaccinia virus Ankara. Virology 251:334-342. 
97. Xiang Y, Simpson DA, Spiegel J, Zhou A, Silverman RH, Condit RC. 
1998. The Vaccinia Virus A18R DNA Helicase Is a Postreplicative 
Negative Transcription Elongation Factor. Journal of Virology 72:7012-
7023. 
98. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, 
Wang X. 1997. Prevention of apoptosis by Bcl-2: release of cytochrome c 
from mitochondria blocked. Science 275:1129-1132. 
99. Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B. 2010. 
Simultaneous high-resolution analysis of vaccinia virus and host cell 
transcriptomes by deep RNA sequencing. Proceedings of the National 
Academy of Sciences 107:11513-11518. 
100. Yu E, Zhai D, Jin C, Gerlic M, Reed JC, Liddington R. 2011. Structural 
determinants of caspase-9 inhibition by the vaccinia virus protein, F1L. J 
Biol Chem 286:30748-30758. 
101. Zhai D, Yu E, Jin C, Welsh K, Shiau CW, Chen L, Salvesen GS, 
Liddington R, Reed JC. 2010. Vaccinia virus protein F1L is a caspase-9 
inhibitor. J Biol Chem 285:5569-5580. 
102. Zhu B, Nethery KA, Kuriakose JA, Wakeel A, Zhang X, McBride JW. 
2009. Nuclear Translocated Ehrlichia chaffeensis Ankyrin Protein Interacts 
with a Specific Adenine-Rich Motif of Host Promoter and Intronic Alu 
Elements. Infection and Immunity 77:4243-4255. 
103. Zoog SJ, Schiller JJ, Wetter JA, Chejanovsky N, Friesen PD. 2002. 
Baculovirus apoptotic suppressor P49 is a substrate inhibitor of initiator 






Chapter 3: Characterizing the effects of insertion of a 5.2 kb region of a 
VACV genome, which contains known immune evasion genes, on MVA 
immunogenicity 
3.1  Introduction 
Vaccinia virus (VACV) (Family Poxviridiae, subfamily Chordopoxvirinae, 
genus Orthopoxvirus, species Vaccinia virus) is a well-studied poxvirus, and an 
example of a successful vaccine (1). Vaccination with VACV protects against 
Variola virus (VARV; the causative agent of smallpox) because VACV and VARV 
are antigenically related. Thus, the robust cellular and humoral responses elicited 
by vaccination cross-protects against VARV infection (2-4). However, VACV is a 
replication-competent virus that encodes many immunomodulatory proteins (5, 
6). These and other properties can cause adverse reactions to smallpox 
vaccinations in some individuals (7). This shortcoming prompted efforts to create 
safer VACV constructs.  
Modified Vaccinia virus Ankara (MVA) is one such VACV that was created 
as a safer vaccine vector (1). MVA was created by serially passaging the VACV 
strain Chorioallantois Vaccinia virus Ankara (CVA) over 500 times in chicken 
embryo fibroblasts (CEFs) (8). Passaging resulted in a virus that has six major 
regions of the parental VACV genome deleted in addition to multiple truncations 
of genes (9, 10). Specifically, many of the genes encoding for immunomodulatory 
proteins and host range are either fragmented or deleted (9, 10). 
MVA has a greatly restricted host range as compared to VACV, and can 
no longer replicate in human cells, making this virus safe. Endogenous or 
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transgene expression still occur during MVA infection (11, 12). These attributes 
make MVA a desirable vaccine vector. However, one drawback is that a higher 
dose or boosts of MVA-based vaccines are required for the same protective 
responses as VACV (13-15). This highlights the need to continue to improve the 
efficacy of MVA without compromising its safety.  
MVA is thought to be less immunogenic because it is replication-
incompetent in human cells and therefore has limited antigen accumulation 
during infection (1). Because of this premise, efforts have gone into testing 
replication-competent viruses and increasing immune cell infiltration via the 
addition of host range proteins and deletion of immunomodulatory proteins, 
respectively (16). However, another hypothesis that has not been examined is 
whether delay of viral clearance, via re-insertion of missing VACV immune 
evasion genes back into MVA, could boost immunogenicity via increasing time 
for antigen presentation during an MVA infection.  
To test this hypothesis, we examined the immunogenicity of MVA/5.2kb, 
which is also referred to as MVA/K1L in several publications (10, 12, 17, 18). 
This is a construct in which an EcoRI-digested, 5.2 kb region of VACV DNA 
(strain CVA) is stably inserted into MVA (10). This 5.2 kb region contains the 
following genes: N2L, M1L, M2L, K1L, K2L, K3L, and K4L (10). When comparing 
the CVA and MVA genomes (19), the genes that are in MVA/5.2kb versus MVA 
are M1L (apoptosis antagonist) (20), M2L (MEK/ERK and NF-κB inhibitor) (21, 
22) and K1L (PKR and NF-κB inhibitor, and host range protein) (10, 18, 23-25). 
The rationale for investigating the MVA/5.2kb virus is as follows: Of all peripheral 
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blood mononuclear cells (PBMCs), MVA preferentially infects the antigen 
presenting cells (APCs), including macrophages and dendritic cells (DCs) (26-
28). Removal of MVA-infected cells is rapid because MVA induces apoptosis in 
APCs (29-32). Additionally, MVA infection activates NF-κB, which could trigger 
the production of anti-viral host molecules (33, 34). As APCs are critical for 
activation of the adaptive immune system (35), the hypothesis is that MVA/5.2kb 
infection would decrease apoptosis of infected APCs, and delay pro-inflammatory 
cytokine production. In turn, this may allow for prolonged production and display 
of antigenic proteins to enhance viral immunogenicity. To this end, we compared 
APC viability, maturation, and cytokine production in vitro during MVA/5.2kb 
infection. We then examined the induction of VACV-specific CD8+ T cells during 
MVA and MVA/5.2kb infection in vivo.  
 
3.2  Materials and methods 
Cells and viruses 
Human acute monocytic leukemia cells (THP-1 cells), human embryonic 
kidney cells (293T), and African green monkey kidney cells (Vero) were obtained 
from the American Type Culture Collection (ATCC). Primary chicken embryo 
fibroblasts (CEFs) were obtained from Charles River Laboratories. Unstimulated 
THP-1 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 
mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (designated 
complete medium). For all experiments using stimulated THP-1 cells, cells were 
differentiated in medium containing 100 ng/ml phorbol 12-myristate 13-acetate 
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(PMA; Sigma) for 48 h prior to infection. The 293T, CEF, and Vero cell lines were 
cultured in complete Eagle’s minimal essential medium (MEM).  
Human monocyte derived dendritic cells (HMDDCs) were derived as 
follows: Peripheral blood mononuclear cells (PBMCs) were isolated from blood of 
consenting healthy donors by Ficoll-Paque (GE Healthcare) gradient 
centrifugation under an approved institutional review board protocol. Cells were 
plated into 24-well tissue culture dishes in complete RPMI medium for 30 min to 
allow monocytes to attach. Then, non-adherent lymphocytes were removed by 
washing. After overnight culture, monocytes were incubated in medium 
containing 1000 U/ml of GM-CSF and 500 U/ml of IL-4 (PeproTech) for 5 days to 
induce differentiation into dendritic cells. Medium with fresh cytokines was 
replenished halfway through the incubation period (36). Cells were then 
detached, counted, plated at a concentration of 8.5x105 cells/well in a 24-well 
plate and incubated overnight before being infected. 
VACV strains Western Reserve (WR) and MVA were gifts from Dr. 
Bernard Moss (National Institutes of Health). MVA/5.2kb is a MVA virus in which 
the 5.2kb EcoRI fragment of the parental Ankara DNA was inserted into MVA by 
homologous recombination, and was described previously (10). MVA/M2L 
contains the M2L gene and its promoter from the WR virus and has been 
described previously (21). MVA/K1L virus was a gift from Gerd Sutter (Ludwig-
Maximilians-University of Munich). It contains the entire K1L gene and its 
promoter from the WR virus and has been described previously (37). MVA-based 
viruses were propagated in CEFs, while WR was propagated in Vero cells. Virus 
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medium (RPMI supplemented with 1% FBS) was used for virus adsorption 
phases and for virus infections. Viruses used for inoculation of mice were 
propagated and then purified by sucrose cushion centrifugation. Viruses used for 
all other in vitro experiments were crude preparations in which virus-infected cells 
were collected by centrifugation, freeze-thawed three times, and aliquoted as 
previously described (18).  
 
Detection of genes in the MVA/5.2kb virus 
For PCR amplification of genes in the 5.2kb region, confluent 293T cellular 
monolayers were either mock-infected or infected with VACV strain WR, MVA or 
MVA/5.2kb at an MOI of 10 PFU/cell. At 24 h post-infection (PI), cells were 
harvested, and total DNA was extracted from cells following manufacturer’s 
directions from the Qiagen BloodAmp kit. DNA was incubated in the primers 
listed below that were specific for each gene, and PCR amplified for 25 cycles. A 
portion of each PCR reaction was separated by electrophoresis in a 2% agarose 
gel and DNA was visualized by using ethidium bromide staining of the gel. The 
primers used to PCR amplify the poxvirus genes were as follows: N2L: (5’-
CAGATCAATGGTGTGATG-3’) and (5’-ATCATGACGTCCTCTGCAATGG-3’); 
M1L: (5’-CATCGAATACTTCGTAAGATACT-3’) and (5’-GAGAGTAAATTGTTGC 
AAATATA-3’); M2L: (5’-GTCAAGAAGGCACTGGTTTAGT-3’) and (5’-GATGGTT 
TACAAATTAGTCTTGCT); K1L: (5’-CACAATTGACGTACATGAGTCTG-3’) and 
(5’-CAGACATGGATGTGTCACGAATT-3’); K2L: (5’-TATTAAGGAGATTCTACCT 
TACCC-3’) and (5’-GCGTTATTGATACTATCGTTAACG-3’); K3L: (5’-GATGTCT 
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ACACATCCTTTTGTAAT-3’) and (5’-GATGCTTGCATTTTGTTATTCGTT-3’); 
K4L: (5’-CGGGCTCGTAAATTGGGATAAAA-3’) and (5’-CGATACTAGTCCTACT 
AAAAGGT-3’). 
 To detect expression of the M2 and K1 proteins, confluent 293T 
monolayers were either mock-infected or infected at an MOI of 10 with MVA, 
MVA/5.2kb, MVA/M2L or MVA/K1L. At the indicated times PI, cells were 
collected and lysed. Proteins were analyzed via SDS-PAGE and immunoblotted 
using either anti-M2 or anti-K1 antiserum as previously described (22, 25) 
 
Viability assays 
For trypan blue exclusion assays, PMA-stimulated THP-1 (1x106) cells in 
12-well plates were mock infected, infected at an MOI of 5, or treated with 1 µM 
staurosporine (STS; Selleck Chemicals) for 24 h. Detached and adherent cells 
were collected, centrifuged (250 x g, 5 min), and resuspended in complete 
medium. An aliquot was mixed 1:1 with trypan blue dye (Thermo Scientific). Cells 
were counted by using a hemocytometer (Fisher), and viability was calculated as 
the percentage of cells that excluded trypan blue divided by the total number of 
cells. Results are represented as the mean ± standard deviation (SD). The 
Student t test was used to determine statistically significant differences in cellular 
viability among experimental conditions. Asterisks indicated the values that were 
significantly different between the indicated groups (*P <0.05). 
For PrestoBlue assays, PMA-stimulated THP-1 (5x104) cells in a 96-well 
plate were mock-infected or infected at an MOI of 5 PFU/cell in triplicate. An 
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additional set of cells was incubated in medium containing 1 µM STS in a total 
volume of 90 µl in triplicate. At 24 h pi or post-STS (Selleck Chemicals) 
incubation, 10 µl of PrestoBlue dye (Invitrogen) were added to each well, and 
wells were incubated at 37°C for 5 h. Fluorescence (560/590 excitation/emission) 
was recorded using a SpectraMax M2 Microplate Reader (Molecular Devices). 
Viability is represented as mean fluorescence intensity ± SD. The Student’s t-test 
was used to determine statistically significant differences in cellular viability 
amongst experimental conditions. Asterisks indicated the values that were 
significantly different between the indicated groups (*P <0.05). 
  
Detection of IκBα and PARP by using immunoblotting 
PMA-stimulated THP-1 (1x106) cells in 12-well plates or HMDDCs (8x105) 
in 24-well plates were mock-infected or infected at a MOI = 5 with either MVA or 
MVA/5.2kb. An additional set of cells was incubated in medium containing 1 µM 
STS when examining PARP protein levels. For detection of IκBα protein levels, 
cells were collected by scraping and concentrated by centrifugation (18,000 g for 
30 sec). Cellular pellets were resuspended and lysed in 40 µl CE buffer (23) 
containing HALT protease inhibitor (Thermo Scientific), NaF and Na3VO4 for 15 
min at 4°C. For detection of PARP protein levels, cells were collected as above, 
but cellular pellets were lysed in 150 µl RIPA buffer (20) containing HALT 
protease inhibitor for 20 min at 4°C. Cellular lysates were centrifuged (18,000 x g 
for 10 min), and clarified supernatants were transferred to new tubes. The protein 
concentration of each lysate was determined using the BCA Protein Assay Kit 
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(Pierce). Either 10 µg (IκBα) or 15 µg (PARP) of protein from each lysate was 
incubated with 5X Non-Reducing Lane Marker (Thermo Scientific) and 2 µl of 2-
mercaptoethanol (Fisher Scientific), boiled for 5 min and then separated using 
SDS-PAGE. Proteins were transferred to polyvinylidene difluoride (PVDF) 
membranes (Millipore) and membranes were incubated in 5 % (w/v) milk in Tris-
buffered saline and Tween 20 (TBST; 150 mM NaCl, 50 mM Tris base and 0.05 
% Tween 20) for at least 30 min at room temperature. Membranes were 
incubated with the indicated primary antibodies overnight at 4°C. Next, 
membranes were washed three times in large volumes of TBST, and incubated 
with a HRP-conjugated secondary antibody. Immunoblots were developed by 
using chemilluminescence reagents (Thermo Scientific and Amersham) 
according to the manufacturer’s instructions and images were detected by 
autoradiography. 
Primary antibodies used in these experiments were: anti-PARP (1:1,000; 
Santa Cruz, sc-25780), anti-IκBα (1:2,500; Cell Signaling, 9242) and anti-β-Actin 
(1:5,000; Sigma, A5060). Secondary HRP-conjugated anti-rabbit antibody was: 
goat anti-rabbit (1:10,000; Calbiochem, 401393)  
 
ELISA to detect cytokine expression 
PMA-stimulated THP-1 (1x106) cells in 12-well plates or HMDDCs (8x105) 
in 24-well plates were mock-infected or infected at a MOI of 5 with either MVA or 
MVA/5.2kb for 24 h. As a control, an additional set of uninfected cells were 
treated with 10ng/ml of lipopolysaccharide (LPS; Alpha Diagnostic) for 24 h. Cell-
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free supernatants were collected from each sample and the concentrations of 
TNF-α, IL-6 or IL-8 were assayed by enzyme-linked immunosorbent assay 
(ELISA) reagents (Invitrogen; TNF-α, CHC1753; IL-6, CHC1263, IL-8, CHC1303) 
according to manufacturer’s instructions with the following modifications. Cells 
were incubated for 1 h with streptavidin-HRP (1:2500; Jackson 
ImmunoResearch, 016-030-084) as the secondary antibody. The following 
substrate solution was used: 102.8 mM Na2HPO4 and 48.6 mM citric acid 
supplemented with 1:2500 H2O2 and OPD powder. Absorbance at 450 nm 
(reference absorbance: 650) was read using a SpectraMax M2 Microplate 
Reader (Molecular Devices). Data were analyzed with Prism 7.0c, using a 4-
parameter logistic curve for standard analysis. The Student’s t-test was used to 
determine statistically significant differences between infection conditions. 
 
Flow cytometry to evaluate CD86 surface expression 
HMDDCs (8x105) in 24-well plates were either mock-infected, infected 
either MVA, MVA/5.2kb or WR (MOI = 5), or incubated with medium containing 
100 ng/ml lipopolysaccharide (LPS; Alpha Diagnostic) for 24 h. Cells were 
detached using 10 mM EDTA in PBS at room temperature, centrifuged (300 x g 
for 5 min), resuspended and blocked in 300 µl flow buffer (1x PBS supplemented 
with 10% rabbit serum and 0.3% sodium azide) on ice for 30 min. Cells were 
then centrifuged (300 x g for 5 min), resuspended in 100µl of flow buffer 
containing either phycoerythrin (PE)-conjugated anti-CD86 antibody (clone IT2.2; 
1:20; eBioscience) or isotype control phycoerythrin (PE)-conjugated anti-IgG2b 
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antibody (clone eBMG2b; 1:20; eBioscience) and incubated on ice for 30 min. 
After antibody incubation, cells were washed in 300µl flow buffer, fixed in 4% 
paraformaldehyde for 15 min, and analyzed using BD FACSCanto™ II (BD 
Biosciences). Data were analyzed with FCS Express software version 6 (DeNovo 
Software).  
 
Detection of VACV-specific, IFN-γ-expressing CD8+ T cells 
BALB/c mice were inoculated i.p. with 100 µl of PBS (n=3), WR (1x106 
PFU; n=3), MVA (1x108 PFU; n=4) or MVA/5.2kb (1x108 PFU; n=4). At 7 d post-
infection mice were euthanized and spleens were harvested. Single-cell 
suspensions of spleens were prepared as described in Bravo Cruz et al. (38). 
Briefly, spleens were forced through a 70 µM nylon mesh (Thermo Fisher 
Scientific), and then erythrocytes were removed by treating samples with 
ammonium-chloride-potassium (ACK) red cell lysis buffer. Single spleen cell 
suspensions (1x106 cells) from each animal were either incubated in regular 
medium (unstimulated) or in medium containing VACV-specific peptide 
(VGPSNSPTF; E3140-148 epitope) for 4 h. After the first hour of incubation, all 
cellular suspensions received brefeldin A (5 µg/ml; Acros Organics). Incubations 
then proceeded for an additional 3 h. Cells were then incubated with 
phycoerythrin (PE)-conjugated anti-CD8 antibody (clone 53-6.7; 1:150; BD 
Biosciences) in FACS buffer (PBS with 2% FBS) for 30 min on ice. Samples 
were washed in FACS buffer, followed by a wash in PBS. Cells were then fixed 
for 20 min at room temperature in 1% paraformaldehyde. Cells were washed in 
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FACS buffer and incubated with allophycocyanin (APC)-conjugated anti-IFN-γ 
(clone XMG1.2, 1:200, BD Biosciences) in FACS buffer containing 0.5% saponin 
(to permeabilize cells) overnight at 4°C. Samples were washed and then 
resuspended in FACS buffer for analysis. Flow cytometry was performed with a 
BD FACSCanto™ II (BD Biosciences), and data were analyzed with FCS 
Express software version 6 (DeNovo Software). Events were first gated for live 
lymphocytes on forward versus side scatter. Live cells were gated for CD8+ T cell 
populations, and these cells were subsequently analyzed for IFN-γ expression. 
The percentage of CD8+ IFN-γ+ T cells from an unstimulated sample was 
subtracted from the value obtained from the stimulated sample for each animal. 
These values were then averaged. The Student’s t-test was used to determine 
statistically significant differences between the percentages of VACV-specific 
IFN-γ+ CD8+ T cells. Asterisks indicated the values that were significantly 
different between the indicated groups (*P <0.05). 
 
3.3  Results 
Description and detection of genes in the MVA/5.2kb virus 
The MVA/5.2kb virus (originally referred to as MVA/K1L), is a virus in 
which the K1L-containing 5.2 kb EcoRI region of CVA was stably re-inserted into 
MVA (10). MVA/5.2kb increases the host range of MVA to include certain rabbit 
cell lines, which is attributed to the K1L gene (10, 12, 17, 39). The following CVA 
genes are present in the 5.2kb fragment: N2L, M1L, M2L, K1L, K2L, K3L and 
K4L. Of these seven genes, the K2L, K3L, and K4L genes remain identical in the 
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attenuated MVA genome as compared to the parental CVA. The others are either 
truncated (N2L, K1L) or deleted (M1L, M2L) (9, 19). The MVA K1 product is 
predicted to be 98 amino acids versus 284 amino acids in CVA (40), and this 98-
residue protein appears to be non-functional (18). The MVA N2 protein is 5 
residues smaller than that of CVA (19). However, the MVA N2 protein appears to 
retain its function because an MVA deleted for N2L is more immunogenic than 
MVA (41). It is of interest to note that the M1L gene of CVA is fragmented into 
two adjacent open reading frames (19). Whether a functional M1 protein is made 
by CVA has not been examined. Thus, insertion of the 5.2kb region should allow 
expression of the K1, M2, and potentially M1, proteins. 
We verified the presence of the genes in the 5.2kb region via PCR 
amplification of DNA from cells infected with either MVA, wild-type VACV strain 
Western Reserve (WR) or MVA/5.2kb (Fig. 1A). The M1L-, M2L- and K1L-
containing amplicons were only visible when WR or MVA/5.2kb DNA was used 
as template. As MVA possesses wild-type sequences for K2L, K3L and K4L and 
only a small truncation of N2L (9, 19), these genes were detected by PCR 
amplification in all virus-infected cells.  
To verify that the insertion of the 5.2kb region results in protein expression 
we evaluated K1 and M2 expression in MVA/5.2kb-infected cells via 
immunoblotting (Fig. 1B and 1C). Despite our best attempts, we could not raise 
antiserum against the M1 protein, therefore this protein could not be examined. 
Only cells infected with MVA/5.2kb or the MVA virus expressing the gene of 
interest (e.g., MVA/M2L or MVA/K1L) demonstrated expression of M2 or K1. 
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These proteins were not detected in MVA- or mock-infected cells. Note that we 
consistently observed a K1 with higher mobility in MVA/5.2kb- versus MVA/K1L-
infected lysates, but the reason for this difference remains unclear. Regardless, 
the 5.2kb region is stably inserted into the MVA genome and expressed during 
infection.  
 
MVA/5.2kb infection decreases cell death and apoptosis 
MVA infection of APCs induces a type of cell death called apoptosis (28, 
29, 42, 43). We initially asked if MVA/5.2kb altered the viability of PMA-
stimulated THP-1 cells. Cellular viability was first evaluated via a trypan blue dye 
exclusion assay (Fig. 2A). An increase in the number of viable cells was 
observed in MVA/5.2kb-infected cells compared to MVA infection. As a control, 
mock-infected cells were incubated either in regular medium or medium 
containing staurosporine (STS), a drug that triggers intrinsic apoptosis (44). As 
expected, the viability of STS-treated cellular populations was greatly decreased 
as compared to mock-infected cellular populations. To corroborate this result, 
viability was also measured quantitatively via a red fluorescent dye (20). As 
shown in Fig. 2B, MVA/5.2kb-infected cellular populations had higher viability 
than MVA-infected cells. These data suggested that MVA/5.2kb increased the 
viability of infected cells as compared to MVA infection. 
The 5.2kb region contains one or more immune evasion genes which 
could regulate apoptosis either directly or indirectly. Therefore, we examined if 
MVA/5.2kb infection inhibited MVA-induced apoptosis. It is well-known that 
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apoptosis results in the activation of caspase-3, which consequently cleaves 
cellular poly ADP-ribose polymerase (PARP), among other cellular substrates 
(45). In viable cells, PARP is a 113-kDa protein (46). During apoptosis, PARP is 
cleaved by caspase-3 into 89- and 24-kDa forms at residue 214 (47). Thus, we 
examined infected cell lysates for the disappearance of the full-length form of 
PARP as an indicator of apoptosis by using immunoblotting. The 89-kDa form 
was not detected as we used a monoclonal PARP antibody that was raised to 
residues 1-300 of PARP and therefore does not detect the 89-kDa product. Full-
length PARP levels from two different sets of lysates are shown in Fig. 2C as 
representatives to demonstrate variances among infected cells. Full-length PARP 
protein levels were highest in mock-infected cells, as determined by the intensity 
of the PARP-containing band. In contrast, little to no full-length PARP was 
detectable in STS-treated cellular lysates, indicating apoptosis. Similarly, PARP 
levels were dramatically decreased during MVA infection, implying that apoptosis 
occurred. In contrast, PARP levels were higher in MVA/5.2kb-infected cells. This 
suggested that MVA/5.2kb infection likely increases the viability of infected cells 
via reduction of MVA-induced apoptosis of infected APCs.  
 
MVA/5.2kb infection inhibits NF-κB activation in THP-1 cells and HMDDCs 
MVA infection activates NF-κB in several cell types (18, 34, 48). We 
previously demonstrated that the MVA/5.2kb virus inhibits MVA-induced NF-κB 
activity in two cell lines (e.g., 293T, RK13) (18). At least two proteins from this 
5.2kb region (K1 and M2) are known to inhibit NF-κB activation (21-24). 
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However, it was not known if MVA/5.2kb would inhibit MVA-induced NF-κB 
activity in APCs.  
We initially compared IκBα protein levels in infected cells as an indirect 
measure of NF-κB activation. IκBα binds to and sequesters NF-κB in the 
cytoplasm of unstimulated cells (49). Upon IκBα degradation, the nuclear 
translocation signal of NF-κB is exposed and freed NF-κB translocates to the 
nucleus (50). As observed in Figs. 3A and 3B, the intensities of IκBα-containing 
bands are relatively high in mock-infected cells, indicating that NF-κB is inactive. 
IκBα levels were decreased during MVA infection of either the THP-1 cell line 
(Fig. 3A) or primary human monocyte-derived dendritic cells (HMDDCs) (Fig. 
3B), indicating activation of the NF-κB pathway. However, in both cell types, IκBα 
protein levels were higher in MVA/5.2kb- versus MVA-infected cells at multiple 
times post-infection. Actin levels were similar between samples, ensuring that a 
decrease in IκBα protein levels was not due to overall protein degradation after 
infection. Therefore, for both cell types, MVA/5.2kb inhibited NF-κB activation 
compared with MVA.  
As a second measure of NF-κB activation, we quantified TNF-α, a 
cytokine whose gene is controlled by the NF-κB transcription factor (51-53), in 
the supernatants of infected cells. Results are shown in Fig. 3C (THP-1 cells) 
and 3D (HMDDC). Supernatants from MVA-infected THP-1 or HMDDCs had the 
highest levels of TNF-α, implying NF-κB activation. TNF-α levels were decreased 
in supernatants from MVA/5.2kb infections. Thus, data from Fig. 3 showed that 
MVA/5.2kb greatly reduced NF-κB activation in APCs.  
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MVA/5.2kb infection produces IL-6 and IL-8 levels comparable to MVA infection 
Now confident that the MVA/5.2kb virus inhibited both apoptosis and NF-
κB activation in APCs, we asked if the 5.2kb gene cluster affected virus 
immunogenicity. For example, NF-κB activation leads to the production of 
molecules (e.g., cytokines and chemokines) that attract immune cells to areas of 
infection (33). Because the MVA/5.2kb virus inhibits NF-κB activation in infected 
APCs (Fig. 2), perhaps MVA/5.2kb infection would dampen overall expression 
these molecules, resulting in decreased infiltration of immune cells to an area of 
inoculation. We investigated this by quantifying the expression of one pro-
inflammatory molecule (IL-6) and one chemokine (IL-8) during virus infection 
(Fig. 4). We chose these two molecules because each one is upregulated during 
an MVA infection (32). Additionally, THP-1 cells have the capacity to produce IL-
6 and IL-8 (54). As expected, IL-6 (Fig. 4A) and IL-8 (Fig. 4B) protein levels were 
higher in supernatants from MVA- versus mock-infected cells. A separate set of 
mock-infected cells was incubated in medium containing lipopolysaccharide 
(LPS), which is known to induce cytokine expression (54), as a positive control. 
Interestingly, MVA/5.2kb did not reduce production of IL-6 or IL-8 proteins as 
compared to MVA infection. It is unlikely that this was due to the preparation of 
viruses because the same virus preparations were used to examine TNF-α, IL-6 
and IL-8 levels, and differences in TNF-α protein production were observed 
between MVA and MVA/5.2kb. No other cytokine levels were examined because 
it appeared that MVA/5.2kb infection was not globally dampening cytokine 
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production. This is likely because some cytokines and chemokines are controlled 
by transcription factors other than, or in addition to, NF-κB (55, 56).  
 
MVA/5.2kb infection does not inhibit surface expression of CD86 
APCs, including DCs, bridge the innate and adaptive immune responses. 
One key step to DC activation is maturation, an event that can be measured by 
the upregulation of surface proteins like CD80 and CD86 (57). MVA infection 
induces DC maturation, as increases in surface proteins (e.g., CD86) can be 
seen compared to mock-infected cells (28, 30, 31). We asked if MVA/5.2kb 
infection inhibited this process since NF-κB activation is linked to APC maturation 
(33, 57), and MVA/5.2kb inhibits NF-κB activation. 
CD86 surface expression was quantified in infected HMDDCs as a proxy 
for DC maturation by using flow cytometry (Fig. 5). THP-1 cells were not used for 
this experiment because CD86 is not expressed in these cells (58). A subset of 
uninfected cells was incubated in medium containing LPS to induce CD86 protein 
expression as a positive control (59). CD86 levels were slightly higher in MVA-
infected cells versus mock-infected cells, as observed by a shift in the intensity of 
signal (Fig. 5A) and a greater mean fluorescence intensity (MFI) (Fig. 5B). Our 
findings are consistent with previous reports (30, 31). In contrast, VACV strain 
WR inhibits DC maturation (30, 60), and we observed this trend in agreement 
with these reports. CD86 expression was lower in WR-infected cells compared to 
mock-infected cells, and this is probably due to the fact that WR infection inhibits 
host cell protein synthesis (60). When cells were infected with MVA/5.2kb, the 
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intensity of CD86 signal was modestly reduced compared to MVA. This may be 
due to the K1L and M2L genes in MVA/5.2kb: CD86 gene expression is 
controlled, in part, by NF-κB, and K1 and M2 inhibit NF-κB. Nevertheless, the 
CD86 expression levels in MVA/5.2kb-infected cells were slightly higher than 
mock-infected cells and closer to that observed in MVA-infected cells as opposed 
to WR-infected cells. Thus, MVA/5.2kb infection, like MVA infection, probably 
cannot completely inhibit DC maturation. We also examined CD80 expression 
levels in virus-infected HMDDCs, however observed no differences, even with 
LPS treatment. Therefore, these results were not included. However, CD86 
levels are a more accurate representation of MVA-induced maturation as 
upregulation of CD80 during maturation of HMDDCs after MVA infection was 
seen by some groups (30) but not others (31). 
 
MVA/5.2kb infection dampens VACV-specific CD8+ T cell responses 
 We showed that MVA-5.2kb-infected APCs have increased viability (Fig. 
2) and decreased NF-κB activation (Fig.3) as compared to MVA-infected cells. 
Additionally, MVA/5.2kb-infected APCs showed similar cytokine production (Fig. 
4) and maturation (Fig. 5) as compared to MVA infection. Therefore, we were 
curious what effect MVA/5.2kb would have on immune response to infection.  
To answer this question, we quantified VACV-specific CD8+ T cells in the 
spleens of poxvirus-infected mice (4, 61). CD8+ T cells and antibody production 
are required for protection against a lethal poxvirus challenge. CD8+ cells are 
required for prevention of weight loss in naïve animals, presumably by providing 
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a non-specific cell-mediated response until the advent of a humoral response 
(62). Therefore, we chose to examine CD8+ T cell immunogenicity as activation 
of CD8+ lymphocytes in VACV-vaccinated mice and humans serve as correlates 
of protection (63, 64). 
Splenocytes were collected from inoculated mice and incubated in 
medium lacking or containing a VACV E3 peptide. Cells that were CD8+ and 
expressed IFN-γ were considered VACV-specific, stimulated T cells and were 
expressed as a percentage of the cellular population. For each animal, the 
%CD8+IFN- γ+ T cell population from cells incubated in regular medium was 
subtracted from those incubated in medium containing the E3 peptide. The 
averaged results are displayed in Fig. 6, along with the data collected for each 
individual animal below the graph.  
VACV-specific CD8+ T cell populations were very low in PBS-inoculated 
mice. Infection with either the VACV strain WR or MVA induced an appreciable, 
and statistically significant, virus-specific CD8+ T cell response in comparison to 
PBS-inoculated mice, consistent with previous reports (62, 65-67). Note that 
there was no statistically significant difference in IFN-γ+CD8+ T cell populations 
between WR- and MVA-infected mice, as expected due to a higher dose utilized 
in MVA infected mice (65). Infection with MVA/5.2kb elicited an increase in 
VACV-specific CD8+ T cell response in comparison to PBS-inoculated mice. 
However, MVA/5.2kb significantly diminished VACV-specific CD8+ T cell 
response as compared to MVA infection. Therefore, despite the potential immune 
143 
 
stimulatory capacity we observed in vitro, MVA/5.2kb did not increase the ability 
of MVA to elicit a VACV-specific immune response in vivo. 
 
3.4  Discussion 
MVA is a safe and widely-used attenuated vaccine vector, however its 
limited immunogenicity is a subject of ongoing improvement efforts (1, 16). Here 
we asked how the re-introduction of a 5.2kb region of VACV DNA that encodes 
known immune evasion genes into the MVA backbone would alter the immune 
responses in infected APCs. We demonstrated that the presence of the 5.2kb 
region reduced MVA-induced apoptosis and NF-κB activation during infection of 
APCs.  
We hypothesized that these effects may enhance the viability and delay 
clearance of virus-infected cells in the host, resulting in an increased duration of 
VACV-specific antigen presentation. MVA/5.2kb did not appear to dramatically 
alter IL-6 and IL-8 production after infection compared to MVA, or virus-induced 
APC maturation, as measured by CD86 expression. This suggested that 
MVA/5.2kb retained the ability to activate immune responses, as cytokine and 
chemokine production could draw in immune cells and antigen presentation 
could occur by APCs. However, MVA/5.2kb infection decreased the number of 
VACV-specific CD8+ T cells in comparison to MVA infection. These results 




 Multiple strategies have been used to enhance the immunogenicity of 
MVA. Several groups inserted host immune-stimulating genes into MVA in effort 
to bolster MVA efficacy. Recombinant MVA viruses encoding IL-12, IFN-γ, IL-2, 
IL-15 or GM-CSF increase immune responses (16). Another strategy is to re-
insert VACV genes into MVA to create a replication-competent recombinant 
MVA. Melmin et al. examined the recombinant MVA/51.1 and MVA44/47.1 
viruses (68). Each virus gains the ability to replicate in human and other cell lines 
(17, 68). However, each recombinant MVA did not produce significantly improved 
humoral and cell-mediated responses versus MVA infection (68). Another 
replication-restricted virus altered to increase host range is the attenuated 
NYVAC (1). Quakkelaar et al. demonstrated that a NYVAC virus containing the 
K1L and C7L host range genes gained replication-competence in human cells, 
remained safe, and increased immunogenicity compared to the parental NYVAC 
as measured by antigen presentation and memory CD8+ T cells (69, 70). 
Therefore, the insertion of genes back into attenuated strains did not hinder 
immune responses, and in some cases, improves immunogenicity. Although the 
K1L gene has been re-inserted into MVA in MVA/5.2kb, MVA/5.2kb still cannot 
replicate in human cells (17). This allowed us to investigate the unique question 
of whether insertion of immunoregulatory proteins, that do not affect host range, 
could affect immunogenicity. 
 Multiple publications show that deletion of remaining viral 
immunomodulatory genes in MVA increases MVA efficacy. For example, 
individual deletion of cytokine/chemokine binding proteins (B16, C12, A41), NF-
145 
 
κB inhibitors (K7, A46), interferon inhibitors (C6, N2), or an apoptosis inhibitor 
(F1), increases the immunogenicity of MVA (41, 71-80). However, the deletion of 
immune regulatory proteins does not always increase MVA immunogenicity. For 
example, a mutant MVA construct missing a viral chemokine-binding protein 
(B7), showed no enhanced immunogenicity (72). We were curious if the opposite 
strategy, that of introducing more immune evasion molecules, might also 
increase MVA efficacy, and this was examined using the MVA/5.2kb virus. We 
hypothesized that inhibition of apoptosis may delay viral clearance and increase 
potential for antigen presentation. We found that, while MVA/5.2kb inhibited 
MVA-induced apoptosis, immunogenicity was not increased; VACV-specific 
CD8+ T cells were lower in mice infected with MVA/5.2kb versus MVA. Our 
results complement reports showing that an MVA lacking the F1 anti-apoptosis 
protein has increased immunogenicity (77). It is speculated that this is because a 
MVA virus lacking F1L stimulates apoptosis in APCs and other host cells, an 
event that would increase cross-presentation of viral antigens (77, 81). 
Therefore, it appears that apoptosis can, to some extent, dictate MVA efficacy. 
We should note that antibody responses were not examined in this body of work, 
and it is difficult to predict if protective antibody responses would also be lower in 
MVA/5.2kb- versus MVA-infected mice. 
 MVA/5.2kb also contains the K1 and M2 inhibitors of NF-κB (10, 18), a 
pro-inflammatory transcription factor. While NF-κB activation is one factor for 
immune response stimulation, it has been previously postulated that decreased 
viral activation of NF-κB may allow infection without clearance of the virus (34). 
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This is supported by recent study by Bravo Cruz et al., which suggests that 
decreased cytokine production during an in vivo VACV infection can still lead to a 
protective responses (38). Hence, we examined if MVA/5.2kb increased immune 
responses after infection. MVA/5.2kb infected APCs showed similar phenotypes 
in vitro to MVA-infected cells despite the inhibition of NF-κB, a player in APC 
maturation and cytokine production (33). However, MVA/5.2kb did not elicit equal 
or enhanced immunogenicity as compared to MVA infection in vivo. Our study 
demonstrates that APC properties, such as maturation and cytokine production, 
rely on a variety of stimuli other than NF-κB. Additionally, this study 
demonstrates the complexity of in vivo systems compared to in vitro systems. 
While in vitro maturation was observed after infection with MVA/5.2kb, this did 
not translate to T cell activation in vivo. This type of disjunct has been reported 
previously as wild-type VACV infected APCs do not demonstrate maturation in 
vitro, but do in vivo (82, 83).  
Altogether, our results demonstrate that using in vitro studies alone, one 
cannot accurately predict the effect of genetic manipulation of MVA on 
immunogenicity. This demonstrates a need to examine recombinant viruses for 
their ability to initiate immune responses not only in vitro, but in vivo. Overall, this 
study examined an unexplored strategy to alter MVA immunogenicity, and the 




3.5  Figures 
 
Figure 3.1: Detection of genes in the MVA/5.2kb virus (A) 293T cells were 
either mock-infected or infected with MVA, WR or MVA/5.2kb (MOI = 10). At 24 h 
post infection (PI), cells were harvested and lysed. DNA was subjected to PCR 
amplification using primers to amplify the N2L, M1L, M2L, K1L, K2L, K3L, or K4L 
genes. A portion of each PCR reaction was separated by agarose gel 
electrophoresis, and DNA was visualized using ethidium bromide staining. (B and 
C) 293T cells were either mock-infected or infected with MVA, MVA/5.2kb, (B) 
MVA/M2L or (C) MVA/K1L (MOI = 10). At (B) the indicated times PI or (C) 2 h PI, 
cells were lysed and analyzed by SDS-PAGE. Proteins were transferred to a 
PVDF membrane and the membrane was probed with (B) anti-M2L or (C) anti-
K1L antiserum to detect viral protein expression. Samples in B were analyzed in 






Figure 3.2: MVA/5.2kb infection decreases cell death and apoptosis PMA-
stimulated THP-1 cells were either mock-infected, infected with MVA or 
MVA/5.2kb (MOI = 5), or incubated in medium containing 1 μM staurosporine 
(STS) for 24 h. (A) All cells were collected, and cell death was quantified by using 
a trypan blue dye exclusion assay. Results are presented as the mean 
percentage of cells that excluded trypan blue (live cells) divided by the total 
number of live and dead cells. Cells from each sample were counted in triplicate, 
and data shown are the mean ± SD. The graph shown here is a representative of 
data obtained from at least three independent experiments. (B) PrestoBlue 
reagent was added to each well of cells. The fluorescence of each well was 
quantified by using a microplate reader. Results are presented as the mean 
fluorescence ± SD for each sample. Assays were performed in technical 
triplicate, and the graph shown here is a representative of data obtained from at 
least three independent experiments. For A and B, the Student t test was used to 
determine statistically significant differences in cellular viability among 
experimental conditions. Asterisks indicated the values that were significantly 
different between the indicated groups (*P <0.05). (C) Cells were collected and 
lysed in RIPA buffer. Fifteen μg of protein from each sample were separated by 
using SDS-8% PAGE. Proteins were transferred to a PVDF membrane and the 
membrane was probed with anti-PARP antiserum. Blots subsequently were 
incubated with anti-actin antiserum and re-developed. Data shown is from two 
independent experiments and representative of results from at least three 
independent experiments. Samples were analyzed in the same gel and gel 






Figure 3.3: MVA/5.2kb infection inhibits NF-κB activation in THP-1 cells and 
HMDDCs (A and C) PMA-stimulated THP-1 cells or (B and D) HMDDCs were 
either mock-infected or infected with MVA or MVA/5.2kb (MOI = 5). (A and B) At 
the indicated times post-infection (PI), cells were collected and lysed in CE 
buffer. Ten μg of each sample was analyzed by SDS-10% PAGE. Proteins were 
transferred to a PVDF membrane and the membrane was probed with anti-IκBα 
antibody. Blots subsequently were incubated with anti-actin antiserum, and re-
developed. Data shown is a representative of results from at least three 
independent experiments. (C and D) At 24 h PI, supernatants from infected cells 
were collected and analyzed for TNF-α by using ELISA. Results are presented 
either as (C) the mean protein level ± SD for each sample or (D) the protein level 
for each sample from two different blood donors. Data are representative of at 
least three independent experiments. The Student t test was used to determine 
statistical significance and asterisks indicate conditions in which MVA/5.2kb-






Figure 3.4: MVA/5.2kb infection produces IL-6 and IL-8 levels comparable to 
MVA infection PMA-stimulated THP-1 cells were either mock-infected, infected 
with MVA or MVA/5.2kb (MOI = 5), or incubated in medium containing 10 ng/ml 
lipopolysaccharide (LPS) for 24 h. Supernatants from infected cells were 
collected and analyzed for (A) IL-6 or (B) IL-8 expression via ELISA. Results are 
presented as the mean protein level ± SD for each sample. Data shown is a 





Figure 3.5: MVA/5.2kb infection does not inhibit surface expression of 
CD86 HMDDCs were either mock-infected, infected with MVA, MVA/5.2kb or WR 
(MOI = 5), or incubated in medium containing 100 ng/ml lipopolysaccharide 
(LPS) for 24 h. Cells were collected, stained with either phycoerythrin (PE)-
conjugated anti-CD86 or PE-conjugated IgG2b isotype control, fixed and 
analyzed for levels of CD86 via flow cytometry. Results are presented as (A) a 
histogram of CD86 levels and (B) the corresponding mean fluorescence intensity 







Figure 3.6: MVA/5.2kb infection dampens VACV-specific CD8+ T cell 
responses BALB/c mice (n=3 per group for PBS and WR; n = 4 per group for 
MVA and MVA/5.2kb) were inoculated i.p. with PBS, 106 PFU WR or 108 PFU 
MVA or MVA/5.2kb. At 7 days post-infection mice were euthanized and spleens 
were harvested. Single-cell suspensions were prepared from each sample and 
incubated with medium lacking or containing VACV E3140-148 peptide and 
brefeldin A. Cells were then stained for extracellular CD8 and intracellular IFN-γ, 
and activated VACV-specific CD8+ T cells were quantified by using flow 
cytometry. For each animal, the %CD8+IFN- γ+ T cell population from regular 
medium was subtracted from those incubated in medium containing the E3 
peptide, and are displayed under the graph. These percentages were averaged 
and are displayed as the average ± SD for each condition. The Student’s t-test 
was used to determine statistically significant differences between infection 
conditions, and significance between MVA and MVA/5.2kb is denoted by an 
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Chapter 4: The VACV M1 protein is an inhibitor of multiple caspases 
4.1  Introduction 
 The cysteine-aspartic protease (caspase) family of proteins are critical 
players in the host response to pathogens, including viruses (10). Caspases exist 
in the host cell as inactive zymogens (procaspases) that often become activated 
after cleavage. Their activation is well-known to result in initiation of apoptosis 
(caspases -3, -6, -7, -8, -9, and -10) and inflammation (caspases-1, 4, 5, and -12) 
(21, 24). Other caspases, such as caspase-2, while implicated in regulation of 
cell death are less characterized (14). Initiation of caspases occurs through a 
variety of stimuli, such as viral infection. Therefore, viruses often encode proteins 
to block caspases, allowing viral propagation and spread via inhibition of cell 
death and immune cell infiltration (7).  
Poxviruses are double-stranded DNA viruses that are master manipulators 
of the host response, and they encode viral proteins that inhibit a multitude of 
pathways and proteins, including caspases (37). While some poxviral 
immunomodulatory proteins inhibit specific caspases (e.g., F1, B22) some inhibit 
multiple caspases (e.g., CrmA, B13) (26, 37). Interestingly, inhibition of multiple 
caspases by viral proteins is also exhibited by other viruses, such as the 
baculovirus P35 and P49 proteins (7). 
We reported that the vaccinia virus (VACV) ankyrin repeat (ANK) M1 
protein inhibits intrinsic (caspase-9) apoptosis. We were interested as to whether 
M1 inhibited other caspases during a VACV infection. To investigate this, the 
attenuated poxvirus Modified Vaccinia virus Ankara (MVA) containing the M1L 
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open reading frame (MVA/M1L) was utilized. This virus was used as wild-type 
VACV encodes multiple caspase inhibitors that would mask the effects of M1 (3, 
15, 25, 26, 37, 39). Additionally, transfection of the M1 protein into human cells, 
and a yeast system were utilized to investigate the inhibition of human caspases 
by the M1 protein independent of infection (17, 18). 
Inhibition of caspases-3/-7 and -9 by M1 has been reported (31). Here we 
demonstrate that M1 inhibits other caspases, including caspases -1, -2, -5, -7, 
and -8. This suggests that M1 prevents activation of a multitude of caspases, 
potentially through interaction of one or more of its ANK repeats. Because of this 
hypothesis, the region important for the characterized caspase-9 inhibition by M1 
is further characterized. M1 represents another poxvirally-encoded protein that 
can inhibit multiple caspases during infection to enhance viral survival and 
propagation. 
 
4.2  Materials and methods 
Cell lines 
Human cervical carcinoma (HeLa) cells and human acute monocytic 
leukemia (THP-1 cells) were obtained from the American Type Culture Collection 
(ATCC).  Chicken embryo fibroblast (CEF) cells were obtained from Charles 
River Laboratories. Jurkat cells were obtained from Dr. Ralph Budd (University of 
Vermont). Wild-type and Apaf-1 knockout mouse embryonic fibroblasts (MEFs) 
were a kind gift from Dr. Xuejun Jiang (Memorial Sloan Kettering Cancer Center). 
HeLa and 293T cells were cultured in Eagle’s minimal essential medium (EMEM) 
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supplemented with 10% FBS and 2 mM L-glutamine. MEF cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 2 
mM L-glutamine. THP-1 and Jurkat lines were cultured in RPMI-1640 medium 
supplemented with 10% FBS and 2 mM L-glutamine. For all experiments using 
THP-1 cells, cells were differentiated with medium containing 100 ng/mL phorbol 
12-myristate 13-acetate (PMA; Sigma) for 48 h prior to infection. 
 
Plasmids and transfections 
 Plasmid pM1L-V5 has been described previously (31). A synthetic M1L 
gene with codons optimized for E. coli expression was purchased from Bioneer 
Pacific (Kew East, Victoria, Australia) and the coding region was amplified using 
Phusion polymerase, with the pairs of oligonucleotides listed below: 
M1-FLAG: 5’-GCGGATCCGCCATGATCTTCGTTATTGAAAG-3’ and 5’-GCCTC 
GAGTTACTTGTCATCGTCGTCCTTGTAGTCCATAAAATAGTCATCAAAAACTT
C-3’; M11-212: 5’-GCGGATCCGCCATGGACATGATCTTCGTTA-3’ and 5’-GCCT 
CGAGCTACGGGTTATCGCTCATTAG-3’; M1139-320: 5’-GCGGATCCGCCATGA 
GCGGTACCGATGATGAG-3’ and 5’-GCCTCGAGCTATTTACCCTTATCATTGA 
TAA-3’; M1210-472: 5’-GCGGATCCGCCATGGATAACCCGAAAGCAAGCAC-3’ 
and 5’-GCCTCGAGCTAAAAATAGTCATCAAAAAC-3’. The products were each 
cut with BamHI and XhoI and ligated into pGALL-(TRP1)-MCS for yeast 
expression (20).  All mammalian expression plasmids were transiently 
transfected into HeLa cells using the TransIT 2020 reagent (Mirus) following the 
manufacturer’s instructions.   
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Detection of procaspase cleavage using immunoblotting 
For assays involving infections, cells were either mock-infected or infected 
with MVA or MVA/M1L (31) for the times indicated. Infections of adherent PMA-
stimulated THP-1 cells were performed by removing PMA-containing medium 
and inoculating monolayers with medium containing viruses.  For infection of the 
Jurkat suspension cell lines, cells were first concentrated by centrifugation (250 x 
g, 5 min), resuspended and then counted prior to infection.  The absorption 
phase of infection for Jurkat cells occurred in a small volume at 37°C.  After the 
absorption phase, Jurkat cells were centrifuged (250 x g, 5 min), supernatants 
were removed, and infected cells were resuspended in complete medium and 
transferred to 12-well tissue culture plates. A subset of mock-infected cells was 
treated with 10ng/mL TNF-α (TNF; Roche) and 10ng/mL cycloheximide (CHX; 
Sigma). Cells were harvested at the indicated times. For transfection assays, 
subconfluent HeLa cellular monolayers in six-well plates were transfected with 
1,000 ng of either pCI or pM1L-V5. At 24 h post-transfection, cells were 
incubated in medium absent for or containing TNF+CHX for 2, 4 or 6 h. 
For both infected and transfected cells, cells were collected, and cellular 
pellets were lysed in 100 µL RIPA buffer (150 mM NaCl, 1% sodium 
deoxycholate, 1% NP-40, 0.1% SDS and 0.01M Tris-HCl) containing HALT 
protease inhibitor (Thermo Scientific) for 20 min at 4°C.  Cellular lysates were 
then centrifuged (18,000 x g for 10 min). Clarified supernatants were collected 
and transferred to new tubes. The protein concentration of lysates from each 
sample was determined using the BCA Protein Assay Kit (Pierce). 50 µg 
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(caspase-8: THP-1 and HeLa) or 30 µg (caspase 8: Jurkat; caspase-3 and 
caspase-1) of protein from each lysate was incubated with 5X Non-Reducing 
Lane Marker (Thermo Scientific) and 2 µL of 2-mercaptoethanol (Fisher 
Scientific), boiled for 5 min and then separated using SDS-PAGE.  Proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes (Millipore) and 
membranes were incubated in 5 % (w/v) milk in Tris-buffered saline and Tween 
20 (TBST; 150mM NaCl, 50mM Tris base and 0.05 % Tween 20) for at least 30 
min at room temperature.  Membranes were incubated with the indicated primary 
antibodies overnight at 4°C.  Next, membranes were washed three times in large 
volumes of TBST, and incubated with the appropriate HRP-conjugated 
secondary antibodies.  Immunoblots were developed by using 
chemilluminescence reagents (Thermo Scientific and Amersham) according to 
the manufacturer’s instructions and images were detected by autoradiography.   
Primary caspase antibodies used in these experiments were: anti-
caspase-3 (1:1,000; Cell Signaling, 9665), anti-caspase-8 (1:1,000; Cell 
Signaling, 4790), and anti-caspase-1 (1:1,000; Cell Signaling, 2225). Other 
antibodies used included mouse monoclonal anti-E3L (1:5,000; a gift from Dr. 
Stuart Isaacs, University of Pennsylvania), anti-V5 (1:5,000; Millipore, AB3792), 
and anti-β-Actin (1:5,000; Sigma, A5060).  Secondary HRP-conjugated 
antibodies were obtained from either Calbiochem (goat anti-rabbit IgG; 1:10,000) 





ELISA to detect IL-1β expression 
PMA-stimulated THP-1 (1x106) cells in 12-well plates were mock-infected 
or infected at a MOI of 5 with either MVA or MVA/M1L for 24 h. As a control, an 
additional set of uninfected cells were treated with 1 µg/ml of lipopolysaccharide 
(LPS; Alpha Diagnostic) for 24 h. Cell-free supernatants were collected from 
each sample and the concentrations of IL-1β were assayed by enzyme-linked 
immunosorbent assay (ELISA) reagents (Invitrogen; CHC1213) according to 
manufacturer’s instructions with the following modifications. Cells were incubated 
for 1 h with streptavidin-HRP (1:2500; Jackson ImmunoResearch, 016-030-084) 
as the secondary antibody. The following substrate solution was used: 102.8 mM 
Na2HPO4 and 48.6 mM citric acid supplemented with 1:2500 H2O2 and OPD 
powder. Absorbance at 450 nm (reference absorbance: 650) was read using a 
SpectraMax M2 Microplate Reader (Molecular Devices) and data were analyzed 
in Excel. The Student’s t-test was used to determine statistically significant 
differences between infection conditions. 
 
Yeast assay 
The Saccharomyces cerevisiae yeast strain W303α was transformed and 
analyzed in survival assays as previously described (6). Plasmids directing yeast 
expression of caspase-3-lacZ (17), caspase-1, caspase-2, caspase-3, rcaspase-
3, caspase-5, rcaspase-6, caspase-753, caspase-8, caspase-9 and Apaf-1 (6) 
have all been previously described. Construction of the M1L yeast expression 
plasmids are outlined above. 
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Creation and characterization of tagged MVA/M1L viruses 
 The modified vaccinia virus Ankara (MVA) strain of VACV was obtained 
from Dr. Bernard Moss (National Institutes of Health) (3). MVA viruses containing 
FLAG-tagged (MVA/M1L-FLAG) or HA-tagged (MVA/M1L-HA) versions of the 
M1L transcriptional unit were created as previously described (31) using the 
forward primer 5’-GGCGTGACATTGCGGCCGCAACTAAACC-3’ and reverse 
primer (5’-CATGATCCTGCAGAAAAAAATTATTTGTCGTCGTCGTCCTTGTAAT 
CAAAA TAATCATCGAATAC-3’) for FLAG or (5’-GTCATGCTGCAGAAAAAAAT 
TAAGCGTAGTCAGGTACATCGTATGGGTAAAAATAATCATCGAATAC-3’) for 
HA.  
 The expression of tagged M1 proteins were detected by immunoblotting. 
Chicken embryo fibroblasts (CEFs), Apaf KO mouse embryonic fibroblasts 
(MEFs), or PMA stimulated THP-1 cells were either mock-infected or infected 
with MVA/M1L-FLAG or MVA/M1L-HA an MOI of 10 (CEF) or MOIs of 2 and 5 
(MEF, THP-1). At 24 h pi, or the indicated times indicated pi (THP-1), proteins 
were collected in RIPA buffer and ran on SDS-8% PAGE gels as described in the 
immunoblotting section above. Primary antibodies utilized were anti-FLAG 
(1:000; Sigma, F3165) and anti-HA (Sigma, H9658).  
 
4.3  Results 
M1 inhibits virally- and chemically-induced procaspase-8 cleavage 
MVA infection induces extrinsic (caspase-8 mediated) and intrinsic 
(caspase-9 mediated) apoptosis of antigen presenting cells (APCs) (2, 9, 16). 
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Additionally, activation of extrinsic apoptosis can feed into the intrinsic pathway 
(5, 36).  We previously reported that the M1 protein inhibits MVA-induced 
apoptosis (31). Additionally, we showed that M1 inhibits MVA-induced apoptosis 
in caspase-8 deficient (C8 -/-) Jurkat cells, demonstrating M1 inhibition of the 
intrinsic pathway. However, inhibition by M1 in C8 -/- Jurkat cells, while 
significant, was less pronounced than in wild-type Jurkat cells. This suggested 
M1 may also have a role in inhibition of extrinsic apoptosis. 
To investigate this, we examined procaspase-8 cleavage after infection of 
APC-like PMA stimulated THP-1 cells (Fig. 1A) and Jurkat T cells (Fig. 1B), with 
either MVA or MVA/M1L. Mock-infected cells showed no cleavage of 
procaspase-8, indicating a lack of apoptosis. As a positive control, a set of mock-
infected cells was treated with TNF-α (TNF) and cycloheximide (CHX), which 
together induce procaspase-8 cleavage (40). With this treatment, the levels of 
cleaved caspase-8 were increased in both THP-1 and Jurkat cells. As expected, 
infection with MVA increased the levels of cleaved caspase-8, indicating 
activation of the extrinsic apoptosis pathway. Interestingly, infection with 
MVA/M1L inhibited procaspase-8 cleavage compared to MVA-infection, 
suggesting M1 inhibits MVA-induced cleavage of procaspase-8. This was not 
due to differences in infection, as the early VACV E3 protein was detected at 
similar levels in all infected cells. Additionally, equal levels of protein were 
detected, as verified by actin levels. 
To verify these findings, we examined if M1 could inhibit the cleavage of 
procaspase-8 independent of infection. HeLa cells were transfected with empty 
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vector (pCI) or a plasmid containing a V5 epitope-tagged M1 protein (pM1L-V5), 
and then treated with TNF+CHX for 2, 4 or 6 hours to induce extrinsic apoptosis 
(Fig. 1C). In pCI transfected cells, treatment with TNF+CHX induced cleavage of 
procaspase-8, as well as the downstream executioner caspase procaspase-3, 
indicating apoptosis. In corroboration with our infection results, cells transfected 
with M1 had lower levels of cleaved caspase-8 and caspase-3. This was not due 
to unequal protein loading as actin levels were the same for all conditions. 
Therefore, the M1 protein, in addition to inhibiting caspase-9 cleavage, inhibited 
cleavage of caspase-8. 
 
M1 inhibits procaspase-1 activation in THP-1 cells 
Another caspase that becomes activated (cleaved) during MVA infection is 
the proinflammatory caspase-1 protein, which then mediates the processing and 
activation of the IL-1β cytokine (11). As M1 inhibited both procaspase-9 and 
procaspase-8 cleavage, we were interested as to whether M1 could also inhibit 
the activation of caspase-1. To answer this, we examined the levels of 
procaspase-1 after infection with MVA or MVA/M1L (Fig. 2A). Cleaved caspase-1 
was undetectable in our system, therefore we only assayed the pro/full-length 
form. Mock-infected cells had high levels of procaspase-1 protein, while 
liposaccharide (LPS), an activator of caspase-1 (34), treated cells had little 
detectable procaspase-1. MVA induced cleavage of procaspase-1, consistent 
with previous reports (11), while MVA/M1L infection increased protein levels of 
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procaspase-1. This suggested that M1 not only inhibited apoptotic caspases, but 
also could inhibit a proinflammatory caspase. 
To validate these findings, we assayed the levels of IL-1β protein in the 
supernatants of infected cells by ELISA. IL-1β can only be secreted after 
processing by caspase-1, therefore this serves as an indirect measure of 
caspase-1 activation (34). As previously reported, MVA infection induced 
secretion of IL-1β compared to mock-infected cells (11). However, this was 
greatly reduced by infection with the MVA/M1L virus. Overall, these results 
suggest that the poxviral M1 protein inhibited the cleavage of caspase-1. 
 
M1 inhibits multiple caspases in a yeast system 
To examine whether M1 inhibits other caspases, we utilized S. cerevisiae 
as a system to induce caspase-mediated cell death in the presence or absence 
of the M1 protein. In this system, the over-expression of mammalian caspases is 
lethal to yeast (6). Cell viability only occurs if an inhibitor of the protein used to 
induce cell death (e.g., caspases) is present. Therefore, this system allows 
identification of direct caspase inhibitors.  
We previously utilized this system to demonstrate the ability of M1 to 
inhibit caspase-9 (31). Here we examined whether M1 could inhibit yeast cell 
death induced by caspase-1, -2, -3, -5, -6, -7, or -8 (Fig. 3). Each caspase is 
under the control of a galactose-inducible promoter. Upon addition of galactose, 
yeast that do not contain mammalian caspases remain viable, while those 
transformed with each caspase no longer survive (6) (lane 1 vs. lane 2). For each 
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caspase construct, the baculovirus broad spectrum caspase inhibitor P35 was 
used a control to demonstrate inhibition of cell death (lane 3). Additionally, the 
mammalian Bcl-xL, which is not a direct target of caspases (5), did not inhibit 
caspase-induced cell death (lane 4).  
When M1 was expressed in this system (lane 5 and lane 6), inhibition was 
observed for caspase-1, -2, -3-lacZ, -5, and -753 (Fig. 3A). The inhibition of 
caspase-1 corroborates our findings in Fig. 2. Interestingly, caspase-8 inhibition 
was not detected in this yeast system (Fig. 3B), but was demonstrated during 
virally- and chemically-induced apoptosis (Fig. 1). This demonstrates a potential 
disconnect between the yeast system and our cell culture system, and validates 
the need to verify these yeast findings in mammalian cell culture. Additionally, 
inhibition by M1 was not observed for rcasp-3 and rcasp-6 (Fig. 3B), caspase 
constructs in which the caspase small and large subunits are swapped to mimic 
the structure of active caspases (6). However, lack of inhibition is likely not due to 
the reversed structure of the caspase proteins, as rcasp-9 was previously seen to 
be inhibited by M1 (31). Nevertheless, in the yeast system, M1 inhibited multiple, 
but not all, caspases tested. 
 
The C-terminus of M1 is sufficient for inhibition of apoptosome-induced death in a 
yeast system 
M1 consists of 14 predicted ANK repeats, a motif known for protein-
protein interactions (22, 31). Because we observed direct inhibition of multiple 
caspases by M1 (Fig. 3), the inhibition was likely due to interaction of one or 
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more ANK repeats with the caspase proteins. We were interested in better 
understanding what specific ANK repeats are necessary for caspase inhibition. 
We previously characterized M1 inhibition of apoptosome-induced cell death in 
the yeast system used in Fig. 3 (31). Therefore, to begin to answer the question 
of what ANK repeats of M1 are important for caspase inhibition, we tested the 
ability of M1 mutants to inhibit apoptosome-induced cell death in the yeast 
system. We assayed how mutant M1 proteins containing either the N terminus 
(amino acid residues 1-212), middle region (amino acid residues 139-320), or C 
terminus (amino acid residues 210-472) inhibited apoptosome-induced cell death 
(Fig. 4). 
As previously reported, full length (FL) M1 protein inhibited cell death 
induced by apoptosome reconstitution (lane 3). Interestingly, when the truncated 
versions of M1 were tested (lanes 4-6), only the protein containing amino acid 
residues 210-472 (lane 6) inhibited apoptosome-induced cell death. This 
suggested that for inhibition of caspase-9, the C-terminal region of M1 is 
sufficient. Additionally, the M1 mutant spanning from to amino acids 139-320 
(Lane 5) did not inhibit apoptosome-induced yeast cell death, further suggesting 
that aa 320-472 contain the region sufficient for apoptosome inhibition. 
Therefore, predicted ANK repeats 11-14 of M1 were sufficient for inhibition of 






Creation and characterization of tagged MVA/M1L viruses 
 We demonstrated the ability of M1 to inhibit multiple caspases both in the 
context of an infection, and independent of infection. However, the data obtained 
from the yeast system need to be validated in a cell culture system to verify the 
relevance of the interactions seen. While transfections of cells with an M1 
plasmid can begin to validate these findings, a MVA virus that expresses a 
tagged-version of the M1 protein would greatly aid in determining the physiologic 
relevance of caspase inhibition, as well as potential caspase interactions, by M1.  
Therefore, we created two MVA viruses, each expressing a differentially 
tagged version of the M1 protein under the control of its natural viral promoter 
(Fig 5A). A two-gene cassette containing the GFP gene along with either a C-
terminal FLAG-tagged or HA-tagged M1L gene was inserted into the del III 
region of the MVA genome via homologous recombination (31). The created 
viruses were then tested for tagged M1 protein expression in CEF cells, a 
permissible cell line for MVA replication (8) (Fig. 5B and 5C). Infection of CEFs 
at a multiplicity of infection (MOI) of 10 with either MVA/M1L-FLAG or MVA/M1L-
HA demonstrated specific recognition of each epitope, at the molecular weight 
of the M1 protein (54kDa). These results were verified in other cell lines (MEF 
and THP-1) at MOIs that have been used in our previous study with M1 (31). 
Note that the M1 protein migrated to a lower molecular weight than in CEF cells. 
This could be due to the percentage gel chosen for analysis or processing of the 
M1 protein in these cell lines that is unknown to us at this time. Nevertheless, 
175 
 
we confirmed the creation of two viruses that express tagged versions of the M1 
protein during infection, which could serve as valuable tools for future studies. 
 
4.4  Discussion 
Here we demonstrated the VACV M1 protein inhibits multiple caspases 
during infection with MVA as well as via ectopic expression of the M1 protein in 
cell culture and in yeast. First, this data suggests that M1 is a broad-spectrum 
caspase inhibitor. Second, the yeast system suggests that M1 is a direct inhibitor 
of these caspases. Finally, as caspases are important for apoptosis and 
proinflammatory signaling, this suggests the M1 protein benefits VACV in a 
multifunctional manner during a viral infection by delaying these pathways. 
Other viral and cellular proteins function as broad-spectrum caspase 
inhibitors. The first caspase inhibitor discovered was the cowpox (CPXV), a virus 
in the same genus as VACV, CrmA protein. CrmA was initially demonstrated to 
inhibit the IL-1β converting enzyme, caspase-1, and later identified to also inhibit 
caspases-4, -5, -8, -9, and -10 (7, 30, 39). Due to its 92% amino acid identity with 
CrmA, the VACV encoded B13 was identified as a broad-spectrum caspase 
inhibitor, assumed to inhibit the same caspases as CrmA (39). The baculovirus 
protein P35, used as a control in this study, is also a broad-spectrum viral 
inhibitor as it inhibits caspases-1, -3, -6, -7. -8, and -10. Cellular homologues of 
viral caspase inhibitors, such as mammalian XIAP, discovered via the presence 
of baculoviral inhibitor of apoptosis protein (IAP) repeat (BIR) motifs (38), is a 
well-characterized inhibitor of caspases-3, -7 and -9 (7, 28). These viral and 
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cellular proteins bind the catalytic site of active caspases and act as 
pseudosubstrates (7, 26)  Interestingly, the M1 protein has no identifiable 
caspase cleavage motif, and cleavage of the M1 protein was not observed after 
initiation of apoptosis (data not shown). Therefore, while our data suggest M1 
can directly inhibit multiple caspases, it is unlikely that M1 functions as a 
competitive substrate. 
M1 is an ANK repeat-containing protein, a motif important for protein-
protein interactions (22). ANK containing proteins have a wide range of functions, 
such as cell cycle and transcriptional regulation, however viral and cellular ANK 
containing proteins have been identified as apoptosis inhibitors. However, most 
of these proteins inhibit caspase activation through indirect mechanisms (1, 4, 
12, 19, 23, 27). A possible exception is the P-vank-1 protein from Campoletis 
sonorensis ichnovirus (CsIV), which inhibits caspase activity through an as-yet-
identified mechanism (13). Here we demonstrated M1 inhibited multiple 
caspases through a direct mechanism, making it unique amongst ANK proteins 
found in nature.  
Interestingly, the concept of ANK-directed inhibition of caspases is 
currently being explored through the development of designed ANK repeat 
proteins (DARPins). While naturally occurring psuedosubstrate inhibitors, such 
as CrmA and XIAP, as well as synthetic inhibitors which target the caspase 
active-site, inhibit multiple caspases, there is difficulty in achieving inhibition of 
one caspase (e.g., caspase-3) but not a closely related one (e.g., caspase-7) due 
to the conservation of their active sites (32). Therefore, ANK-repeat libraries are 
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being utilized to discover novel DARPins that have high affinity for a specific 
caspase, potentially in an area other than the active site (29). Novel DARPins 
against caspase-2 (35) and caspase-3 (33) have been identified which bind 
specifically. As initial data suggested M1 does not work as a caspase 
pseudosubstrate, a better understanding of the M1 mechanism of inhibition could 





4.5  Figures 
 
Figure 4.1: M1 inhibits virally- and chemically-induced procaspase-8 
cleavage. (A) PMA-treated THP-1 cells or (B) Jurkat were either mock-infected, 
or infected with MVA or MVA/M1L (MOI = 2). A separate set of uninfected cells 
was incubated in medium containing 10 ng/mL TNF-α (TNF) and 10 ng/mL 
cycloheximide (CHX). (C) Subconfluent HeLa cellular monolayers were 
transfected with 1 μg of either empty vector (pCI) or pM1L-V5.  At 24 h post-
transfection, cells were treated with medium either lacking (-) or containing 10 
ng/mL TNF and 10ng/mL CHX. At the indicated times post-infection (PI) or post-
treatment, cells were collected and lysed in RIPA buffer. (A and C) 50 μg or (B) 
30 μg of each sample was analyzed by SDS-PAGE and proteins were 
transferred to a PVDF membrane. The membrane was probed with anti-caspase-
8 antiserum which detects the full length and cleaved forms of caspase-8. Blots 
were subsequently incubated with either (A and B) anti-E3 or anti-actin antisera 
or (C) anti-caspase-3 or anti-V5 or anti-actin antisera, and developed. Data 






Figure 4.2: M1 inhibits procaspase-1 activation in THP-1 cells. PMA-treated 
THP-1 cells were either mock-infected or infected with MVA or MVA/M1L at the 
indicated MOI. A separate set of uninfected cells was incubated in medium 
containing 1μg/mL lipopolysaccharide (LPS). (A) After 24 h, cells were collected 
and lysed in RIPA buffer. 30 μg of each sample was analyzed by SDS-PAGE and 
proteins were transferred to a PVDF membrane. The membrane was probed with 
anti-caspase-1 antiserum. Blots were subsequently incubated with either anti-E3 
or anti-actin antisera, and developed. Data shown are a representative of data 
obtained from at least three independent experiments. (B) After 24 h, 
supernatants from infected cells (MOI = 5) and LPS treated cells were collected 
and analyzed for IL-1β expression via ELISA. Results are presented as the mean 






Figure 4.3: M1 inhibits multiple caspases in a yeast system. Yeast were 
transformed with the indicated expression plasmids and lethality was induced 
either by over-expressing the indicated caspase protein. Suspensions containing 
equivalent concentrations of each transformant were serially diluted and 5 µl of 
each dilution were spotted onto plates containing galactose (to induce transgene 
expression) or glucose (to repress transgene expression). Growth on inducing 
plates indicates survival and proliferation of yeast expressing the transgenes. 
Yeast cell death inhibited by M1 are shown in (A), while caspase inducers that 





Figure 4.4: The C-terminus of M1 is sufficient for inhibition of apoptosome-
induced apoptosis in a yeast system. (A) Yeast were transformed with the 
indicated expression plasmids and lethality was induced either by over-
expressing Apaf-1, procaspase-9 (Casp-9) and procaspase-3 (Casp-3). 
Suspensions containing equivalent concentrations of each transformant were 
serially diluted and 5 µl of each dilution were spotted onto plates containing 
galactose (to induce transgene expression) or glucose (to repress transgene 
expression). Growth on inducing plates indicates survival and proliferation of 
yeast expressing the transgenes. (B) The amino acids (aa) of each predicted 
ANK repeat domain of M1 is listed, and the corresponding M1 mutants are 
depicted. ANK repeats in bold represent those sufficient for survival in (A). 
 














Figure 4.5: Creation and characterization of tagged MVA/M1L viruses. (A) 
Schematic showing insertion of tandem GFP and tagged M1L genes into the del 
III region of the MVA genome, in which the GFP gene is under the control of the 
poxvirus p11 promoter (p11) and the M1L gene is under the control of its natural 
promoter (NP). (B and C) CEF monolayers were mock-infected or infected with 
MVA, MVA/M1L-HA, or MVA/M1L-FLAG (MOI = 10) for 24 h. (D and E) Apaf KO 
MEF monolayers were mock-infected or infected with MVA, (D) MVA/M1L-FLAG 
or (E) MVA/M1L-HA at the indicated MOI for 24 h. (F) PMA-stimulated THP-1 
cells were mock infected or infected with MVA, MVA/M1L-HA, or MVA/M1L-
FLAG at the indicated MOI for the indicated times. For all cells, after infection 
cells were collected and lysed in RIPA buffer. 30 μg of each sample was 
analyzed by SDS-PAGE and proteins were transferred to a PVDF membrane. 
The membrane was probed with anti-FLAG or anti-HA antisera to detect 
expression of the tagged viral M1 protein. (B-E) Blots were subsequently 
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Chapter 5: Summary and future directions 
5.1  Thesis summary 
This thesis investigated the ability of the VACV M1 protein to inhibit 
caspase activity, and the immunogenicity invoked during infection with the 
recombinant MVA/5.2kb virus. These studies generated novel findings for the 
poxvirus field as M1 was uncharacterized in its function, and the insertion of 
VACV immune evasion proteins back into MVA had not been investigated as a 
strategy to alter viral immunogenicity. Therefore, these investigations will direct 
future investigations of poxviral regulation of the host response. 
The M1 protein of VACV was characterized as an ANK-containing protein 
(1, 9), however no function had been ascribed. It was hypothesized to be 
involved in host range due to its similarity to the poxviral K1 protein (9, 11). We 
demonstrate that M1 does not affect host range, but instead inhibits apoptosome-
induced apoptosis (chapter 2) (15). A MVA virus expressing the M1L gene 
(MVA/M1L) inhibits MVA-induced apoptosis in THP-1 and Jurkat cells. MVA can 
activate both intrinsic and extrinsic apoptosis (10), therefore we demonstrate M1 
inhibits caspase-9 via inhibition of apoptosis by MVA/M1L in caspase-8 deficient 
Jurkat cells. Furthermore, ectopic expression of M1 inhibits STS-induced 
(intrinsic) apoptosis in HeLa cells and apoptosome-induced cell death in yeast. 
The M1 protein inhibits conformationally active caspase-9-induced cell death in 
yeast and co-immunoprecipitates with the apoptosome complex, suggesting it 
inhibits at the level of the caspase-9 protein after apoptosome formation. This is 
a previously unidentified mechanism for a poxviral inhibitor of apoptosis, and for 
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an ANK-containing protein. Therefore, M1 is a novel protein that inhibits intrinsic 
apoptosis during a VACV infection to dampen antiviral host responses.  
The M1 protein is one of many proteins encoded by VACV for evasion of 
the host immune response (16). The attenuated MVA strain of VACV lacks many 
of these genes (1). Interestingly, while safe, MVA is less immunogenic than wild-
type VACV (8). We examined if delaying viral clearance, a result of viral 
immunomodulatory proteins, would enhance MVA immunogenicity. The 
MVA/5.2kb virus, a recombinant virus expressing the M1, K1, and M2 immune 
evasion genes, was examined for its effects on APCs and VACV-specific T cell 
activation (chapter 3). MVA/5.2kb inhibited apoptosis and the pro-inflammatory 
NF-κB transcription factor in infected APCs. Maturation and production of some 
cytokines was similar to those induced by MVA, suggesting potential immune 
stimulatory capacity of MVA/5.2kb. However, VACV-specific T cells were 
dampened after in vivo infection with MVA/5.2kb compared to MVA. This study 
examined an unexplored strategy to alter MVA immunogenicity. A more 
immunogenic virus was not discovered, however these results demonstrated the 
complexity of MVA-based immune responses and the difficulty to predict 
immunogenicity from in vitro experiments. 
In this thesis, the M1 protein was identified as an inhibitor of caspase-9-
mediated apoptosis. This begged the question as to whether M1 inhibited other 
caspases. To answer this, M1 inhibition of caspases activated during MVA 
infection (caspase-1 and -8) (7, 10) and caspase-induced death in yeast (2) was 
examined (chapter 4). The M1 protein inhibited virus induced caspase-8 and 
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caspase-1 activation, as well as caspase-1, -2, -3, -5, and -7 induced death in 
yeast. This demonstrated the capacity of M1 to inhibit multiple caspases, likely 
through a direct mechanism as direct inhibition is needed for survival in the yeast 
system. Other poxviral proteins can inhibit multiple caspases (5, 16, 18), however 
none inhibit such a large number of caspases. Additionally, there are no 
identified ANK proteins with the ability to inhibit this wide a variety of caspases. 
Therefore, M1 is a unique protein that inhibits multiple caspases during a VACV 
infection. Additionally, future studies of the M1 protein could yield important 
information about caspase inhibition by ANK repeat-containing proteins.  
 
5.2  Future directions 
Does M1 directly interact with caspase-9? 
 We demonstrate M1 inhibits intrinsic apoptosis via association with the 
apoptosome. Additionally, the yeast data show M1 inhibits conformationally 
active caspase-9 in the absence of Apaf-1, suggesting M1 inhibits at the level of 
caspase-9. However, this has not been directly shown as Apaf-1 was present in 
the cell culture system, and procaspase-3 needed for the yeast system. 
Therefore, direct association of M1 with caspase-9 should be examined.  
 To inspect this, co-immunoprecipitations can be done in Apaf-1 knockout 
mouse embryonic fibroblasts infected with MVA/M1L-FLAG or MVA/M1L-HA, or 
transfected with pM1L-V5. M1 or caspase-9 proteins can be immunoprecipitated 
and association with the other examined. A potential issue with this is M1 was 
seen to associate with caspase-9 in its conformationally active state (rCasp-9 in 
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yeast or associated with Apaf-1 in cell culture). Therefore, procaspase-9 may not 
be in the correct conformation in Apaf-1 KO cells to bind M1, as Apaf-1 is needed 
to obtain conformationally active caspase-9 (3). If no binding is seen between 
procaspase-9 and M1, mutants of the caspase-9 molecule could be examined to 
determine if smaller regions are sufficient for M1 binding, or a conformationally 
active caspase-9-expressing plasmid that expresses in MEFs would be searched 
for. These experiments would help determine if the inhibition by M1 is due to 
direct interaction with caspase-9. Further studies as to how caspase-9 is inhibited 
by M1 (e.g., binding of the active site or inhibition of post-translational 
modifications) could then be examined, and results potentially applied to other 
caspases inhibited by M1.   
 
Validate M1 inhibition and binding of caspases observed in yeast 
 The yeast system demonstrated direct inhibition of caspases-1, -2, -3, -5, 
and -7 by M1. However, inhibition of caspase-8, whose cleavage was blocked by 
M1 in cell culture, was not observed in the yeast system. Therefore, the ability of 
M1 to inhibit each caspase in mammalian cell culture should be explored. 
Caspase cleavage is an indicator of activation (13), therefore the cleavage of 
each caspase after chemical activation can be explored in the absence and 
presence of M1. Chemical stimulation would be the best method of activation, as 
MVA-induced activation of the caspases mentioned above has not been well 
documented. Additionally, assays in which a fluorescent substrate that is only 
cleaved by an active caspase (e.g., caspase-glo) can be used to examine 
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activation of each individual caspase in the presence or absence of M1. These 
studies would verify if the VACV M1 protein inhibits these caspases in cell 
culture. 
Additionally, caspase binding by M1 should be examined. To do this, co-
immunoprecipitations of M1 (via viral expression or plasmid expression) with 
each caspase should be completed. Additionally, after corroboration of binding, 
mutants of each caspase should be examined to determine the sites of M1 
binding, which could yield information as to the mechanism of inhibition. This 
information would be extremely beneficial, as the binding location of M1 between 
each caspase could be compared to see the similarity or differences.  
 
What ANK repeats are needed for caspase inhibition? 
 We demonstrated apoptosome-induced apoptosis in yeast was inhibited 
by the C-terminal domain of M1, consisting of ANK repeats 11-14. Further 
analysis of the specific ANK repeat(s) necessary for inhibition would yield better 
understanding of M1 function. Additionally, exploration as to if the same or 
different ANK repeats of M1 are utilized for inhibition of different caspases would 
be informative. To begin to answer this question, the yeast system can be utilized 
to detect inhibition of the other caspases by the N-terminus, middle region, and 
C-terminus mutants described in chapter 4. This would tell if the same region of 
M1 is needed for inhibition of different caspases. Furthermore, individual ANK 
mutants of M1 can be created and tested for caspase inhibition. Additionally, 
plasmids and viruses that contain M1 mutants expressing various ANK repeat 
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regions and individual ANKs in mammalian cell culture should be made and 
tested to validate the yeast system. These results would yield a better 
understanding of how M1 regulates caspases by determining the regions of the 
M1 protein needed for inhibition of each caspase protein. 
 
Contributions of M1 in vivo 
 M1 is an inhibitor of multiple caspases, proteins which regulate host 
responses such as apoptosis and inflammation (6). Additionally, M1 inhibition of 
apoptosome-induced apoptosis is unique compared to other VACV inhibitors. 
This begs the question as to the role of M1 during viral pathogenesis. To answer 
this question, a wild-type VACV virus deleted for the M1L gene can be created 
and examined in vivo. The two models utilized to determine the contributions of 
M1 during infection would be the intranasal (IN) and intradermal (ID) models. 
 The IN model of infection causes a systemic infection, and infection with 
wild-type VACV is pathogenic (4, 19). IN infection with a M1L deletion virus 
would determine the role of M1 on pathogenesis. Deletion of VACV inhibitor 
genes often leads to viral attenuation (12), therefore it would be interesting to 
determine if the same occurs after an infection with a VACV lacking M1. Mice 
would be infected with wild-type VACV and a VACV lacking the M1L gene, and 
viral pathogenicity would be measured via weight loss and clinical scores (4). 
Additionally, the ability of M1 to serve as a protective vaccine could be examined 
using this model. Mice would be infected with wild-type VACV, which is known to 
be protective against a lethal VACV challenge (19), and with the M1 deletion 
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virus. A survival curve of mice then challenged with a lethal dose of VACV would 
determine if the VACV virus lacking M1 had any effect on the immunogenicity of 
the wild-type virus. 
The ID model of infection is a more localized infection, that more closely 
mimics a vaccination (14, 17). Infection of the ear pinnae yields a lesion with 
wild-type VACV, indicating pathogenicity. A virus deleted for M1 would be 
infected into the mouse ear, and lesion sizes compared to wild-type infected mice 
would be examined. If a smaller size occurs, this would suggest that M1 is 
important for the pathogenicity of the virus.  
The deletion of inhibitors of apoptosis from wild-type VACV have yielded 
attenuated viruses, therefore it is hypothesized that the same will occur after 
infection with a VACV lacking M1 (18). If M1 alters the pathogenicity of either of 
these models, then viral titers would be examined, as well as cytokine production 
and immune cell infiltration to determine if those are altered by M1. Additionally, 
caspase activation between wild-type and the deletion virus would be examined 
to see if there is a connection between the in vitro and in vivo functions of the M1 
protein. This information would determine the contribution of M1 during a VACV 
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